

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/002059

International filing date: 21 January 2005 (21.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/538,149
Filing date: 21 January 2004 (21.01.2004)


Date of receipt at the International Bureau: 03 March 2005 (03.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1288416



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 23, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/538,149

FILING DATE: *January 21, 2004*

RELATED PCT APPLICATION NUMBER: PCT/US05/02059



Certified by

Don W. Dudes

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

Express Mail No.: EL 997679835 US
Attorney Docket No.: 21101.0048U1
PATENT

PROVISIONAL APPLICATION
FOR
UNITED STATES LETTERS PATENT
FOR

**MUTANT SODIUM CHANNEL Na_v1.7 AND METHODS RELATED
THERE TO**

BY

Mark F. Leppert, a citizen of the United States of America, residing at 1466
Westminster Avenue, Salt Lake City, Utah 84105 and **Nanda A. Singh**, a citizen
of the United States of America, residing at 101 Timberlakes, Heber City, Utah
84032.

MUTANT SODIUM CHANNEL Na_v1.7 AND METHODS RELATED
THERE TO

ACKNOWLEDGEMENTS

This invention was made with government support under federal grant
5 R01-NS-32666 awarded by the National Institutes of Health. The Government
has certain rights to this invention.

BACKGROUND

Voltage-gated sodium channels are transmembrane proteins that mediate
regenerative inward currents that are responsible for the initial depolarization of
10 action potentials in excitable cells, such as neurons and muscle. Sodium channels
are typically a complex of various subunits, the principle one being the alpha-
subunit. The alpha-subunit is the pore-forming subunit, and it alone is sufficient
for all known sodium channel function. However, in certain sodium channels,
smaller, auxiliary subunits called beta-subunits are known to associate with the
15 larger alpha-subunit and are believed to modulate some of the functions of the
alpha-subunit. (*See Kraner, et al. (1985) J Biol Chem 260:6341-6347; Tanaka, et
al. (1983) J Biol Chem 258:7519-7526; Hartshorne, et al. (1984) J Biol Chem
259:1667-1675; Catterall, (1992) Physiol Rev 72:S14-S48; Anderson, et al.
(1992) Physiol Rev 72:S89-S158.*) A review of sodium channels is presented in
20 Catterall, (1995) Ann Rev Biochem 64:493-531.

The primary structures of sodium channel alpha-subunits from a variety of
tissues (brain, peripheral nerve, skeletal muscle, and cardiac muscle) and
organisms (jellyfish, squid, eel, rat, human) have been identified, and their amino
acid sequences show individual regions which have been conserved over a long
25 evolutionary period (*see Alberts, et al., eds., "Molecular Biology of the Cell" 534-
535, Garland Pub., New York, N.Y. (1994)*). From these studies it is known that
the alpha-subunit of a sodium channel is a large glycoprotein containing four
homologous domains (labeled I-IV in Fig. 1) connected by intracellular loops.
The N-terminus of the alpha-subunit extends intracellularly at domain I (*i.e.*, DI)
30 and the C-terminus of the alpha-subunit extends intracellularly at domain IV (*i.e.*,
DIV). In the plasma membrane, the four domains orient in such a way as to create
a central pore whose structural constituents determine the selectivity and

conductance properties of the sodium channel.

Each domain of the sodium channel alpha-subunit contains six transmembrane alpha-helices or segments (labeled 1-6 in Fig. 1). Five of these transmembrane segments are hydrophobic, whereas one segment is positively charged with several lysine or arginine residues. This highly charged segment is the fourth transmembrane segment in each domain. Extracellular loops connect segment 1 (*i.e.*, S1) to segment 2 (*i.e.*, S2) and segment 3 (*i.e.*, S3) to segment 4 (*i.e.*, S4). Intracellular loops connect S2 to S3 and S4 to segment 5 (*i.e.*, S5). An extracellular re-enterant loop connects S5 to segment 6 (*i.e.*, S6). (See Agnew, *et al.* (1978) Proc Natl Acad Sci USA 75:2606-2610; Agnew, *et al.* (1980) Biochem Biophys Res Comm 92:860-866; Catterall, (1986) Ann Rev Biochem 55:953-985; Catterall, (1992) Physiol Rev 72:S14-S48.)

Voltage-gated sodium channels can be named according to a standardized form of nomenclature outlined in Goldin, *et al.* (2000) Neuron 28:365-368. According to that system, voltage-gated sodium channels are grouped into one family from which nine mammalian isoforms have been identified and expressed. These nine isoforms are given the names Na_v1.1 through Na_v1.9. Also, splice variants of the various isoforms are distinguished by the use of lower case letters following the numbers (*e.g.*, "Na_v1.1a").

Because of the important role sodium channels play in the transmission of action potentials in excitable cells like neurons and muscle, sodium channels have been implicated in many sensory, motor, and neurologic disorders. Accordingly, sodium channels have been the focus of much scientific research. However, while a great deal has been learned about sodium channels, there remains a need for further understanding of the functioning of sodium channels, and means to diagnose, predict, prevent, and treat diseases, disorders, and conditions that result from variations and abnormalities of sodium channels. These and other objects and advantages of the materials, compositions, articles, devices, and methods described herein, as well as additional inventive features, will be apparent from the following disclosure.

SUMMARY

In accordance with the purposes of the disclosed materials, compositions, articles, devices, and methods, as embodied and broadly described herein, the disclosed subject matter, in one aspect, relates to a method of characterizing a nucleic acid sequence that encodes a Na_v1.7 sodium channel alpha-subunit, 5 wherein the method comprises the step of identifying mutations at one or more sites in regions of the nucleic acid sequence that encode an intracellular *N*-terminal region, an extracellular loop in domain I, an intracellular loop between domains I and II, an intracellular loop between domains II and III, an intramembrane region of domain II, or any combination thereof, such identified 10 nucleotides indicating the character of the nucleic acid sequence.

In another aspect, the disclosed subject matter relates to a method for determining a Na_v1.7 haplotype in a human subject, wherein the method comprises identifying one or more nucleotides encoding amino acid residues 62, 149, 641, 655, 739, 1123, or any combination thereof, wherein the nucleotide or 15 nucleotides indicate the haplotype.

In yet another aspect, the disclosed subject matter relates to a method for determining a subject's predisposition to a neurologic disorder associated with a sodium channel mutation comprising comparing the subject's Na_v1.7 haplotype with one or more reference haplotypes that correlate with the neurologic disorder, 20 a similar haplotype in the subject's Na_v1.7 haplotype as compared to the reference haplotype or haplotypes indicating a predisposition to the neurologic disorder.

In a still further aspect, described herein is a method of identifying a compound that modulates mutant Na_v1.7 sodium channels, wherein the method comprises contacting with a test compound a cell containing a mutant Na_v1.7 25 nucleic acid that encodes a mutant Na_v1.7 sodium channel comprising one or more mutations at residue 62, residue 149, residue 641, residue 655, residue 739, or residue 1123, detecting Na_v1.7 sodium channel activity, and comparing the Na_v1.7 sodium channel activity in the contacted cell with the amount of Na_v1.7 sodium channel activity in a control cell, wherein the control cell is not contacted 30 by the test compound, an increased or decreased Na_v1.7 sodium channel activity in the test cell as compared to the control cell indicating a compound that modulates mutant Na_v1.7 sodium channels.

Also, described herein are isolated nucleic acids comprising nucleotide sequences encoding mutant Na_v1.7 sodium channel alpha-subunits, expression vectors made from such nucleic acids, cultured cells comprising such vectors, and methods of making mutant Na_v1.7 sodium channel alpha-subunits comprising
5 culturing such cells under conditions allowing expression of the polypeptide encoded by the nucleic acids, wherein the polypeptide comprises a mutant Na_v1.7 sodium channel alpha-subunit. Further, described herein are isolated polypeptides comprising mutant Na_v1.7 sodium channel alpha-subunits and fragments thereof as well as purified antibodies that bind to epitopes of such mutant Na_v1.7 sodium
10 channel alpha-subunits.

Additional advantages will be set forth in part in the description that follows, and in part will be obvious from the description, or may be learned by practice of the aspects described below. The advantages described below will be realized and attained by means of the elements and combinations particularly
15 pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive.

BRIEF DESCRIPTION OF DRAWINGS

The accompanying drawings, which are incorporated in and constitute a
20 part of this specification, illustrate several aspects described below.

Figure 1 is a diagram of the secondary structure of a sodium channel alpha-subunit. Not shown is the pore region in each of the four domains, which consists of an inward loop between transmembrane regions 5 and 6.

Figure 2 is a diagram showing the segregation of the N641Y mutation and
25 phenotypic findings of kindred 4425. The following abbreviations are used in the diagram: “fs” means febrile seizures; “afs” means afebrile seizures; “+” means wild type; and “m” means mutant.

Figure 3 is a diagram of the secondary structure of a Na_v1.7 sodium channel alpha-subunit where the locations of various mutations are identified.

30 DETAILED DESCRIPTION

The materials, compositions, articles, devices, and methods described

herein may be understood more readily by reference to the following detailed description of specific aspects of the disclosed subject matter, and methods and the Examples included therein and to the Figures and their previous and following description.

- 5 Before the present materials, compositions, articles, devices, and methods are disclosed and described, it is to be understood that the aspects described below are not limited to specific synthetic methods or specific reagents, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting.
- 10 Disclosed herein are materials, compositions, and components that can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed method and compositions. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific
- 15 reference of each various individual and collective combinations and permutation of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a Na_v1.7 sodium channel is disclosed and a number of modifications that can be made to a number of amino acid residues or nucleotides, including those related to the mutant Na_v1.7 sodium
- 20 channel are discussed, each and every combination and permutation that are possible are specifically contemplated unless specifically indicated to the contrary. Thus, if a class of substituents A, B, and C are disclosed as well as a class of substituents D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited, each is individually and
- 25 collectively contemplated. Thus, in this example, each of the combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. Likewise, any subset or combination of these is also specifically contemplated and disclosed. Thus, for example, the sub-group of A-
- 30 E, B-F, and C-E are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. This concept applies to all aspects of this disclosure including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there

are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the disclosed methods, and that each such combination is specifically contemplated and should be considered disclosed.

5 Throughout this specification, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them
10 that is discussed in the sentence in which the reference is relied upon.

Definitions

In this specification and in the claims that follow, reference will be made to a number of terms, which shall be defined to have the following meanings:

15 As used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a nucleotide” includes mixtures of two or more such nucleotides, reference to “an amino acid” includes mixtures of two or more such amino acids, reference to “the sodium channel” includes mixtures of two or more such sodium channels, and the like.

20 “Optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. For example, the phrase “the array can optionally comprise the most commonly found allele at a second...position” means that the most commonly found allele at a
25 second position may or may not be present in the array and that the description includes both arrays without the most commonly found allele at the second position and arrays where there is the most commonly found allele at the second position.

30 Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the

antecedent "about," it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.

5 "Subject," as used herein, means an individual. In one aspect, the subject is a mammal such as a primate, and, in another aspect, the subject is a human. The term "subject" also includes domesticated animals (*e.g.*, cats, dogs, etc.), livestock (*e.g.*, cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (*e.g.*, mouse, rabbit, rat, guinea pig, etc.).

10 "Nav1.7," as used herein, refers to an isoform of a sodium channel known in the art by names such as NaS, hNE-Na, and PN1. The traditional gene symbol for a Nav1.7 sodium channel is *SCN9A*, and thus the term Nav1.7, as used herein, is synonymous with the term *SCN9A*. There are a variety of sequences related to the Nav1.7 gene having the following Genbank Accession Numbers: NM 002977
15 (human), U35238 (rabbit), X82835 (human), U79568 (rat), and AF000368 (rat), these nucleic acid sequences, the polypeptides encoded by them, and other nucleic acid and polypeptide sequences are herein incorporated by reference in their entireties as well as for individual subsequences contained therein.

 There are a variety of compositions disclosed herein that are amino acid
20 based, including for example Nav1.7 sodium channel alpha-subunits. Thus, as used herein, "amino acid," means the typically encountered twenty amino acids which make up polypeptides. In addition, it further includes less typical constituents which are both naturally occurring, such as, but not limited to formylmethionine and selenocysteine, analogs of typically found amino acids, and
25 mimetics of amino acids or amino acid functionalities. Non-limiting examples of these and other molecules are discussed herein.

 As used herein, the terms "peptide" and "polypeptide" refer to a class of compounds composed of amino acids chemically bound together. Non-limiting examples of these and other molecules are discussed herein. In general, the amino
30 acids are chemically bound together via amide linkages (CONH); however, the amino acids may be bound together by other chemical bonds known in the art. For example, the amino acids may be bound by amine linkages. Peptide as used

herein includes oligomers of amino acids and small and large peptides, including polypeptides and proteins.

There are a variety of compositions disclosed herein that are nucleic acid based, including for example the nucleic acids that encode, for example, Na_v1.7 sodium channel alpha-subunits. Thus, as used herein, "nucleic acid" means a molecule made up of, for example, nucleotides, nucleotide analogs, or nucleotide substitutes. Non-limiting examples of these and other molecules are discussed herein. A nucleic acid can be double stranded or single stranded. It is understood that, for example, when a vector is expressed in a cell the expressed mRNA will typically be made up of A, C, G, and U. Likewise, it is understood that if, for example, an antisense molecule is introduced into a cell or cell environment through, for example, exogenous delivery, it is advantageous that the antisense molecule be made up of nucleotide analogs that reduce the degradation of the antisense molecule in the cellular environment.

As used herein, "nucleotide" is a molecule that contains a base moiety, a sugar moiety and a phosphate moiety. Nucleotides can be linked together through their phosphate moieties and sugar moieties creating an internucleoside linkage. The base moiety of a nucleotide can be adenine-9-yl (A), cytosine-1-yl (C), guanine-9-yl (G), uracil-1-yl (U), and thymine-1-yl (T). The sugar moiety of a nucleotide is a ribose or a deoxyribose. The phosphate moiety of a nucleotide is pentavalent phosphate. A non-limiting example of a nucleotide would be 3'-AMP (3'-adenosine monophosphate) or 5'-GMP (5'-guanosine monophosphate).

"Nucleotide analog," as used herein, is a nucleotide which contains some type of modification to either the base, sugar, or phosphate moieties. Modifications to nucleotides are well known in the art and would include for example, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, and 2-aminoadenine as well as modifications at the sugar or phosphate moieties.

"Nucleotide substitutes," as used herein, are molecules having similar functional properties to nucleotides, but which do not contain a phosphate moiety, such as peptide nucleic acid (PNA). Nucleotide substitutes are molecules that will recognize nucleic acids in a Watson-Crick or Hoogsteen manner, but which are

linked together through a moiety other than a phosphate moiety. Nucleotide substitutes are able to conform to a double helix type structure when interacting with the appropriate target nucleic acid.

5 It is also possible to link other types of molecules (conjugates) to nucleotides or nucleotide analogs to enhance for example, cellular uptake. Conjugates can be chemically linked to the nucleotide or nucleotide analogs. Such conjugates include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger, *et al.* (1989) Proc Natl Acad Sci USA, 86:6553-6556.)

10 A "Watson-Crick interaction" is at least one interaction with the Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute. The Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute includes the C2, N1, and C6 positions of a purine based nucleotide, nucleotide analog, or nucleotide substitute and the C2, N3, C4 positions of a pyrimidine based nucleotide, nucleotide analog, or nucleotide substitute.

15 A "Hoogsteen interaction" is the interaction that takes place on the Hoogsteen face of a nucleotide or nucleotide analog, which is exposed in the major groove of duplex DNA. The Hoogsteen face includes the N7 position and reactive groups (NH₂ or O) at the C6 position of purine nucleotides.

20 "Deletion," as used herein, refers to a change in an amino acid or nucleotide sequence in which one or more amino acid or nucleotide residues, respectively, are absent relative to the reference sequence.

"Insertion" or "addition," as used herein, refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid or nucleotide residues, respectively, as compared to the reference sequence.

25 "Substitution," as used herein, refers to the replacement of one or more amino acids or nucleotides by one or more different amino acids or nucleotides, respectively, in a reference sequence.

30 "Isolated," as used herein refers to material, such as a nucleic acid or a polypeptide, which is: (1) substantially or essentially free from components which normally accompany or interact with it as found in its naturally occurring environment. Although, the isolated material optionally comprises material not found with the material in its natural environment; or (2) if the material is in its

natural environment, the material has been synthetically (non-naturally) altered by deliberate human intervention to a composition and/or placed at a locus in the cell (e.g., genome or subcellular organelle) not native to a material found in that environment. The alteration to yield the synthetic material can be performed on
5 the material within or removed from its natural state.

Characterizing Mutant Na_v1.7 Nucleic Acid Sequences

It has been found that, in certain neurologic disorders, specific sites in the Na_v1.7 gene are mutated, *i.e.*, the nucleotide at a specific position or at specific positions differs from that observed in the most commonly found Na_v1.7 gene
10 sequence. Accordingly, disclosed herein are methods of characterizing mutant nucleic acid sequences that encode a Na_v1.7 sodium channel alpha-subunit and the use of such nucleic acids to diagnose and treat disease states and neurologic disorders, such as seizures.

In one aspect, disclosed herein is a method of characterizing a nucleic acid
15 sequence that encodes a Na_v1.7 sodium channel alpha-subunit, comprising the step of identifying mutations at one or more sites in regions of the nucleic acid sequence that encode various regions of the Na_v1.7 sodium channel alpha-subunit. While mutations can be present in any region of the Na_v1.7 nucleic acid sequence, specific regions of the nucleic acid sequence where mutations can be identified
20 include, but are not limited to, those regions that encode an intracellular N-terminal region, an extracellular loop in domain I, an intracellular loop between domains I and II, an intracellular loop between domains II and III, an intramembrane region of domain II, or any combination thereof. Such identified nucleotides can indicate the character of the nucleic acid sequence.

25 The terms "mutation" and "mutant," as used herein, mean that, at one or more specific positions in a nucleic acid or amino acid sequence, a nucleotide or amino acid that differs from the most commonly found nucleotide or amino acid can be identified. A mutation includes deletions, additions, insertions, and substitutions in the nucleotide or amino acid sequence. For example, in one
30 particular mutant Na_v1.7 nucleic acid sequence disclosed herein, position 184 of the nucleic acid sequence contains a substitution; that is, the most commonly found nucleotide at position 184 of the Na_v1.7 gene is A, whereas in the mutant

Na_v1.7 nucleic acid sequence, the nucleotide found at position 184, *i.e.*, the mutated site, is G. One of skill in the art can analyze position 184 and determine which of the two amino acids (A or G) is present. As another example, in one particular mutant Na_v1.7 sodium channel alpha-subunit disclosed herein, position 5 62 of the amino acid sequence contains a substitution; that is, the most commonly found amino acid at position 62 of the Na_v1.7 amino acid sequence is isoleucine, whereas in the mutant Na_v1.7 amino acid sequence, the amino acid found at position 62, *i.e.*, the mutated site, is valine. Also, one of skill in the art can analyze position 62 of the amino acid sequence and determine which of the two 10 amino acids (isoleucine or valine) is present. Further, as used herein, "mutant" also includes combinations of mutations at more than one position in the Na_v1.7 nucleic acid or amino acid sequence. Mutations may provide functional differences in the genetic sequence, through changes in the encoded polypeptide, changes in mRNA stability, binding of transcriptional and translation factors to 15 the DNA or RNA, and the like. The mutations can also be used as single nucleotide or single amino acid mutations to detect genetic linkage to phenotypic variation in activity and expression of sodium channels.

As utilized herein, the "character" of the Na_v1.7 nucleic acid sequence can be the combination of nucleotides present at mutated sites that make up the Na_v1.7 20 sodium channel alpha-subunit haplotype as well as the biological activity associated with a particular mutation or combination of mutations.

In one specific aspect, a mutation can be present in the nucleic acid region encoding the intracellular *N*-terminus region of the Na_v1.7 sodium channel alpha-subunit. For example, such a mutation can be at the site that encodes amino acid 25 residue 62. The mutated site can be at position 184 of the Na_v1.7 nucleic acid sequence. In one particular aspect, the mutation can encode a valine at amino acid residue 62.

In another aspect, a mutation can be present in the nucleic acid region encoding the extracellular loop of domain I of the Na_v1.7 sodium channel alpha-subunit. For example, such a mutation can be at the site that encodes amino acid 30 residue 149. The mutated site can be at position 446 of the Na_v1.7 nucleic acid sequence. In one specific aspect, the mutation can encode a glutamine at amino acid residue 149.

In yet another aspect, mutations can be present in the nucleic acid region encoding the intracellular loop between domains I and II of the Na_v1.7 sodium channel alpha-subunit. For example, such mutations can be at sites that encode amino acid residue 641 and/or amino acid residue 655. The mutated sites can be
5 at positions 1921 and/or 1964 of the Na_v1.7 nucleic acid sequence. In one specific aspect, the mutation can encode a tyrosine at amino acid residue 641. In another aspect, the mutation can encode an arginine at amino acid residue 655.

In a further aspect, a mutation can be present in the nucleic acid region encoding the intramembrane region of domain II of the Na_v1.7 sodium channel
10 alpha-subunit. For example, such a mutation can be at the site that encodes amino acid residue 739. The mutated site can be at position 2215 of the Na_v1.7 nucleic acid sequence. In one specific aspect, the mutation can encode a valine at amino acid residue 739.

In still another aspect, a mutation can be present in the nucleic acid region
15 encoding the intracellular loop between domains II and III of the Na_v1.7 sodium channel alpha-subunit. For example, such a mutation can be at the site that encodes amino acid residue 1123. The mutated site can be at position 3369 of the Na_v1.7 nucleic acid sequence. In one specific aspect, the mutation can encode a phenylalanine at amino acid residue 1123.

20 Mutations can also be present in more than one region of the nucleic acid sequence, such as in regions that encode an intracellular *N*-terminal region and an extracellular loop in domain I; an intracellular *N*-terminal region and an intracellular loop between domains I and II; an intracellular *N*-terminal region and an intracellular loop between domains II and III; an intracellular *N*-terminal region
25 and an intramembrane region of domain II; an extracellular loop in domain I and an intracellular loop between domains I and II; an extracellular loop in domain I and an intracellular loop between domains II and III; an extracellular loop in domain I and an intramembrane region of domain II; an intracellular loop between domains I and II and an intracellular loop between domains II and III; an
30 intracellular loop between domains I and II and an intramembrane region of domain II; and an intracellular loop between domains II and III and an intramembrane region of domain II.

Some of the mutations that can be identified by the methods disclosed herein include, but are not limited to, mutations at positions 184, 446, 1921, 1964, 2215, 3369, or any combination thereof, of the Na_v1.7 nucleic acid sequence. Any individual mutation can be analyzed at any of these positions, or combinations of
5 mutant variants at more than one position can be identified and analyzed by the methods disclosed herein.

A number of methods are available for analyzing nucleic acids for the presence of a specific sequence. For all of the methods described herein, genomic DNA can be extracted from a sample and this sample can be from any organism
10 and can be, but is not limited to, peripheral blood, bone marrow specimens, primary tumors, embedded tissue sections, frozen tissue sections, cell preparations, cytological preparations, exfoliate samples (e.g., sputum), fine needle aspirations, amnion cells, fresh tissue, dry tissue, and cultured cells or tissue. Such samples can be obtained directly from a subject, commercially
15 obtained or obtained via other means. Thus, the methods described herein can be utilized to analyze a nucleic acid sample that comprises genomic DNA, amplified DNA (such as a PCR product), cDNA, cRNA, a restriction fragment or any other desired nucleic acid sample. When one performs one of the herein described methods on genomic DNA, typically the genomic DNA will be treated in a
20 manner to reduce viscosity of the DNA and allow better contact of a primer or probe with the target region of the genomic DNA. Such reduction in viscosity can be achieved by any desired methods, which are known to the skilled artisan, such as DNase treatment or shearing of the genomic DNA, preferably lightly.

If sufficient DNA is available, genomic DNA can be used directly.
25 Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. The nucleic acid may be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see the publication entitled
30 "PCR Methods and Applications" (1991, Cold Spring Harbor Laboratory Press), which is incorporated herein by reference in its entirety for amplification methods. In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample

along with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are extended. Thereafter,
5 another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between the primer sites. PCR has further been described in several patents including U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,965,188. Each of these publications is incorporated herein by reference in its entirety for
10 PCR methods. One of skill in the art would know how to design and synthesize primers flanking any of the nucleic acid sequences disclosed herein.

For example, the disclosed method provides primers
GTCCCGCCCCATTGCCTGACAC (SEQ ID NO: 20) and
TTCTGGTCATGATATGGTTATTCAC (SEQ ID NO: 21), which can be utilized
15 to amplify the region of the Na_v1.7 nucleic acid sequence comprising nucleotide position 184 in order to identify a mutation at this site. The disclosed method also provides primers TGATAGATGCGTTGATGACATTGG (SEQ ID NO: 22) and TTCATAAATGCAGTAACTTCCTGG (SEQ ID NO: 23), which can be utilized
20 to amplify the region of the Na_v1.7 nucleic acid sequence comprising nucleotide position 446 in order to identify a mutation at this site. Also, the disclosed method provides primers TGTTTCTTTTAAGTCAGTACAGAG (SEQ ID NO: 24) and AGAGCCATTACAAAGACCAGAG (SEQ ID NO: 25), which can be utilized to amplify the region of the Na_v1.7 nucleic acid sequence comprising
25 nucleotide position 1921 in order to identify a mutation at this site. Additionally, the disclosed method provides primers ACTCAGAAAGGCAGAGAGGTG (SEQ ID NO: 26) and TTGCCATGTTATCAATGTCTGTG (SEQ ID NO: 27), which can be utilized to amplify the region of the Na_v1.7 nucleic acid sequence comprising nucleotide position 1964 in order to identify a mutation at this site. Further, the disclosed method provides primers
30 GACTGATTTGTATCTGGTTAGGAG (SEQ ID NO: 28) and GCAATGTAATTAGGAAGGTGTGAG (SEQ ID NO: 29), which can be utilized to amplify the region of the Na_v1.7 nucleic acid sequence comprising nucleotide position 2215 in order to identify a mutation at this site. For example, the

disclosed method provides primers TTTGAATGAACTCTAAATGAACTACC (SEQ ID NO: 30) and TAAGTATTAGGCGTTAAGACAAACC (SEQ ID NO: 31), which can be utilized to amplify the region of the Na_v1.7 nucleic acid sequence comprising nucleotide position 3369 in order to identify a mutation at this site. One of skill in the art would know how to design primers accordingly to amplify any region of the Na_v1.7 nucleic acid sequence for the purposes of identifying a mutation at any nucleotide position throughout the Na_v1.7 sodium channel alpha-subunit sequence. Amplification may also be used to determine whether a mutation is present by using a primer that is specific for the mutation.

Various methods are known in the art that utilize oligonucleotide ligation as a means of detecting mutations, for examples see Riley, *et al.* (1990) Nucleic Acids Res 18:2887-2890; and Delahunty, *et al.* (1996) Am J Hum Genet 58:1239-1246, which are incorporated herein by reference in their entirety for methods of detecting mutations. Such methods include single base chain extension (SBCE), oligonucleotide ligation assay (OLA) and cleavase reaction/signal release (Invader methods, Third Wave Technologies).

LCR and Gap LCR are exponential amplification techniques. Both depend on DNA ligase to join adjacent primers annealed to a DNA molecule. In Ligase Chain Reaction (LCR), probe pairs are used which include two primary (first and second) and two secondary (third and fourth) probes, all of which are employed in molar excess to target. The first probe hybridizes to a first segment of the target strand and the second probe hybridizes to a second segment of the target strand, the first and second segments being contiguous so that the primary probes abut one another in 5'-phosphate-3'-hydroxyl relationship, and so that a ligase can covalently fuse or ligate the two probes into a fused product. In addition, a third (secondary) probe can hybridize to a portion of the first probe and a fourth (secondary) probe can hybridize to a portion of the second probe in a similar abutting fashion. Of course, if the target is initially double stranded, the secondary probes also will hybridize to the target complement in the first instance. Once the ligated strand of primary probes is separated from the target strand, it will hybridize with the third and fourth probes, which can be ligated to form a complementary, secondary ligated product. It is important to realize that the ligated products are functionally equivalent to either the target or its complement.

By repeated cycles of hybridization and ligation, amplification of the target sequence is achieved. A method for multiplex LCR has also been described (WO 9320227, which is incorporated herein by reference in its entirety for the methods taught therein). Gap LCR (GLCR) is a version of LCR where the probes are not
5 adjacent but are separated by 2 to 3 bases.

A method for typing single nucleotide mutations in DNA, labeled Genetic Bit Analysis (GBA), has been described in Nikiforov, *et al.* (1994) Nucleic Acid Res 22:4167-4175. In this method, specific fragments of genomic DNA containing the mutated site(s) are first amplified by the polymerase chain reaction
10 (PCR) using one regular and one phosphorothioate-modified primer. The double-stranded PCR product is rendered single-stranded by treatment with the enzyme T7 gene 6 exonuclease, and captured onto individual wells of a 96 well polystyrene plate by hybridization to an immobilized oligonucleotide primer. This primer is designed to hybridize to the single-stranded target DNA
15 immediately adjacent from the mutated site of interest. Using the Klenow fragment of *E. coli* DNA polymerase I or the modified T7 DNA polymerase (Sequenase), the 3' end of the capture oligonucleotide is extended by one base using a mixture of one biotin-labeled, one fluorescein-labeled, and two unlabeled dideoxynucleoside triphosphates. Antibody conjugates of alkaline phosphatase
20 and horseradish peroxidase are then used to determine the nature of the extended base in an ELISA format. Additionally, minisequencing with immobilized primers has been utilized for detection of mutations in PCR products (*see* Pastinen, *et al.* (1997) Genome Res 7:606-614).

The effect of phosphorothioate bonds on the hydrolytic activity of the 5'--
25 >3' double-strand-specific T7 gene 6 exonuclease is used in order to improve upon GBA. The use of phosphorothioate primers and exonuclease hydrolysis for the preparation of single-stranded PCR products and their detection by solid-phase hybridization can be used. (*See* Nikiforov, *et al.* (1994) PCR Methods and Applications 3:285-291.) Double-stranded DNA substrates containing one
30 phosphorothioate residue at the 5' end were found to be hydrolyzed by this enzyme as efficiently as unmodified ones. The enzyme activity was, however, completely inhibited by the presence of four phosphorothioates. On the basis of these results, a method for the conversion of double-stranded PCR products into

full-length, single-stranded DNA fragments was developed. In this method, one of the PCR primers contains four phosphorothioates at its 5' end, and the opposite strand primer is unmodified. Following the amplification, the double-stranded product is treated with T7 gene 6 exonuclease. The phosphorothioated strand is
5 protected from the action of this enzyme, whereas the opposite strand is hydrolyzed. When the phosphorothioated PCR primer is 5' biotinylated, the single-stranded PCR product can be easily detected colorimetrically after hybridization to an oligonucleotide probe immobilized on a microtiter plate. A simple and efficient method for the immobilization of relatively short
10 oligonucleotides to microtiter plates with a hydrophilic surface in the presence of salt can be used.

DNA analysis based on template hybridization (or hybridization plus enzymatic processing) to an array of surface-bound oligonucleotides is well suited for high density, parallel, low cost and automatable processing (Ives, *et al.* (1996)
15 Proc SPIE-Int Soc Opt Eng 2680 (Ultrasensitive Biochemical Diagnostics) 258-269). Direct fluorescence detection of labeled DNA provides the benefits of linearity, large dynamic range, multianalyte detection, processing simplicity and safe handling at reasonable cost. The Molecular Tool Corporation has applied a proprietary enzymatic method of solid phase genotyping to DNA processing in
20 96-well plates and glass microscope slides. Detecting the fluor-labeled GBA dideoxynucleotides requires a detection limit of approximately 100 mols/ μm^2 . Commercially available plate readers detect about 1000 mols/ μm^2 , and an experimental setup with an argon laser and thermoelectrically-cooled CCD can detect approximately 1 order of magnitude less signal. The current limit is due to
25 glass fluorescence. Dideoxynucleotides labeled with fluorescein, eosin, tetramethylrhodamine, Lissamine and Texas Red have been characterized, and photobleaching, quenching and indirect detection with fluorogenic substrates have been investigated.

Other amplification techniques that can be used in the context of the
30 present invention include, but are not limited to, Q-beta amplification as described in European Patent Application No 4544610, strand displacement amplification as described in EP 684 315A and, target mediated amplification as described in PCT Publication WO 9322461, the disclosures of which are incorporated herein by

reference in their entirety for the methods taught therein.

Allele specific amplification can also be utilized for biallelic markers. Discrimination between the two alleles of a biallelic marker can also be achieved by allele specific amplification, a selective strategy, whereby one of the alleles is amplified without amplification of the other allele. For allele specific amplification, at least one member of the pair of primers is sufficiently complementary with a region of a reference sequence (*i.e.*, Na_v1.7) comprising the polymorphic base of a biallelic marker of the present invention to hybridize therewith. Such primers are able to discriminate between the two alleles of a biallelic marker. This can be accomplished by placing the mutated base at the 3' end of one of the amplification primers. Such allele specific primers tend to selectively prime an amplification or sequencing reaction so long as they are used with a nucleic acid sample that contains one of the two alleles present at a biallelic marker because the extension forms from the 3' end of the primer, a mismatch at or near this position has an inhibitory effect on amplification. Therefore, under appropriate amplification conditions, these primers only direct amplification on their complementary allele. Determining the precise location of the mismatch and the corresponding assay conditions are well within the ordinary skill in the art.

A detectable label may be included in an amplification reaction. Suitable labels include fluorochromes, *e.g.*, fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or *N,N,N',N'*-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, *e.g.*, ³²P, ³⁵S, ³H; etc. The label may be a two stage system, where the amplified DNA is conjugated to biotin, haptens, etc. having a high affinity binding partner, *e.g.*, avidin, specific antibodies, etc., where the binding partner is conjugated to a detectable label. The label may be conjugated to one or both of the primers. Alternatively, the pool of nucleotides used in the amplification is labeled, so as to incorporate the label into the amplification product.

The sample nucleic acid, *e.g.*, amplified or cloned fragment, can be analyzed by one of a number of methods known in the art. The nucleic acid can

be sequenced by dideoxy or other methods. Hybridization with the variant sequence can also be used to determine its presence, by Southern blots, dot blots, etc. The hybridization pattern of a control (reference) and variant sequence to an array of oligonucleotide probes immobilized on a solid support, as described in

5 U.S. Pat. No. 5,445,934 and WO 95/35505, which are incorporated herein by reference in their entirety for the methods, may also be used as a means of detecting the presence of variant sequences. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), mismatch cleavage detection, and heteroduplex analysis in gel matrices are used

10 to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a mutation creates or destroys a recognition site for a restriction endonuclease (restriction fragment length polymorphism, RFLP), the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested.

15 Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

The disclosed materials, compositions, and methods also provide the use of the nucleic acid sequences described herein in methods using a mobile solid support to analyze mutations. *See*, for example, WO 01/48244, which is

20 incorporated herein by reference in its entirety for the methods taught therein.

The method of performing a Luminex FlowMetrix-based SNP analysis involves differential hybridization of a PCR product to two differently-colored FACS-analyzable beads. The FlowMetrix system currently consists of uniformly-sized 5 micron polystyrene-divinylbenzene beads stained in eight concentrations

25 of two dyes (orange and red). The matrix of the two dyes in eight concentrations allows for 64 differently-colored beads that can each be differentiated by a FACScalibur suitably modified with the Luminex PC computer board. In the Luminex SNP analysis, covalently-linked to a bead is a short (approximately 18-20 bases) "target" oligodeoxynucleotide (oligo). The nucleotide positioned at the

30 center of the target oligo encodes the polymorphic base. A pair of beads are synthesized; each bead of the pair has attached to it one of the polymorphic oligonucleotides. A PCR of the region of DNA surrounding the to-be analyzed SNP is performed to generate a PCR product. Conditions are established that

allow hybridization of the PCR product preferentially to the bead on which is encoded the precise complement. In one format ("without competitor"), the PCR product itself incorporates a fluorescein dye and it is the gain of the fluorescein stain on the bead, as measured during the FACScalibur run, that indicates hybridization. In a second format ("with competitor,"), the beads are hybridized with a competitor to the PCR product. The competitor itself in this case is labeled with fluorescein. And it is the loss of the fluorescein by displacement by unlabeled PCR product that indicates successful hybridization.

Isolated Na_v1.7 Nucleic Acid Sequences

The nucleic acid sequences disclosed herein can be isolated by methods known in the art and described herein. In one aspect, disclosed herein are isolated nucleic acids comprising nucleotide sequences encoding mutant Na_v1.7 sodium channel alpha-subunits. For example, in one aspect, disclosed herein is an isolated nucleic acid sequence comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2. In another aspect, disclosed herein is an isolated nucleic acid sequence comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3. In yet another aspect, disclosed herein is an isolated nucleic acid sequence comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 4. In a further aspect, disclosed herein is an isolated nucleic acid sequence comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 5. In a still further aspect, disclosed herein is an isolated nucleic acid sequence comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 6. In one aspect, disclosed herein is an isolated nucleic acid sequence comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 7.

Also, disclosed herein is an isolated nucleic acid comprising a nucleotide sequence encoding at least 5 contiguous residues of the Na_v1.7 sodium channel alpha-subunit. For example, in one aspect, disclosed herein is an isolated nucleic acid comprising a nucleotide sequence encoding at least 5 contiguous residues of the amino acid sequence of SEQ ID NO: 2, wherein one of the amino acid residues comprises a valine in a position that corresponds to position 62 in SEQ ID NO: 2. In another aspect, disclosed herein is an isolated nucleic acid comprising a nucleotide sequence encoding at least 5 contiguous residues of the

amino acid sequence of SEQ ID NO: 3, wherein one of the amino acid residues comprises a glutamine in a position that corresponds to position 149 in SEQ ID NO: 3. In yet another aspect, disclosed herein is an isolated nucleic acid comprising a nucleotide sequence encoding at least 5 contiguous residues of the amino acid sequence of SEQ ID NO: 4, wherein one of the amino acid residues comprises a tyrosine in a position that corresponds to position 641 in SEQ ID NO: 4. In a further aspect, disclosed herein is an isolated nucleic acid comprising a nucleotide sequence encoding at least 5 contiguous residues of the amino acid sequence of SEQ ID NO: 5, wherein one of the amino acid residues comprises a arginine in a position that corresponds to position 655 in SEQ ID NO: 5. In a still further aspect, disclosed herein is an isolated nucleic acid comprising a nucleotide sequence encoding at least 5 contiguous residues of the amino acid sequence of SEQ ID NO: 6, wherein one of the amino acid residues comprises a valine in a position that corresponds to position 739 in SEQ ID NO: 6. In one aspect, disclosed herein is an isolated nucleic acid comprising a nucleotide sequence encoding at least 5 contiguous residues of the amino acid sequence of SEQ ID NO: 7, wherein one of the amino acid residues comprises a phenylalanine in a position that corresponds to position 1123 in SEQ ID NO: 7.

Reference Nucleic Acid Sequences

Reference sequences of the Na_v1.7 gene comprising the most commonly found allele are provided herein. As utilized herein, “reference sequence” refers to a nucleic acid sequence that encodes a Na_v1.7 sodium channel alpha-subunit or fragment thereof comprising a specific nucleotide at a particular position(s) in the Na_v1.7 nucleic acid sequence. Optionally, the reference sequence comprises the most commonly found nucleotide or allele at the particular position or positions. This reference sequence can be a full-length Na_v1.7 nucleic acid sequence or fragments thereof. An example of a full-length human Na_v1.7 nucleic acid sequence is provided herein as SEQ ID NO: 1.

The term “wild-type” may also be used to refer to the reference sequence comprising the most commonly found allele. It will be understood by one of skill in the art that the designation as “wild-type” is merely a convenient label for a common allele and should not be construed as conferring any particular property on that form of the sequence.

Alternatively, one of skill in the art can utilize a reference sequence or a fragment thereof comprising a nucleotide or allele that is not the most commonly found nucleotide or allele at a specific nucleotide position(s) in the Na_v1.7 nucleic acid sequence or can utilize a reference sequence that comprises alternative nucleotides at a specific position(s). An example of a full-length Na_v1.7 nucleic acid sequence that comprises such an alternative nucleotide at position 184 is provided herein as SEQ ID NO: 8. Therefore, when utilizing this reference sequence or a fragment thereof, the nucleotide at position 184 can be A or G. Other examples of full-length Na_v1.7 reference sequences that comprise such alternative nucleotides at positions 446, 1921, 1964, 2215, and 3369 are provided herein as SEQ ID NO's: 9, 10, 11, 12, and 13, respectively. Therefore, when utilizing these reference sequences or fragments thereof, respectively, the nucleotide at position 446 can be C or A, the nucleotide at position 1921 can be A or T, the nucleotide at position 1964 can be position A or G, the nucleotide at position 2215 can be A or T, and the nucleotide at position 3369 can be G or T.

In one aspect, the reference sequence can comprise a fragment of the Na_v1.7 nucleic acid sequence. For example, disclosed herein is a reference sequence comprising the nucleotide sequence GCCCTTCATCTATGG (SEQ ID NO: 14), corresponding to nucleotides 177 to 191 of the Na_v1.7 gene sequence. This reference sequence has an "A" at position 184, which is the most commonly found nucleotide at this position. Therefore, one of skill in the art can compare this reference sequence to a test sequence and determine if the most commonly found nucleotide (A) is present at position 184 of the test sequence or if another nucleotide (G) is present at position 184 of the test sequence. Also provided are nucleotide sequence corresponding to any fragment of SEQ ID NO: 14 that includes the A at position 184 or the corresponding sequence with a G at position 184.

As another example, disclosed herein is a reference sequence comprising the nucleotide sequence AACCCGCCGACTGG (SEQ ID NO: 15), corresponding to nucleotides 439 to 453 of the Na_v1.7 gene sequence. This reference sequence has a "C" at position 446, which is the most commonly found nucleotide at this position. Therefore, one of skill in the art can compare this reference sequence to a test sequence and determine if the most commonly found

nucleotide (C) is present at position 446 of the test sequence or if another nucleotide (A) is present at position 446 of the test sequence. Also provided are nucleotide sequence corresponding to any fragment of SEQ ID NO: 15 that includes the C at position 446 or the corresponding sequence with a A at position
5 446.

Also, disclosed herein is a reference sequence comprising the nucleotide sequence GCTCCCAATGGACA (SEQ ID NO: 16), corresponding to nucleotides 1914 to 1928 of the Na_v1.7 gene sequence. This reference sequence has an "A" at position 1921, which is the most commonly found nucleotide at this
10 position. Therefore, one of skill in the art can compare this reference sequence to a test sequence and determine if the most commonly found nucleotide (A) is present at position 1921 of the test sequence or if another nucleotide (G) is present at position 1921 of the test sequence. Also provided are nucleotide sequence corresponding to any fragment of SEQ ID NO: 16 that includes the A at position
15 1921 or the corresponding sequence with a G at position 1921.

Further, disclosed herein is a reference sequence comprising the nucleotide sequence ATACACAAGAAAAGG (SEQ ID NO: 17), corresponding to nucleotides 1956 to 1971 of the Na_v1.7 gene sequence. This reference sequence has an "A" at position 1964, which is the most commonly found nucleotide at this
20 position. Therefore, one of skill in the art can compare this reference sequence to a test sequence and determine if the most commonly found nucleotide (A) is present at position 1964 of the test sequence or if another nucleotide (G) is present at position 1964 of the test sequence. Also provided are nucleotide sequence corresponding to any fragment of SEQ ID NO: 17 that includes the A at position
25 1964 or the corresponding sequence with a G at position 1964.

In yet another example, disclosed herein is a reference sequence comprising the nucleotide sequence TCTTGCAATTACCAT (SEQ ID NO: 18), corresponding to nucleotides 2208 to 2222 of the Na_v1.7 gene sequence. This reference sequence has an "A" at position 2215, which is the most commonly
30 found nucleotide at this position. Therefore, one of skill in the art can compare this reference sequence to a test sequence and determine if the most commonly found nucleotide (A) is present at position 2215 of the test sequence or if another nucleotide (G) is present at position 2215 of the test sequence. Also provided are

nucleotide sequence corresponding to any fragment of SEQ ID NO: 18 that includes the A at position 2215 or the corresponding sequence with a G at position 2215.

5 In still another example, disclosed herein is a reference sequence comprising the nucleotide sequence ACCCTTTGCCTGGAG (SEQ ID NO: 19), corresponding to nucleotides 3362 to 3376 of the Na_v1.7 gene sequence. This reference sequence has a "G" at position 3369, which is the most commonly found nucleotide at this position. Therefore, one of skill in the art can compare this reference sequence to a test sequence and determine if the most commonly found
10 nucleotide (G) is present at position 3369 of the test sequence or if another nucleotide (T) is present at position 3369 of the test sequence. Also provided are nucleotide sequence corresponding to any fragment of SEQ ID NO: 19 that includes the G at position 3369 or the corresponding sequence with a T at position 3369.

15 **Probes and Primers**

Nucleic acids of interest comprising the mutations provided herein can be utilized as probes or primers. The complementary sequences of the Na_v1.7 nucleic acid sequences disclosed herein are also provided. For the most part, the nucleic acid fragments will be of at least about 15 nucleotides, usually at least
20 about 20 nucleotides, often at least about 50 nucleotides. Such fragments are useful as primers for PCR, hybridization screening, etc. Larger nucleic acid fragments, for example, greater than about 100 nucleotides are useful for production of promoter fragments, motifs, etc. For use in amplification reactions, such as PCR, a pair of primers will be used. The exact composition of primer
25 sequences is not critical to the invention, but for most applications the primers will hybridize to the subject sequence under stringent conditions, as known in the art.

"Probes," as used herein, are molecules capable of interacting with a target nucleic acid, typically in a sequence specific manner, for example, through hybridization. The hybridization of nucleic acids is well understood in the art and
30 is discussed herein. Typically, a probe can be made from any combination of nucleotides or nucleotide derivatives or analogs available in the art.

By "hybridizing under stringent conditions" or "hybridizing under highly

stringent conditions” is meant that the hybridizing portion of the hybridizing nucleic acid, typically comprising at least 15 (*e.g.*, 20, 25, 30, or 50 nucleotides), hybridizes to all or a portion of the provided nucleotide sequence under stringent conditions. The term “hybridization” typically means a sequence driven

5 interaction between at least two nucleic acid molecules, such as a primer or a probe and a gene. Sequence driven interaction means an interaction that occurs between two nucleotides or nucleotide analogs or nucleotide derivatives in a nucleotide specific manner. For example, G interacting with C or A interacting with T are sequence driven interactions. Typically sequence driven interactions

10 occur on the Watson-Crick face or Hoogsteen face of the nucleotide. The hybridization of two nucleic acids is affected by a number of conditions and parameters known to those of skill in the art. For example, the salt concentrations, pH, and temperature of the reaction all affect whether two nucleic acid molecules will hybridize. Generally, the hybridizing portion of the hybridizing nucleic acid

15 is at least 80%, for example, at least 90%, 95%, or 98%, identical to the sequence of or a portion of the Na_v1.7 nucleic acid of the invention, or its complement. Hybridizing nucleic acids of the invention can be used, for example, as a cloning probe, a primer (*e.g.*, for PCR), a diagnostic probe, or an antisense probe.

Hybridization of the oligonucleotide probe to a nucleic acid sample typically is

20 performed under stringent conditions. Nucleic acid duplex or hybrid stability is expressed as the melting temperature or T_m , which is the temperature at which a probe dissociates from a target DNA. This melting temperature is used to define the required stringency conditions. If sequences are to be identified that are related and substantially identical to the probe, rather than identical, then it is

25 useful to first establish the lowest temperature at which only homologous hybridization occurs with a particular concentration of salt (*e.g.*, SSC or SSPE). Assuming that a 1% mismatch results in a 1°C decrease in the T_m , the temperature of the final wash in the hybridization reaction is reduced accordingly (for example, if sequence having >95% identity with the probe are sought, the final

30 wash temperature is decreased by 5°C). In practice, the change in T_m can be between 0.5°C and 1.5°C per 1% mismatch. Stringent conditions involve hybridizing at 68°C in 5x SSC/5x Denhardt’s solution/1.0% SDS, and washing in 0.2x SSC/0.1% SDS at room temperature. Moderately stringent conditions include washing in 3x SSC at 42°C. The parameters of salt concentration and

temperature can be varied to achieve the optimal level of identity between the probe and the target nucleic acid. Additional guidance regarding such conditions is readily available in the art, for example, in Sambrook, *et al.*, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, New York, N.Y. (1989) ; and Ausubel, *et al.*, eds., Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., at Unit 2.10 (1995).

Synthetic analogs of nucleic acids may be preferred for use as probes because of superior stability under assay conditions. Modifications in the native structure, including alterations in the backbone, sugars or heterocyclic bases, have been shown to increase intracellular stability and binding affinity. Among useful changes in the backbone chemistry are phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are substituted with sulfur; phosphoroamidites; alkyl phosphotriesters and boranophosphates. Achiral phosphate derivatives include 3'-O'-5'-S-phosphorothioate, 3'-S-5'-O-phosphorothioate, 3'-CH₂-5'-O-phosphonate and 3'-NH-5'-O-phosphoroamidate. Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage.

Sugar modifications are also used to enhance stability and affinity. The alpha-anomer of deoxyribose may be used, where the base is inverted with respect to the natural beta-anomer. The 2'-OH of the ribose sugar may be altered to form 2'-O-methyl or 2'-O-allyl sugars, which provides resistance to degradation without compromising affinity.

Modification of the heterocyclic bases must maintain proper base pairing. Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2'-deoxycytidine and 5-bromo-2'-deoxycytidine for deoxycytidine. 5-propynyl-2'-deoxyuridine and 5-propynyl-2'-deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.

In one aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence encoding an amino acid sequence of a mutated Na_v1.7 sodium channel alpha-subunit but not to a nucleic acid sequence that encodes the

amino acid sequence of the wild-type Na_v1.7 sodium channel alpha-subunit. For example, in one aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2 but not to the nucleic acid sequence that encodes SEQ ID NO: 38. In another aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 but not to the nucleic acid sequence that encodes SEQ ID NO: 38. In yet another aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 4 but not to the nucleic acid sequence that encodes SEQ ID NO: 38. In an further aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 5 but not to the nucleic acid sequence that encodes SEQ ID NO: 38. In a still further aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 6 but not to the nucleic acid sequence that encodes SEQ ID NO: 38. In one aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 7 but not to the nucleic acid sequence that encodes SEQ ID NO: 38.

In another aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a mutated Na_v1.7 nucleic acid sequence or a fragment thereof but not to a wild-type Na_v1.7 nucleic acid sequence. For example, in one aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid sequence of SEQ ID NO: 8, or a fragment thereof, such as SEQ ID NO: 14, but not to the nucleic acid sequence of SEQ ID NO: 1. In another aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid of SEQ ID NO: 9, or a fragment thereof,

such as SEQ ID NO: 15, but not to the nucleic acid sequence of SEQ ID NO: 1. In yet another aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid sequence of SEQ ID NO: 10, or a fragment thereof, such as SEQ ID NO: 16, but not to the
5 nucleic acid sequence of SEQ ID NO: 1. In an further aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid sequence of SEQ ID NO: 11, or a fragment thereof, such as SEQ ID NO: 17, but not to the nucleic acid sequence of SEQ ID NO: 1. In a still further aspect, disclosed herein are isolated nucleic acids comprising a
10 sequence that hybridizes under stringent conditions to a nucleic acid sequence of SEQ ID NO: 12, or a fragment thereof, such as SEQ ID NO: 18, but not to the nucleic acid sequence of SEQ ID NO: 1. In one aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid sequence of SEQ ID NO: 13, or a fragment thereof,
15 such as SEQ ID NO: 19, but not to the nucleic acid sequence of SEQ ID NO: 1.

In yet another aspect, disclosed herein are isolated nucleic acids encoding mutant Na_v1.7 sodium channels comprising a sequence that hybridizes under stringent conditions to a mutated Na_v1.7 nucleic acid comprising a nucleotide sequence encoding an amino acid sequence of sodium channel alpha-subunit but
20 not to a wild-type Na_v1.7 nucleic acid sequence. For example, in one aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2 but not to the nucleic acid sequence of SEQ ID NO: 1. In another aspect, disclosed herein are isolated
25 nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 but not to the nucleic acid sequence of SEQ ID NO: 1. In yet another aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a
30 nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 4 but not to the nucleic acid sequence of SEQ ID NO: 1. In an further aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence encoding

the amino acid sequence of SEQ ID NO: 5 but not to the nucleic acid sequence of SEQ ID NO: 1. In a still further aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID
5 NO: 6 but not to the nucleic acid sequence of SEQ ID NO: 1. In one aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 7 but not to the nucleic acid sequence of SEQ ID NO: 1.

10 In a further aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a mutated Na_v1.7 nucleic acid sequence or a fragment thereof but not to the nucleic acid sequence that encodes SEQ ID NO: 38. For example, in one aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent
15 conditions to a nucleic acid sequence of SEQ ID NO: 8, or a fragment thereof, such as SEQ ID NO: 14, but not to the nucleic acid sequence that encodes SEQ ID NO: 38. In another aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid of SEQ ID NO: 9, or a fragment thereof, such as SEQ ID NO: 15, but not to the nucleic acid
20 sequence that encodes SEQ ID NO: 38. In yet another aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid sequence of SEQ ID NO: 10, or a fragment thereof, such as SEQ ID NO: 16, but not to the nucleic acid sequence that encodes SEQ ID NO: 38. In an further aspect, disclosed herein are isolated nucleic acids
25 comprising a sequence that hybridizes under stringent conditions to a nucleic acid sequence of SEQ ID NO: 11, or a fragment thereof, such as SEQ ID NO: 17, but not to the nucleic acid sequence that encodes SEQ ID NO: 38. In a still further aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid sequence of SEQ ID NO:
30 12, or a fragment thereof, such as SEQ ID NO: 18, but not to the nucleic acid sequence that encodes SEQ ID NO: 38. In one aspect, disclosed herein are isolated nucleic acids comprising a sequence that hybridizes under stringent conditions to a nucleic acid sequence of SEQ ID NO: 13, or a fragment thereof,

such as SEQ ID NO: 19, but not to the nucleic acid sequence that encodes SEQ ID NO: 38.

Arrays

The disclosed materials, compounds, and methods also provide an array of
5 oligonucleotides for identification of mutations, where discrete positions on the
array are complementary to one or more of the provided mutated sequences, *e.g.*
oligonucleotides of at least 12 nucleotides, frequently 15 nucleotides, 20
nucleotides, or larger, and including the sequence flanking the mutated position.
Such an array may comprise a series of oligonucleotides, each of which can
10 specifically hybridize to a different mutation of the disclosed compositions. An
array may comprise all or a subset of nucleic acid sequences having SEQ ID NOs:
8, 9, 10, 11, 12, and/or 13, or any fragment of at least 15 contiguous nucleotides
thereof, for example SEQ ID NOs: 14, 15, 16, 17, 18, and/or 19. Usually such an
array will include at least 2 different mutated sequences, *i.e.*, mutations located at
15 unique positions within the locus, and may include all of the provided mutations.
Therefore, the array can include wild-type sequences comprising the most
commonly found alleles. The array can optionally comprise the most commonly
found allele at a first, second, third, fourth, fifth, or more positions as well as other
nucleotides at each of these positions. Each oligonucleotide sequence on the array
20 will usually be at least about 12 nucleotides in length (*i.e.*, 10-15 nucleotides),
may be the length of the provided mutated sequences, or may extend into the
flanking regions to generate fragments of 100 to 200 nucleotides in length. For
examples of arrays, see Ramsay, (1998) *Nat Biotech* 16:4044; Hacia, *et al.* (1996)
Nature Genetics 14:441-447; Lockhart, *et al.* (1996) *Nature Biotechnol* 14:1675-
25 1680; and De Risi, *et al.* (1996) *Nature Genetics* 14:457-460, which are
incorporated by reference in their entirety for the methods of making and using
arrays.

Haplotyping

In another aspect, the disclosed materials, compositions, articles, devices,
30 and methods relate to a method for determining a Na_v1.7 haplotype in a human
subject, wherein the method comprises identifying one or more nucleotides
encoding amino acid residues 62, 149, 641, 655, 739, 1123, or any combination

thereof, wherein the nucleotide or nucleotides indicate the haplotype. The disclosed subject matter also provides a method for determining a Na_v1.7 haplotype in a human subject comprising identifying one or more nucleotides present at one or more of sites 184, 446, 1921, 1964, 2215, or 3369, in either or
 5 both copies of the Na_v1.7 gene contained in the subject genomic nucleic acid, wherein the nucleotide present at the mutated site or sites indicates the Na_v1.7 haplotype. It will be recognized by one of skill in the art that numerous haplotypes are possible.

For example, one of skill in the art could identify the nucleotide present in
 10 either or both copies of the Na_v1.7 gene contained in the subject genomic nucleic acid that encodes for amino acid 62 in the Na_v1.7 sodium channel alpha-subunit sequence. The haplotypes for this particular analysis can be I62V, P149Q, N641Y, K655R, I739V, L1123F, or any combination thereof, where the number indicates a position in the Na_v1.7 sodium channel alpha-subunit, the first letter
 15 represents the most common amino acid found at that positions, and the last letter represents the amino acid found in the haplotype. Similarly, one of skill in the art could identify the nucleotide in a Na_v1.7 nucleic acid sequence at position 184, 446, 1921, 1964, 2215, and/or 3369, and determine the Na_v1.7 haplotype. Therefore, any of positions 184, 446, 1921, 1964, 2215, and/or 3369 in the nucleic
 20 acid sequence or positions 62, 149, 641, 655, 739, and/or 1123 in the encoded amino acid sequence can be analyzed individually or in combination to obtain the haplotypes of the disclosed subject matter.

Determining a Predisposition

Disclosed herein is a method for determining a subject's predisposition to
 25 a neurologic disorder associated with a sodium channel mutation comprising comparing the subject's Na_v1.7 haplotype with one or more reference haplotypes that correlate with the neurologic disorder, a similar haplotype in the subject's Na_v1.7 haplotype as compared to the reference haplotype or haplotypes indicating a predisposition to the neurologic disorder.

30 As used herein, "neurologic disorder associated with a sodium channel mutation" includes, but is not limited to, seizure disorders (*e.g.*, febrile seizures, nonfebrile seizures, and epileptic seizures). As used herein "epileptic seizures"

includes, but is not limited to, partial (*e.g.*, simple and complex) and generalized (*e.g.*, absence, myoclonic, and tonic-clonic) seizures, temporal lobe epilepsy, and severe myoclonic epilepsy of infancy.

5 Each haplotype can be correlated with specific neurologic disorders or severity of such disorders to generate a database of reference haplotypes, such that one of skill in the art can compare a subject's haplotype to a reference haplotype or haplotypes and determine whether the subject is at risk for a neurologic disorder.

10 The reference haplotype can comprise nucleotides that encode one or more mutations in the Nav1.7 sodium channel alpha-subunit. For example, the reference haplotype can comprise nucleotides that encode one or more mutations at residue 62, residue 149, residue 641, residue 655, residue 739, or residue 1123 of the encoded amino acid sequence of Nav1.7.

15 Since subjects will vary depending on numerous parameters including, but not limited to, race, age, weight, medical history etc., as more information is gathered on populations, the database can contain haplotype information classified by race, age, weight, medical history etc., such that one of skill in the art can assess the subject's risk of developing neurologic disorders based on information more closely associated with the subject's demographic profile. Where there is a
20 differential distribution of a mutation by racial background or another parameter, guidelines for drug administration can be generally tailored to a particular group.

It will be appreciated by those skilled in the art that the nucleic acids provided herein as well as the nucleic acid and amino acid sequences identified from subjects can be stored, recorded, and manipulated on any medium which can
25 be read and accessed by a computer. As used herein, the words "recorded" and "stored" refer to a process for storing information on a computer medium. A skilled artisan can readily adopt any of the presently known methods for recording information on a computer readable medium to generate a list of sequences comprising one or more of the nucleic acids of the invention. Another aspect of
30 the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, 50, 100, 200, 250, 300, 400, 500, 1000, 2000, 3000, 4000 or 5000 nucleic acids of the invention or nucleic acid sequences identified

from subjects.

Computer readable media include magnetically readable media, optically readable media, electronically readable media and magnetic/optical media. For example, the computer readable media may be a hard disc, a floppy disc, a
5 magnetic tape, CD-ROM, DVD, RAM, or ROM as well as other types of other media known to those skilled in the art.

Embodiments of the present invention include systems, particularly computer systems which contain the sequence information described herein. As used herein, "a computer system" refers to the hardware components, software
10 components, and data storage components used to store and/or analyze the nucleotide sequences of the present invention or other sequences. The computer system preferably includes the computer readable media described above, and a processor for accessing and manipulating the sequence data.

Preferably, the computer is a general purpose system that comprises a
15 central processing unit (CPU), one or more data storage components for storing data, and one or more data retrieving devices for retrieving the data stored on the data storage components. A skilled artisan can readily appreciate that any one of the currently available computer systems are suitable.

In one particular aspect, the computer system includes a processor
20 connected to a bus which is connected to a main memory, preferably implemented as RAM, and one or more data storage devices, such as a hard drive and/or other computer readable media having data recorded thereon. In some embodiments, the computer system further includes one or more data retrieving devices for reading the data stored on the data storage components. The data retrieving
25 device may represent, for example, a floppy disk drive, a compact disk drive, a magnetic tape drive, a hard disk drive, a CD-ROM drive, a DVD drive, etc. In some embodiments, the data storage component is a removable computer-readable medium such as a floppy disk, a compact disk, a magnetic tape, etc. containing control logic and/or data recorded thereon. The computer system may
30 advantageously include or be programmed by appropriate software for reading the control logic and/or the data from the data storage component once inserted in the data retrieving device. Software for accessing and processing the nucleotide

sequences of the nucleic acids of the invention (such as search tools, compare tools, modeling tools, etc.) may reside in main memory during execution.

5 In some aspects, the computer system may further comprise a sequence comparer for comparing the nucleic acid sequences stored on a computer readable medium to another test sequence stored on a computer readable medium. A “sequence comparer” refers to one or more programs which are implemented on the computer system to compare a nucleotide sequence with other nucleotide sequences.

10 Accordingly, one aspect of the present invention is a computer system comprising a processor, a data storage device having stored thereon a nucleic acid of the invention, a data storage device having retrievably stored thereon reference nucleotide sequences to be compared with test or sample sequences and a sequence comparer for conducting the comparison. The sequence comparer may indicate a homology level between the sequences compared or identify a
15 difference between the two sequences. For example, a reference sequence comprising SEQ ID NO: 8 or any fragment thereof, such as SEQ ID NO: 14, can be compared with a test sequence from a subject to determine if the test sequence is the same as the reference sequence, *e.g.*, contains an A at position 184 or a different nucleotide (G).

20 Alternatively, the computer program may be a computer program which compares a test nucleotide sequence(s) from a subject or a plurality of subjects to a reference nucleotide sequence(s) in order to determine whether the test nucleotide sequence(s) differs from or is the same as a reference nucleic acid sequence(s) at one or more positions. Optionally such a program records the
25 length and identity of inserted, deleted or substituted nucleotides with respect to the sequence of either the reference polynucleotide or the test nucleotide sequence. In one embodiment, the computer program may be a program which determines whether the nucleotide sequences of the test nucleotide sequence contains one or more single nucleotide mutations with respect to a reference
30 nucleotide sequence. These single nucleotide mutations may each comprise a single base substitution, insertion, or deletion.

Accordingly, another aspect of the materials, compounds, articles, devices,

and methods disclosed herein is a method for determining whether a test nucleotide sequence differs at one or more nucleotides from a reference nucleotide sequence comprising the steps of reading the test nucleotide sequence and the reference nucleotide sequence through use of a computer program which identifies differences between nucleic acid sequences and identifying differences between the test nucleotide sequence and the reference nucleotide sequence with the computer program. The computer program can be a program which identifies single nucleotide polymorphisms. The method may be implemented by the computer systems described above. The method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30, 50, 100, or more test nucleotide sequences and the reference nucleotide sequences through the use of the computer program and identifying differences between the test nucleotide sequences and the reference nucleotide sequences with the computer program. A computer program that identifies single nucleotide mutations in a Na_v1.7 gene sequence and determines a subject's haplotype is also contemplated by the subject matter disclosed herein. The subject matter disclosed herein also provides for a computer program that correlates haplotypes with Na_v1.7 levels such that one of skill in the art can assess a subject's risk of developing a neurologic disorder, such as febrile seizures, nonfebrile seizures, or epileptic seizures. The computer program can optionally include treatment options or drug indications for subjects with haplotypes associated with increased risk of seizures.

The nucleic acids of the invention (both test nucleic acid sequences and reference nucleic acid sequences) may be stored and manipulated in a variety of data processor programs in a variety of formats. For example, they may be stored as text in a word processing file, such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE. In addition, many computer programs and databases may be used as sequence comparers, identifiers, or sources of reference nucleotide sequences. The following list is intended not to limit the invention but to provide guidance to programs and databases which are useful with the nucleic acid sequences of the invention. The programs and databases which may be used include, but are not limited to: MacPattern (EMBL), DiscoveryBase (Molecular Applications Group), GeneMine (Molecular

Applications Group), Look (Molecular Applications Group), MacLook (Molecular Applications Group), BLAST and BLAST2 (NCBI), BLASTN and BLASTX (Altschul, *et al.* (1990) J Mol Biol 3:403-410), FASTA (Pearson and Lipman, (1988) Proc Natl Acad Sci USA 85:2444-2448), FASTDB (Brutlag *et al.*,
5 (1990) Compt Appl Biosci 6:237-245), Catalyst (Molecular Simulations Inc.), Catalyst/SHAPE (Molecular Simulations Inc.), Cerius.sup.2.DBAccess (Molecular Simulations Inc.), HypoGen (Molecular Simulations Inc.), Insight II (Molecular Simulations Inc.), Discover (Molecular Simulations Inc.), CHARMm (Molecular Simulations Inc.), Felix (Molecular Simulations Inc.), DelPhi,
10 (Molecular Simulations Inc.), QuanteMM, (Molecular Simulations Inc.), Homology (Molecular Simulations Inc.), Modeler (Molecular Simulations Inc.), ISIS (Molecular Simulations Inc.), Quanta/Protein Design (Molecular Simulations Inc.), WebLab (Molecular Simulations Inc.), WebLab Diversity Explorer (Molecular Simulations Inc.), Gene Explorer (Molecular Simulations Inc.),
15 SeqFold (Molecular Simulations Inc.), the EMBL/Swissprotein database, the MDL Available Chemicals Directory database, the MDL Drug Data Report data base, the Comprehensive Medicinal Chemistry database, Derwents's World Drug Index database, the BioByteMasterFile database, the Genbank database, and the Genseqn database. Many other programs and data bases would be apparent.

20 **Delivery of the Na_v1.7 Nucleic Acid Sequence**

Optionally, the nucleic acids described herein are delivered to various expression systems. There are a number of compositions and methods which can be used to deliver nucleic acids to cells, either *in vitro* or *in vivo*. These methods and compositions can largely be broken down into two classes: viral based
25 delivery systems and non-viral based delivery systems. For example, the nucleic acids can be delivered through a number of direct delivery systems such as, electroporation, lipofection, calcium phosphate precipitation, plasmids, viral vectors, viral nucleic acids, phage nucleic acids, phages, cosmids, or via transfer of genetic material in cells or carriers such as cationic liposomes. Appropriate
30 means for transfection, including viral vectors, chemical transfectants, or physico-mechanical methods such as electroporation and direct diffusion of DNA, are described by, for example, Wolff, *et al.* (1990) Science 247:1465-1468; and Wolff, (1991) Nature 352:815-818. Such methods are well known in the art and

readily adaptable for use with the compositions and methods described herein. In certain cases, the methods will be modified to specifically function with large DNA molecules.

Nucleic acid based delivery systems: Vectors

5 In one aspect, disclosed herein are expression vectors comprising a nucleic acid comprising a nucleotide sequence encoding an amino acid sequence of mutated Na_v1.7 sodium channel alpha-subunit wherein the nucleotide sequence is operably linked to an expression control sequence. For example, in one aspect, disclosed herein are expression vectors comprising a nucleic acid comprising a

10 nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2 operably linked to an expression control sequence. In another aspect, disclosed herein are expression vectors comprising a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 operably linked to an expression control sequence. In yet another aspect, disclosed herein are

15 expression vectors comprising a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 4 operably linked to an expression control sequence. In a further aspect, disclosed herein are expression vectors comprising a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 5 operably linked to an expression control

20 sequence. In a still further aspect, disclosed herein are expression vectors comprising a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 6 operably linked to an expression control sequence. In one aspect, disclosed herein are expression vectors comprising a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence

25 of SEQ ID NO: 7 operably linked to an expression control sequence.

Further provided are expression vectors comprising any fragment of the nucleic acid encoding SEQ ID NOs: 2-7. Such fragments preferably encode at least 5 contiguous amino acid sequences of SEQ ID NOs: 2-7.

30 Expression or transfer vectors can be any nucleotide construction used to deliver genes into cells (*e.g.*, a plasmid), or as part of a general strategy to deliver genes, *e.g.*, as part of recombinant retrovirus or adenovirus (Ram, *et al.* (1993) Cancer Res 53:83-88).

As used herein, plasmid or viral vectors are agents that transport the disclosed nucleic acids, such as SEQ ID NOs: 8, 9, 10, 11, 12, and/or 13 into the cell without degradation and include a promoter yielding expression of the gene in the cells into which it is delivered. Viral vectors are, for example, Adenovirus, Adeno-associated virus, Herpes virus, Vaccinia virus, Polio virus, AIDS virus, neuronal trophic virus, Sindbis and other RNA viruses, including those viruses with the HIV backbone. Also preferred are any viral families which share the properties of these viruses which make them suitable for use as vectors. Retroviruses include Murine Maloney Leukemia virus, MMLV, and retroviruses that express the desirable properties of MMLV as a vector. Retroviral vectors are able to carry a larger genetic payload, *i.e.*, a transgene or marker gene, than other viral vectors, and for this reason are a commonly used vector. However, they are not as useful in non-proliferating cells. Adenovirus vectors are relatively stable and easy to work with, have high titers, and can be delivered in aerosol formulation, and can transfect non-dividing cells. Pox viral vectors are large and have several sites for inserting genes, they are thermostable and can be stored at room temperature. In one specific aspect is a viral vector that has been engineered so as to suppress the immune response of the host organism, elicited by the viral antigens. Vectors of this type will carry coding regions for Interleukin 8 or 10.

Viral vectors can have higher transaction (ability to introduce genes) abilities than chemical or physical methods to introduce genes into cells. Typically, viral vectors contain, nonstructural early genes, structural late genes, an RNA polymerase III transcript, inverted terminal repeats necessary for replication and encapsidation, and promoters to control the transcription and replication of the viral genome. When engineered as vectors, viruses typically have one or more of the early genes removed and a gene or gene/promotor cassette is inserted into the viral genome in place of the removed viral DNA. Constructs of this type can carry up to about 8 kb of foreign genetic material. The necessary functions of the removed early genes are typically supplied by cell lines which have been engineered to express the gene products of the early genes in trans.

Retroviral Vectors

A retrovirus is an animal virus belonging to the virus family of Retroviridae, including any types, subfamilies, genus, or tropisms. Retroviral

vectors, in general, are described by Verma, Retroviral vectors for gene transfer. In Microbiology-1985, American Society for Microbiology, pp. 229-232, Washington, (1985), which is incorporated by reference herein in its entirety for retroviral vectors and methods of making them. Examples of methods for using
 5 retroviral vectors for gene therapy are described in U.S. Patent Nos. 4,868,116 and 4,980,286; PCT applications WO 90/02806 and WO 89/07136; and Mulligan, (Science 260:926-932 (1993)); the teachings of which are incorporated by reference herein in its entirety for retroviral vectors and methods of using them.

A retrovirus is essentially a package which has packed into it nucleic acid
 10 cargo. The nucleic acid cargo carries with it a packaging signal, which ensures that the replicated daughter molecules will be efficiently packaged within the package coat. In addition to the package signal, there are a number of molecules which are needed in cis, for the replication, and packaging of the replicated virus. Typically a retroviral genome, contains the gag, pol, and env genes which are
 15 involved in the making of the protein coat. It is the gag, pol, and env genes which are typically replaced by the foreign DNA that it is to be transferred to the target cell. Retrovirus vectors typically contain a packaging signal for incorporation into the package coat, a sequence which signals the start of the gag transcription unit, elements necessary for reverse transcription, including a primer binding site
 20 to bind the tRNA primer of reverse transcription, terminal repeat sequences that guide the switch of RNA strands during DNA synthesis, a purine rich sequence 5' to the 3' LTR that serve as the priming site for the synthesis of the second strand of DNA synthesis, and specific sequences near the ends of the LTRs that enable the insertion of the DNA state of the retrovirus to insert into the host genome.
 25 The removal of the gag, pol, and env genes allows for about 8 kb of foreign sequence to be inserted into the viral genome, become reverse transcribed, and upon replication be packaged into a new retroviral particle. This amount of nucleic acid is sufficient for the delivery of a one to many genes depending on the size of each transcript. It is preferable to include either positive or negative
 30 selectable markers along with other genes in the insert.

Since the replication machinery and packaging proteins in most retroviral vectors have been removed (gag, pol, and env), the vectors are typically generated by placing them into a packaging cell line. A packaging cell line is a cell line

which has been transfected or transformed with a retrovirus that contains the replication and packaging machinery, but lacks any packaging signal. When the vector carrying the DNA of choice is transfected into these cell lines, the vector containing the gene of interest is replicated and packaged into new retroviral particles, by the machinery provided in cis by the helper cell. The genomes for the machinery are not packaged because they lack the necessary signals.

Adenoviral Vectors

The construction of replication-defective adenoviruses has been described (Berkner, *et al.* (1987) *J Virology* 61:1213-1220; Massie, *et al.* (1986) *Mol Cell Biol* 6:2872-2883; Haj-Ahmad, *et al.* (1986) *J Virology* 57:267-274; Davidson, *et al.* (1987) *J Virology* 61:1226-1239; Zhang, (1993) *BioTechniques* 15:868-872). The benefit of the use of these viruses as vectors is that they are limited in the extent to which they can spread to other cell types, since they can replicate within an initial infected cell, but are unable to form new infectious viral particles.

Recombinant adenoviruses have been shown to achieve high efficiency gene transfer after direct, *in vivo* delivery to airway epithelium, hepatocytes, vascular endothelium, CNS parenchyma and a number of other tissue sites (Morsy, (1993) *J Clin Invest* 92:1580-1586; Kirshenbaum, (1993) *J Clin Invest* 92:381-387; Roessler, (1993) *J Clin Invest* 92:1085-1092; Moullier, (1993) *Nature Genetics* 4:154-159; La Salle, (1993) *Science* 259:988-990; Gomez-Foix, (1992) *J Biol Chem* 267:25129-25134; Rich, (1993) *Human Gene Therapy* 4:461-476; Zabner, (1994) *Nature Genetics* 6:75-83; Guzman, (1993) *Circulation Res* 73:1201-1207; Bout, (1994) *Human Gene Therapy* 5:3-10; Zabner, (1993) *Cell* 75:207-216; Caillaud, (1993) *Eur. J. Neuroscience* 5:1287-1291; Ragot, (1993) *J Gen Virology* 74:501-507). Recombinant adenoviruses achieve gene transduction by binding to specific cell surface receptors, after which the virus is internalized by receptor-mediated endocytosis, in the same manner as wild type or replication-defective adenovirus (Chardonnet, *et al.* (1970) *Virology* 40:462-477; Brown, *et al.* (1973) *J Virology* 12:386-396; Svensson, *et al.* (1985) *J Virology* 55:442-449; Seth, *et al.* (1985) *J Virol* 51:650-655; Seth, *et al.* (1984) *Mol Cell Biol* 4:1528-1533; Varga, *et al.* (1991) *J Virology* 65:6061-6070; Wickham, *et al.* (1993) *Cell* 73:309-319).

A viral vector can be one based on an adenovirus which has had the E1 gene removed and these virions are generated in a cell line such as the human 293

cell line. In another aspect, both the E1 and E3 genes are removed from the adenovirus genome.

Adeno-associated viral vectors

Another type of viral vector is based on an adeno-associated virus (AAV).

- 5 This defective parvovirus is a preferred vector because it can infect many cell types and is nonpathogenic to humans. AAV type vectors can transport about 4 to 5 kb and wild type AAV is known to stably insert into chromosome 19. Vectors which contain this site specific integration property are preferred. An especially preferred embodiment of this type of vector is the P4.1 C vector produced by
- 10 Avigen, San Francisco, CA, which can contain the herpes simplex virus thymidine kinase gene, HSV-tk, and/or a marker gene, such as the gene encoding the green fluorescent protein, GFP.

- In another type of AAV virus, the AAV contains a pair of inverted terminal repeats (ITRs) which flank at least one cassette containing a promoter
- 15 which directs cell-specific expression operably linked to a heterologous gene. Heterologous in this context refers to any nucleotide sequence or gene which is not native to the AAV or B19 parvovirus.

- Typically the AAV and B19 coding regions have been deleted, resulting in a safe, noncytotoxic vector. The AAV ITRs, or modifications thereof, confer
- 20 infectivity and site-specific integration, but not cytotoxicity, and the promoter directs cell-specific expression. United States Patent No. 6,261,834 is incorporated by reference herein in its entirety for material related to the AAV vector.

- The disclosed vectors described throughout thus provide nucleic acids
- 25 which are capable of integration into a mammalian chromosome without substantial toxicity. The vectors can also provide nucleic acids that can be expressed in oocytes (including, *e.g.*, *Xenopus* oocytes).

- The inserted genes in viral and retroviral usually contain promoters, and/or enhancers to help control the expression of the desired gene product. A promoter
- 30 is generally a sequence or sequences of nucleic acids that function when in a relatively fixed location in regard to the transcription start site. A promoter contains core elements required for basic interaction of RNA polymerase and

transcription factors, and may contain upstream elements and response elements.

Large payload viral vectors

Molecular genetic experiments with large human herpesviruses have provided a means whereby large heterologous DNA fragments can be cloned, propagated and established in cells permissive for infection with herpesviruses (Sun, *et al.* (1994) *Nature Genetics* 8:33-41; Cotter, *et al.* (1999) *Curr Opin Mol Ther* 5:633-644). These large DNA viruses (herpes simplex virus (HSV) and Epstein-Barr virus (EBV), have the potential to deliver fragments of human heterologous DNA > 150 kb to specific cells. EBV recombinants can maintain large pieces of DNA in the infected B-cells as episomal DNA. Individual clones carried human genomic inserts up to 330 kb appeared genetically stable. The maintenance of these episomes requires a specific EBV nuclear protein, EBNA1, constitutively expressed during infection with EBV. Additionally, these vectors can be used for transfection, where large amounts of protein can be generated transiently *in vitro*. Herpesvirus amplicon systems are also being used to package pieces of DNA > 220 kb and to infect cells that can stably maintain DNA as episomes.

Other useful systems include, for example, replicating and host-restricted non-replicating vaccinia virus vectors.

Non-nucleic acid based systems

The disclosed compositions can also be delivered to the target cells in a variety of ways other than through nucleic acid based methods. For example, the compositions can be delivered through electroporation, or through lipofection, or through calcium phosphate precipitation. The delivery mechanism chosen will depend in part on the type of cell targeted and whether the delivery is occurring for example *in vivo* or *in vitro*.

Thus, the compositions can comprise, in addition to the disclosed mutant Na_v1.7 nucleic acid sequences or vectors, for example, lipids such as liposomes, such as cationic liposomes (*e.g.*, DOTMA, DOPE, DC cholesterol) or anionic liposomes. Liposomes can further comprise proteins to facilitate targeting a particular cell, if desired. Administration of a composition comprising a compound and a cationic liposome can be administered to the blood afferent to a

target organ or inhaled into the respiratory tract to target cells of the respiratory tract. Regarding liposomes, see, e.g., Brigham, *et al.* (1989) Am J Resp Cell Mol Biol 1:95-100; Felgner, *et al.* (1987) Proc Natl Acad Sci USA 84:7413-7417; U.S. Pat. No. 4,897,355. Furthermore, the compound can be administered as a
5 component of a microcapsule that can be targeted to specific cell types, such as macrophages, or where the diffusion of the compound or delivery of the compound from the microcapsule is designed for a specific rate or dosage.

In the methods described above which include the administration and uptake of exogenous DNA into the cells of a subject (*i.e.*, gene transduction or
10 transfection), delivery of the compositions to cells can be via a variety of mechanisms. As one example, delivery can be via a liposome, using commercially available liposome preparations such as LIPOFECTIN, LIPOFECTAMINE (GIBCO-BRL, Inc., Gaithersburg, MD), SUPERFECT (Qiagen, Inc. Hilden, Germany) and TRANSFECTAM (Promega Biotec, Inc.,
15 Madison, WI), as well as other liposomes developed according to procedures standard in the art. In addition, the disclosed nucleic acid or vector can be delivered *in vivo* by electroporation, the technology for which is available from Genetronics, Inc. (San Diego, CA) as well as by means of a SONOPORATION machine (ImaRx Pharmaceutical Corp., Tucson, AZ).

20 The materials may be in solution, suspension (for example, incorporated into microparticles, liposomes, or cells). These may be targeted to a particular cell type via antibodies, receptors, or receptor ligands. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, *et al.* (1991) Bioconjugate Chem. 2:447-451; Bagshawe, *et al.* (1998) Br J
25 Cancer 60:275-281; Bagshawe, *et al.* (1988) Br J Cancer 58:700-703; Senter, *et al.* (1993) Bioconjugate Chem 4:3-9; Battelli, *et al.* (1992) Cancer Immunol Immunother 35:421-425; Pietersz, *et al.* (1992) Immunolog Rev 129:57-80; Roffler, *et al.* (1991) Biochem Pharmacol 42:2062-2065). These techniques can be used for a variety of other specific cell types. Vehicles such as "stealth" and
30 other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic retroviral targeting of murine glioma cells *in vivo*. The following references are

examples of the use of this technology to target specific proteins to tumor tissue (Hughes, *et al.* (1989) Cancer Res 49:6214-6220; Litzinger, *et al.* (1992) Biochimica et Biophysica Acta 1104:179-187). In general, receptors are involved in pathways of endocytosis, either constitutive or ligand induced. These receptors
5 cluster in clathrin coated pits, enter the cell via clathrin coated vesicles, pass through an acidified endosome in which the receptors are sorted, and then either recycle to the cell surface, become stored intracellularly, or are degraded in lysosomes. The internalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules,
10 opportunistic entry of viruses and toxins, dissociation and degradation of ligand, and receptor level regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and ligand concentration. Molecular and cellular mechanisms of receptor mediated endocytosis has been reviewed (*see* Brown, *et al.* (1991) DNA and Cell
15 Biology 10:399-409).

Nucleic acids that are delivered to cells which are to be integrated into the host cell genome, typically contain integration sequences. These sequences are often viral related sequences, particularly when viral based systems are used. These viral integration systems can also be incorporated into nucleic acids which
20 are to be delivered using a non-nucleic acid based system of deliver, such as a liposome, so that the nucleic acid contained in the delivery system can be come integrated into the host genome.

Other general techniques for integration into the host genome include, for example, systems designed to promote homologous recombination with the host
25 genome. These systems typically rely on sequence flanking the nucleic acid to be expressed that has enough homology with a target sequence within the host cell genome that recombination between the vector nucleic acid and the target nucleic acid takes place, causing the delivered nucleic acid to be integrated into the host genome. These systems and the methods necessary to promote homologous
30 recombination are known to those of skill in the art.

Expression

The nucleic acids that are delivered to cells typically contain expression controlling systems. For example, the inserted genes in viral and retroviral systems usually contain expression control sequences, *i.e.*, promoters, and/or enhancers to help control the expression of the desired gene product. A promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site. A promoter contains core elements required for basic interaction of RNA polymerase and transcription factors, and may contain upstream elements and response elements.

Viral Promoters and Enhancers

Preferred promoters controlling transcription from vectors in mammalian host cells may be obtained from various sources, for example, the genomes of viruses such as: polyoma, Simian Virus 40 (SV40), adenovirus, retroviruses, hepatitis B virus and most preferably cytomegalovirus, or from heterologous mammalian promoters, *e.g.*, beta-actin promoter. The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment which also contains the SV40 viral origin of replication (Fiers, *et al.* (1978) *Nature* 273: 113). The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HindIII E restriction fragment (*see* Greenway, *et al.* (1982) *Gene* 18:355-360). Of course, promoters from the host cell or related species also are useful herein.

Enhancer generally refers to a sequence of DNA that functions at no fixed distance from the transcription start site and can be either 5' (Laimins, *et al.* (1981) *Proc Natl Acad Sci USA* 78:993) or 3' (Lusky, *et al.* (1983) *Mol Cell Bio* 3:1108) to the transcription unit. Furthermore, enhancers can be within an intron (Banerji, *et al.* (1983) *Cell* 33:729) as well as within the coding sequence itself (Osborne, *et al.* (1984) *Mol Cell Bio* 4:1293). They are usually between 10 and 300 bp in length, and they function in *cis*. Enhancers function to increase transcription from nearby promoters. Enhancers also often contain response elements that mediate the regulation of transcription. Promoters can also contain response elements that mediate the regulation of transcription. Enhancers often determine the regulation of expression of a gene. While many enhancer sequences are now known from mammalian genes (*e.g.*, globin, elastase, albumin, fetoprotein, and insulin), typically, one will use an enhancer from a eukaryotic cell virus for general

expression. Preferred examples are the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

5 The promotor and/or enhancer may be specifically activated either by light or specific chemical events which trigger their function. Systems can be regulated by reagents such as tetracycline and dexamethasone. There are also ways to enhance viral vector gene expression by exposure to irradiation, such as gamma irradiation, or alkylating chemotherapy drugs.

10 In certain embodiments, the promoter and/or enhancer region can act as a constitutive promoter and/or enhancer to maximize expression of the region of the transcription unit to be transcribed. In certain constructs the promoter and/or enhancer region be active in all eukaryotic cell types, even if it is only expressed in a particular type of cell at a particular time. A preferred promoter of this type is
15 the CMV promoter (650 bases). Other preferred promoters are SV40 promoters, cytomegalovirus (full-length promoter), and retroviral vector LTF.

 It has been shown that all specific regulatory elements can be cloned and used to construct expression vectors that are selectively expressed in specific cell types such as melanoma cells. For example, the glial fibrillary acetic protein
20 (GFAP) promoter has been used to selectively express genes in cells of glial origin.

 Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human or nucleated cells) may also contain sequences necessary for the termination of transcription which may affect mRNA expression. These regions
25 are transcribed as polyadenylated segments in the untranslated portion of the mRNA encoding tissue factor protein. The 3'-untranslated regions also include transcription termination sites. It is preferred that the transcription unit also contains a polyadenylation region. One benefit of this region is that it increases the likelihood that the transcribed unit will be processed and transported like
30 mRNA. The identification and use of polyadenylation signals in expression constructs is well established. It is preferred that homologous polyadenylation signals be used in the transgene constructs. In certain transcription units, the

polyadenylation region is derived from the SV40 early polyadenylation signal and consists of about 400 bases. It is also preferred that the transcribed units contain other standard sequences alone or in combination with the above sequences improve expression from, or stability of, the construct.

5 Markers

The viral vectors can include nucleic acid sequence encoding a marker product. This marker product is used to determine if the gene has been delivered to the cell and once delivered is being expressed. Preferred marker genes are the *E. Coli* lacZ gene, which encodes beta-galactosidase, and green fluorescent protein (GFP).
10

Marker product, as used herein, is synonymous with "reporter protein." As used herein, a "reporter protein" is any protein that can be specifically detected when expressed. Reporter proteins are useful for detecting or quantifying expression from expression sequences. Many reporter proteins are known to one
15 of skill in the art. These include, but are not limited to, beta-galactosidase, luciferase, and alkaline phosphatase that produce specific detectable products. Fluorescent reporter proteins can also be used, such as green fluorescent protein (GFP), green reef coral fluorescent protein (G-RCFP), cyan fluorescent protein (CFP), red fluorescent protein (RFP) and yellow fluorescent protein (YFP).

20 In some embodiments the marker or reporter protein may be a selectable marker. Examples of suitable selectable markers for mammalian cells are dihydrofolate reductase (DHFR), thymidine kinase, neomycin, neomycin analog G418, hydromycin, and puromycin. When such selectable markers are successfully transferred into a mammalian host cell, the transformed mammalian
25 host cell can survive if placed under selective pressure. There are two widely used distinct categories of selective regimes. The first category is based on a cell's metabolism and the use of a mutant cell line which lacks the ability to grow independent of a supplemented media. Two examples are: CHO DHFR cells and mouse LTK cells. These cells lack the ability to grow without the addition of such
30 nutrients as thymidine or hypoxanthine. Because these cells lack certain genes necessary for a complete nucleotide synthesis pathway, they cannot survive unless the missing nucleotides are provided in a supplemented media. An alternative to

supplementing the media is to introduce an intact DHFR or TK gene into cells lacking the respective genes, thus altering their growth requirements. Individual cells which were not transformed with the DHFR or TK gene will not be capable of survival in non supplemented media.

- 5 The second category is dominant selection which refers to a selection scheme used in any cell type and does not require the use of a mutant cell line. These schemes typically use a drug to arrest growth of a host cell. Those cells which have a novel gene would express a protein conveying drug resistance and would survive the selection. Examples of such dominant selection use the drugs
- 10 neomycin, (Southern, *et al.* (1982) J Molec Appl Genet 1:327), mycophenolic acid, (Mulligan, *et al.* (1980) Science 209:1422) or hygromycin, (Sugden, *et al.* (1985) Mol Cell Biol 5:410-413). The three examples employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug G418 or neomycin (geneticin), xgpt (mycophenolic acid) or hygromycin, respectively.
- 15 Others include the neomycin analog G418 and puramycin.

Cultured Cells

- The materials, compositions, articles, devices, and methods disclosed herein, in one aspect, related to a method of making a mutant Nav1.7 sodium channel alpha subunit comprising culturing the cells comprising vectors
- 20 comprising mutant Na_v1.7 nucleic acids under conditions allowing expression of the polypeptide encoded by the nucleic acid, wherein the polypeptide comprises a mutant Na_v1.7 sodium channel.

Transgenic Animals

- In one aspect, disclosed herein are transgenic animals that express one or
- 25 more of the mutant Na_v1.7 sodium channels described herein. For example, disclosed herein is a transgenic mouse comprising cells that encode a mutant Na_v1.7 sodium channel alpha-subunit, wherein the mouse exhibits increased seizure activity as compared to the wild-type animal.

- “Transgenic animal” is used herein to mean an animal comprising a
- 30 transgene. By a “transgene” is meant a nucleic acid sequence that is inserted by artifice into a cell and becomes a part of the genome of that cell and its progeny. Such a transgene may be (but is not necessarily) partly or entirely heterologous

(for example, derived from a different species) to the cell. A transgenic animal can be any non-human animal, such as a mouse, rat, guinea pig, sheep, pig, goat, and the like. Transgenic animals are made by techniques that are well known in the art. For example, a transgenic animal can be prepared by the method used in
5 U.S. Pat. No. 4,736,866

Mutant Na_v1.7 Sodium Channel Alpha- Subunits

In one aspect, disclosed herein are mutant Na_v1.7 sodium channel alpha-subunits and the use of such mutant Na_v1.7 sodium channels to diagnose and treat disease states such as, for example, neurologic disorders associated with a sodium
10 channel mutation. It was found that specific sites in the Na_v1.7 sodium channel alpha-subunit are mutated, *i.e.*, the amino acid at a specific position or at specific positions differs from that observed in the most commonly found Na_v1.7 sodium channel.

As this specification discusses various amino acid sequences it is
15 understood that the nucleic acids that can encode those amino acid sequences are also disclosed. This would include all degenerate sequences related to a specific amino acid sequence, *i.e.* all nucleic acids having a sequence that encodes one particular amino acid sequence as well as all nucleic acids, including degenerate
20 nucleic acids, encoding the disclosed variants and derivatives of the amino acid sequences. Thus, while each particular nucleic acid sequence may not be written out herein, it is understood that each and every sequence is in fact disclosed and described herein through the disclosed amino acid sequence. For example, one of the many nucleic acid sequences that can encode the amino acid sequence of SEQ
ID NO: 2 is set forth in SEQ ID NO: 8. Another nucleic acid sequence that
25 encodes the amino acid sequence of SEQ ID NO: 3 is set forth in SEQ ID NO: 9. Another nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 4 is set forth in SEQ ID NO: 10. Another nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 5 is set forth in SEQ ID NO: 11. Another nucleic acid sequence that encodes the amino acid sequence of SEQ ID
30 NO: 6 is set forth in SEQ ID NO: 12. Another nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 7 is set forth in SEQ ID NO: 13. It is also understood that while no amino acid sequence indicates what particular DNA sequence encodes that protein within an organism, where particular variants of a

disclosed protein are disclosed herein, the known nucleic acid sequence that encodes that amino acid sequence in the particular mutant Na_v1.7 sodium channel alpha-subunit from which that amino acid sequence arises is also known and herein disclosed and described.

5 In one aspect, the mutant Na_v1.7 sodium channel alpha-subunits described herein have one or more mutated sites. For example, in one aspect, disclosed herein is a mutant Na_v1.7 sodium channel alpha-subunit where the amino acid at position 62 is not isoleucine (I) as is commonly found at position 62 but, rather, valine (V) (SEQ ID NO: 2). In another aspect, disclosed herein is a mutant Na_v1.7 sodium channel alpha-subunit where the amino acid at position 149 is not proline (P) as is commonly found at position 149 but, rather, glutamine (Q) (SEQ ID NO: 3). In another aspect, disclosed herein is a mutant Na_v1.7 sodium channel alpha-subunit where the amino acid at position 641 is not asparagines (N) as is commonly found at position 641 but, rather, tyrosine (Y) (SEQ ID NO: 4). In yet another aspect, disclosed herein is a mutant Na_v1.7 sodium channel alpha-subunit where the amino acid at position 655 is not lysine (K) as is commonly found at position 655 but, rather, arginine (R) (SEQ ID NO: 5). In a further aspect, disclosed herein is a mutant Na_v1.7 sodium channel alpha-subunit where the amino acid at position 739 is not isoleucine (I) as is commonly found at position 739 but, rather, valine (V) (SEQ ID NO: 6). In a still further aspect, disclosed herein is a mutant Na_v1.7 sodium channel alpha-subunit where the amino acid at position 1123 is not leucine (L) as is commonly found at position 1123 but, rather, phenylalanine (F) (SEQ ID NO: 7).

Also contemplated are variants and derivatives of the disclosed mutant Na_v1.7 amino acid sequences. It is understood that one way to define the variants and derivatives of the disclosed proteins herein is through defining the variants and derivatives in terms of homology/identity to specific known sequences. For example, SEQ ID NO: 2 sets forth a particular sequence of a mutant I62V mutant sodium channel alpha-subunit, SEQ ID NO: 3 sets forth a particular sequence of a mutant P149Q Na_v1.7 sodium channel alpha-subunit, SEQ ID NO: 4 sets forth a particular sequence of a mutant N641Y Na_v1.7 sodium channel alpha-subunit, SEQ ID NO: 5 sets forth a particular sequence of a mutant K655R Na_v1.7 sodium channel alpha-subunit, SEQ ID NO: 6 sets forth a particular sequence of a mutant

I739V Na_v1.7 sodium channel alpha-subunit, and SEQ ID NO: 7 sets forth a particular sequence of a mutant L1123F Na_v1.7 sodium channel alpha-subunit. Specifically disclosed are variants of these and other proteins herein disclosed which have at least, 70% or 75% or 80% or 85% or 90% or 95% homology to the stated sequence. Also, provided are amino acid sequences comprising the sequences of SEQ ID NOS: 2, 3, 4, 5, 6, and 7, or any fragment thereof wherein the sequence comprises one or more conservative amino acid substitutions. Preferably, the amino acid sequence with conservative amino acid substitutions maintains sodium channel function. Examples of conservative amino acid substitutions are shown in Table 1. Those of skill in the art readily understand how to determine the homology of two proteins. For example, the homology can be calculated after aligning the two sequences so that the homology is at its highest level.

TABLE 1: Amino Acid Substitutions		
Original Residue	Exemplary Substitutions	Conservative
Ala	Ser	
Arg	Gly, Gln	
Asn	Gln; His	
Asp	Glu	
Cys	Ser	
Gln	Asn, Lys	
Glu	Asp	
Gly	Pro	
His	Asn; Gln	
Ile	Leu; Val	
Leu	Ile; Val	
Lys	Arg; Gln;	
Met	Leu; Ile	
Phe	Met; Leu; Tyr	
Ser	Thr	
Thr	Ser	
Trp	Tyr	
Tyr	Trp; Phe	
Val	Ile; Leu	

Another way of calculating homology can be performed by published algorithms. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman (1981) Adv Appl Math

2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J
Mol Biol 48:443, by the search for similarity method of Pearson and Lipman,
(1988) Proc Natl Acad Sci USA 85:2444, by computerized implementations of
these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin
5 Genetics Software Package, Genetics Computer Group, 575 Science Dr.,
Madison, WI), or by inspection.

Also, disclosed herein are isolated polypeptides and fragments of
polypeptides comprising mutant Na_v1.7 sodium channel alpha-subunit amino acid
sequences. For example, disclosed herein are isolated polypeptides having amino
10 acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7. In another aspect, disclosed
herein are fragments of such sequences. For example, disclosed herein are
isolated polypeptides having amino acid sequences of SEQ ID NOs: 32, 33, 34,
35, 36, and 37.

Also, provided are fragments of at least 5 contiguous amino acid
15 sequences corresponding to SEQ ID NOs: 2, 3, 4, 5, 6, and 7. Among these
fragments are those comprising PFVYG (SEQ ID NO: 32), NPQDW (SEQ ID
NO: 33), LPYGQ (SEQ ID NO: 34), IHRKR (SEQ ID NO: 35), LAVTI (SEQ ID
NO: 36), and NPFPG (SEQ ID NO: 37).

Methods of Synthesizing Polypeptides

20 The peptides, polypeptides, and polypeptide fragments disclosed herein
can be chemically synthesized using currently available laboratory equipment
using either Fmoc (9-fluorenylmethyloxycarbonyl) or Boc (tert -
butyloxycarbonyl) chemistry. (Applied Biosystems, Inc., Foster City, CA). One
skilled in the art can readily appreciate that a peptide or polypeptide
25 corresponding to the sodium channels disclosed herein, for example, can be
synthesized by standard chemical reactions. For example, a peptide or
polypeptide fragment can be synthesized and not cleaved from its synthesis resin
whereas another peptide or polypeptide fragment can be synthesized and
subsequently cleaved from the resin, thereby exposing a terminal group which is
30 functionally blocked on the other fragment. By peptide condensation reactions,
these two fragments can be covalently joined via a peptide bond at their carboxyl
and amino termini, respectively, to form an sodium channel, or fragment thereof.

(See Grant GA (1992) Synthetic Peptides: A User Guide. W.H. Freeman and Co., New York, NY (1992); Bodansky M and Trost B., Ed. Principles of Peptide Synthesis. Springer-Verlag Inc., New York, NY (1993)). Alternatively, the peptide or polypeptide is independently synthesized *in vivo* as described above.

5 For example, enzymatic ligation of cloned or synthetic peptide segments allow relatively short peptide fragments to be joined to produce larger peptide fragments, polypeptides or whole protein domains (Abrahmsen, *et al.* (1991) Biochemistry 30:4151). Alternatively, native chemical ligation of synthetic peptides can be utilized to synthetically construct large peptides or polypeptides
10 from shorter peptide fragments. This method consists of a two step chemical reaction (Dawson, *et al.* (1994) Science 266:776-779). The first step is the chemoselective reaction of an unprotected synthetic peptide-alpha-thioester with another unprotected peptide segment containing an amino-terminal Cys residue to give a thioester-linked intermediate as the initial covalent product. Without a
15 change in the reaction conditions, this intermediate undergoes spontaneous, rapid intramolecular reaction to form a native peptide bond at the ligation site. Application of this native chemical ligation method to the total synthesis of a protein molecule is illustrated by the preparation of human interleukin 8 (IL-8) (Baggiolini, *et al.* (1992) FEBS Lett. 307:97-101; Clark-Lewis, *et al.* (1994) J
20 Biol Chem 269:16075; Clark-Lewis, *et al.* (1991) Biochemistry 30:3128; Rajarathnam, *et al.* (1994) Biochemistry 33:6623-30).

Alternatively, unprotected peptide segments are chemically linked where the bond formed between the peptide segments as a result of the chemical ligation is an unnatural (non-peptide) bond (Schnolzer, *et al.* (1992) Science, 256:221).
25 This technique has been used to synthesize analogs of protein domains as well as large amounts of relatively pure proteins with full biological activity (deLisle Milton, *et al.* Techniques in Protein Chemistry IV. Academic Press, New York, pp. 257-267 (1992)).

Antibodies to Mutant Na_v1.7 Sodium Channels

30 The disclosed materials, compositions, articles, devices, and methods disclosed herein, in one aspect, relate to purified antibodies that selectively bind to an epitope of a mutant Na_v1.7 sodium channel alpha-subunit. In one aspect, the

purified antibody selectively binds to an epitope of the I62V mutant Na_v1.7 sodium channel alpha-subunit. In another aspect, the purified antibody selectively binds to an epitope of the P149Q mutant Na_v1.7 sodium channel alpha-subunit. In yet another aspect, the purified antibody selectively binds to an epitope of the
5 N641Y mutant Na_v1.7 sodium channel alpha-subunit. In a further aspect, the purified antibody selectively binds to an epitope of the K655R mutant Na_v1.7 sodium channel alpha-subunit. In a still further aspect, the purified antibody selectively binds to an epitope of the I739V mutant Na_v1.7 sodium channel alpha-subunit. In one aspect, the purified antibody selectively binds to an epitope of the
10 L1123F mutant Na_v1.7 sodium channel alpha-subunit.

By “selectively binds” is meant that the antibody binds to the mutant Na_v1.7 sodium channel without appreciably binding to the non-mutant Na_v1.7 sodium channel. By “binding” is meant such that the signal that indicates binding is at least about 1.5 times the signal for a non-binding control. Thus, without
15 appreciable binding is meant less than or equal to 1.5 times the background of a non-binding control.

The term “antibodies” is used herein in a broad sense and includes both polyclonal and monoclonal antibodies, as well as humanized, fully human, and non-human antibodies. Also provided are fragments of these antibodies wherein
20 the fragments selectively bind with epitopes of mutant Na_v1.7 sodium channel alpha-subunits. The antibodies can be tested for their desired binding activity using the *in vitro* assays described herein, or by analogous methods. Optionally, the antibodies are labeled directly or indirectly and can be used with imaging technologies to detect expression of the mutant Na_v1.7.

25 The term “monoclonal antibody” as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, *i.e.*, the individual antibodies within the population are identical except for possible naturally occurring mutations that may be present in a small subset of the antibody molecules. The monoclonal antibodies herein specifically include “chimeric”
30 antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding

sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired antagonistic activity (*See*, U.S. Pat. No. 4,816,567 and Morrison, *et al.* (1984) Proc Natl Acad Sci USA, 81:6851-6855).

5 The disclosed monoclonal antibodies can be made using any procedure which produces monoclonal antibodies. For example, disclosed monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler, *et al.* (1975) Nature 256:495). In a hybridoma method, a mouse or other appropriate host animal is typically immunized with an immunizing agent to elicit
10 lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*, *e.g.*, using the mutant Na_v1.7 channels described herein.

 The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the
15 disclosed monoclonal antibodies can be readily isolated and sequenced using conventional procedures (*e.g.*, by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). Libraries of antibodies or active antibody fragments can also be generated and screened using phage display techniques, *e.g.*, as described in U.S.
20 Patent Nos. 5,804,440 and 6,096,441.

In vitro methods are also suitable for preparing monovalent antibodies, including, for example, scfv antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can be performed using
25 papain. Examples of papain digestion are described in WO 94/29348 and U.S. Pat. No. 4,342,566. Papain digestion of antibodies typically produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields a fragment that has two antigen combining sites and is still capable of cross linking
30 antigen.

 The fragments, whether attached to other sequences or not, can also include insertions, deletions, substitutions, or other selected modifications of

particular regions or specific amino acids residues, provided the activity of the antibody or antibody fragment is not significantly altered or impaired compared to the non-modified antibody or antibody fragment. These modifications can provide for some additional property, such as to remove/add amino acids capable of disulfide bonding, to increase its bio-longevity, to alter its secretory characteristics, etc. In any case, the antibody or antibody fragment must possess a bioactive property, such as specific binding to its cognate antigen. Functional or active regions of the antibody or antibody fragment may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the antibody or antibody fragment. (See Zoller, (1992) J Curr Opin Biotechnol 3:348-354).

As used herein, the term "antibody" or "antibodies" can also refer to a human antibody and/or a humanized antibody. Many non-human antibodies (*e.g.*, those derived from mice, rats, or rabbits) are naturally antigenic in humans, and thus can give rise to undesirable immune responses when administered to humans. Therefore, the use of human or humanized antibodies in the methods serves to lessen the chance that an antibody administered to a human will evoke an undesirable immune response.

Human antibodies

The disclosed human antibodies can be prepared using any technique. Examples of techniques for human monoclonal antibody production include those described by Cole *et al.* (Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77, 1985) and by Boerner, *et al.* (1991) J Immunol 147:86-95. Human antibodies (and fragments thereof) can also be produced using phage display libraries (*see* Hoogenboom, *et al.* (1991) J Mol Biol 227:381; Marks, *et al.* (1991) J Mol Biol 222:581).

The disclosed human antibodies can also be obtained from transgenic animals. For example, transgenic, mutant mice that are capable of producing a full repertoire of human antibodies, in response to immunization, have been described (*see, e.g.*, Jakobovits, *et al.* (1993) Proc Natl Acad Sci USA 90:2551-

2555; Jakobovits, *et al.* (1993) Nature 362:255-258; Bruggermann, *et al.* (1993) Year in Immunol 7:33). Specifically, the homozygous deletion of the antibody heavy chain joining region (J(H)) gene in these chimeric and germ line mutant mice results in complete inhibition of endogenous antibody production, and the
 5 successful transfer of the human germ line antibody gene array into such germ line mutant mice results in the production of human antibodies upon antigen challenge. Antibodies having the desired activity are selected using the mutant Na_v1.7 sodium channels provided herein.

Humanized antibodies

10 Antibody humanization techniques generally involve the use of recombinant DNA technology to manipulate the DNA sequence encoding one or more polypeptide regions of an antibody molecule. Accordingly, a humanized form of a non-human antibody (or a fragment thereof) is a chimeric antibody or antibody chain (or a fragment thereof, such as an Fv, Fab, Fab', or other antigen
 15 binding portion of an antibody) which contains a portion of an antigen binding site from a non-human (donor) antibody integrated into the framework of a human (recipient) antibody.

To generate a humanized antibody, residues from one or more complementarity determining regions (CDRs) of a recipient (human) antibody
 20 molecule are replaced by residues from one or more CDRs of a donor (non-human) antibody molecule that is known to have desired antigen binding characteristics (*e.g.*, a certain level of specificity and affinity for the target antigen). In some instances, Fv framework (FR) residues of the human antibody are replaced by corresponding non-human residues. Humanized antibodies may
 25 also contain residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by
 30 residues from analogous sites in rodent antibodies. Humanized antibodies generally contain at least a portion of an antibody constant region (Fc), typically that of a human antibody (*see* Jones, *et al.* (1986) Nature 321:522-525; Reichmann, *et al.* (1988) Nature 332:323-327; Presta, (1992) Curr Opin Struct

Biol 2:593-596).

Methods for humanizing non-human antibodies are well known in the art. For example, humanized antibodies can be generated according to the methods of Winter and co-workers (Jones, *et al.* (1986) Nature 321:522-525; Riechmann, *et al.* (1988) Nature 332:323-327; Verhoeyen, *et al.* (1988) Science 239:1534-1536), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Methods that can be used to produce humanized antibodies are also described in U.S. Patent Nos. 4,816,567, 5,565,332, 5,721,367, 5,837,243, 5, 939,598, 6,130,364, and 6,180,377.

In one aspect, as a form of therapy, antibodies can be used to inactivate the function of a mutant protein.

Methods of Drug Screening and Delivery

The materials, compositions, articles, devices and methods disclosed herein, in one aspect, relate to a method of identifying a compound that modulates mutant Na_v1.7 sodium channels comprising contacting, with a test compound, a cell containing a mutant Na_v1.7 nucleic acid that encodes a mutant Na_v1.7 sodium channel comprising one or more mutations at residue 62, residue 149, residue 641, residue 655, residue 739, or residue 1123 of the channel; detecting Na_v1.7 sodium channel activity; and comparing the Na_v1.7 sodium channel activity in the contacted cell with the amount of Na_v1.7 sodium channel activity in a control cell, wherein the control cell is not contacted by the test compound, an increased or decreased Na_v1.7 sodium channel activity in the test cell as compared to the control cell indicating a compound that modulates mutant Na_v1.7 sodium channels. Detecting sodium channel activity can be accomplished by methods known in the art. For example, a suitable protocol for detecting sodium channel activity is described in Kausalia, *et al.* (2003) *J. Neurophysiol.* 10.1152/jn.00676.2003.

The cell can express the mutant channel naturally or can be genetically modified to do so. Optionally, the cell is an oocyte that expressed the mutant sodium channel. The mutant sodium channel can be a I62V, P149Q, N641Y, K655R, I739V, or L1123F mutant. Optionally, a mutant channel can comprise one or more of the site mutations.

Optionally, channel activity is tested using intracellular or extracellular recording to assess changes in membrane potential associated with sodium ion flux. Alternatively, imaging technologies can be used to observe labeled ion flux. Expression can be assessed in *Xenopus* oocytes or mammalian cells such as CHO, HEK and tsA201. Mutations may result in errors of protein trafficking and protein interaction. As such, mutant channels can be assessed for their ability to form functional channels in the cell membrane as opposed to being retained in the endoplasmic reticulum by using labeled antibodies to the wild-type channel, or by attaching a common epitope to the channels and using a specific antibody to that epitope. Mutations that alter interactions with intracellular proteins, such as protein kinase A, protein kinase C or calmodulin kinase, or the sodium channel beta-subunits, can be identified through yeast 2-hybrid studies, co-immunoprecipitation experiments or electrophysiological experiments.

Also, the materials, compositions, articles, devices, and methods disclosed herein, in one aspect, relate to a method of preventing or reducing the effects of neurologic disorders like febrile seizures, afebrile seizures, or epilepsy by treating a subject at risk for neurologic disorders with a composition that modulates mutant Na_v1.7 levels. Thus, a subject with a mutation(s) in Na_v1.7 sodium channel alpha-subunits, consistent with a neurologic disorder or an increased risk of a neurologic disorder, can be treated with a composition comprising a mutant Na_v1.7 modulator identified or manufactured using the methods taught herein.

The materials and compositions disclosed herein can be administered *in vivo* in a pharmaceutically acceptable carrier. By "pharmaceutically acceptable carrier" is meant a material that is not biologically or otherwise undesirable, *i.e.*, the material may be administered to a subject, along with a modulator of Na_v1.7 sodium channel function identified or made by the methods taught herein, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.

The compositions may be administered orally, parenterally (*e.g.*, intravenously), by intramuscular injection, by intraperitoneal injection,

transdermally, extracorporeally, topically or the like, although topical intranasal administration or administration by inhalant is typically preferred. As used herein, "topical intranasal administration" means delivery of the compositions into the nose and nasal passages through one or both of the nares and can comprise

5 delivery by a spraying mechanism or droplet mechanism, or through aerosolization of the composition. The latter may be effective when a large number of animals are to be treated simultaneously. Administration of the compositions by inhalant can be through the nose or mouth via delivery by a spraying or droplet mechanism. Delivery can also be directly to any area of the

10 respiratory system (*e.g.*, lungs) via intubation. The exact amount of the compositions required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the disorder being treated, the particular nucleic acid or modulator used, its mode of administration and the like. Thus, it is not possible to specify an exact amount for every

15 composition. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.

Parenteral administration of the composition, if used, is generally characterized by injection. Injectables can be prepared in conventional forms,

20 either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. *See, e.g.*, U.S. Pat. No. 3,610,795, which is incorporated by reference herein.

25 The materials may be in solution, suspension (for example, incorporated into microparticles, liposomes, or cells). These may be targeted to a particular cell type via antibodies, receptors, or receptor ligands.

Liposomes are vesicles comprised of one or more concentrically ordered lipid bilayers which encapsulate an aqueous phase. They are normally not leaky,

30 but can become leaky if a hole or pore occurs in the membrane, if the membrane is dissolved or degrades, or if the membrane temperature is increased to the phase transition temperature. Current methods of drug delivery via liposomes require that the liposome carrier ultimately become permeable and release the

encapsulated drug at the target site. This can be accomplished, for example, in a passive manner wherein the liposome bilayer degrades over time through the action of various agents in the body. Every liposome composition will have a characteristic half-life in the circulation or at other sites in the body and, thus, by
5 controlling the half-life of the liposome composition, the rate at which the bilayer degrades can be somewhat regulated.

In contrast to passive drug release, active drug release involves using an agent to induce a permeability change in the liposome vesicle. Liposome membranes can be constructed so that they become destabilized when the
10 environment becomes acidic near the liposome membrane (*see, e.g.*, (1987) Proc Natl Acad Sci USA 84:7851; (1989) Biochemistry 28:908, which are hereby incorporated by reference in their entireties for their teachings of liposome construction and administration). When liposomes are endocytosed by a target cell, for example, they can be routed to acidic endosomes which will destabilize
15 the liposome and result in drug release.

Alternatively, the liposome membrane can be chemically modified such that an enzyme is placed as a coating on the membrane which slowly destabilizes the liposome. Since control of drug release depends on the concentration of enzyme initially placed in the membrane, there is no real effective way to
20 modulate or alter drug release to achieve "on demand" drug delivery. The same problem exists for pH-sensitive liposomes in that as soon as the liposome vesicle comes into contact with a target cell, it will be engulfed and a drop in pH will lead to drug release. This liposome delivery system can also be made to target B cells by incorporating into the liposome structure a ligand having an affinity for B cell-
25 specific receptors.

Compositions including the liposomes in a pharmaceutically acceptable carrier are also contemplated.

Transdermal delivery devices have been employed for delivery of low molecular weight proteins by using lipid-based compositions (*i.e.*, in the form of a
30 patch) in combination with sonophoresis. However, as reported in U.S. Pat. No. 6,041,253, which is hereby incorporated by reference in its entirety for the methods taught therein, transdermal delivery can be further enhanced by the

application of an electric field, for example, by ionophoresis or electroporation. Using low frequency ultrasound which induces cavitation of the lipid layers of the stratum corneum, higher transdermal fluxes, rapid control of transdermal fluxes, and drug delivery at lower ultrasound intensities can be achieved. Still further
5 enhancement can be obtained using a combination of chemical enhancers and/or magnetic field along with the electric field and ultrasound.

Implantable or injectable protein depot compositions can also be employed, providing long-term delivery of the composition. For example, U.S. Pat. No. 6,331,311, which is hereby incorporated by reference in its entirety for
10 protein depot compositions and uses, reports an injectable depot gel composition which includes a biocompatible polymer, a solvent that dissolves the polymer and forms a viscous gel, and an emulsifying agent in the form of a dispersed droplet phase in the viscous gel. Upon injection, such a gel composition can provide a relatively continuous rate of dispersion of the agent to be delivered, thereby
15 avoiding an initial burst of the agent to be delivered.

The test compound and modulator taught herein can be, but is not limited to, antibodies, chemicals, small molecules, modified antisense RNAs, ions, siRNAs, receptor ligands, drugs and secreted proteins.

EXAMPLES

20 The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the antibodies, polypeptides, nucleic acids, compositions, and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention.
25 Efforts have been made to ensure accuracy with respect to numbers (*e.g.*, amounts, temperature, etc.), but some errors and deviations should be accounted for.

Example 1

Febrile seizures are the most common seizure disorder of early childhood,
30 exhibiting a prevalence of 2-5% in European and North American children and as high as 9% in the Japanese. The incidence of febrile seizures in first-degree relatives is 31% (Aicardi, *Epilepsy in Children*, Raven Press, New York, N.Y.

(1994)), supporting a strong genetic etiology of febrile seizures. The impact of febrile seizures is considerable because individuals who experience febrile seizures have a 2-7% chance of developing afebrile seizures later in life (Annegers, *et al.* (1987) *N Engl J Med* 316:493-498). These later epileptic
 5 phenomena include cases of various generalized convulsive, as well as simple and complex partial seizures.

Linkage analysis of a febrile seizure kindred K4425 identified a 10 cM region of no recombination on chromosome 2q24 (FEB3, OMIM 604403), which contains five sodium channel alpha-subunit genes (*see* Peiffer, *et al.* (1999) *Ann*
 10 *Neurol* 46:671-678). Three of the sodium channel genes within this critical region, Na_v1.1, Na_v1.2, and Na_v1.3, share over 85% identity and are highly expressed in brain (*see* Catterall, (2000) *Neuron* 26:13-25). Na_v1.7, which also resides within this critical genetic interval, shares approximately 70-80 % homology with Na_v1.1, Na_v1.2, and Na_v1.3 (*see* Catterall, (2000) *Neuron* 26:13-
 15 25; Sangameswaran, *et al.* (1997) *J Biol Chem* 272:14805-14809), is expressed primarily in neurons of the dorsal root ganglia, and shows minimal to no expression in brain (Felts, *et al.* (1997) *Brain Res Mol Brain Res* 45:71-82; Toledo-Aral, *et al.* (1997) *Proc Natl Acad Sci USA* 94:1527-1532). Consequently, Na_v1.7 has been classified as a peripheral nervous system channel
 20 (Catterall, (2000) *Neuron* 26:13-25; Goldin, *et al.* (2001) *Annu Rev Physiol* 63:871-894).

Recently, disease-causing mutations were identified in Na_v1.1 and Na_v1.2 in generalized epilepsy febrile seizure plus (GEFS+), a febrile seizure disorder that is subtly different from the phenotype described in kindred K4425 (*see* Singh,
 25 *et al.* (1999) *Ann Neurol* 45:75-81; Sugawara, *et al.* (2001) *Proc Natl Acad Sci USA* 98:6384-6389; Wallace, *et al.* (2001) *Am J Hum Genet* 68:859-865; Escayg, *et al.* (2000) *Nat Genet* 24: 343-345). Sequence analysis of an affected individual in K4425 did not yield any disease-causing variants in either of these two genes, or in the closely related Na_v1.3 gene. Sequence analysis of the Na_v1.7 large
 30 intracellular loop between domains I and II revealed a missense change (N641Y) in all affected individuals of K4425 that was absent from 236 control chromosomes (*see* Fig. 2).

Na_v1.7 was then sequenced in a panel of 32 sporadic and familial cases

with seizures occurring in the setting of a febrile illness and five additional variants in $Na_v1.7$ that were not found in 180 ethnically matched control chromosomes were identified (Table 2). These variants were identified in the intracellular *N*-terminus (I62V), the DI S1-S2 extracellular loop (P149Q), the DI-DII intracellular loop (K655R), the DII S1 transmembrane domain (I739V), and the DII-DIII intracellular loop (L1123F) (*see* Fig. 3).

Table 2: Amino acid conservation and clinical findings associated with $Na_v1.7$ mutations

Exon	Mutation	Amino Acid	Conservation	Family History	Clinical Findings	
		<i>Species</i> <u>mou/rat/rabb</u>	<i>Gene family</i> <u>$Na_v1.1/1.2/1.3$</u>		<i>Presentation (age)</i>	<i>Clinical Course</i>
1	I62V	✓	✓	-	FS (2yr)	FS until 2 yr
3	P149Q	P/P/A	✓	-	FS (2yr)	FS until 4 yr
11	N641Y	✓	V/A/T	+	FS (mean 1.3 yr)	GTC, PC, SP, GT, GA until 6-16 yr
12	K655R	✓	R/R/R	+	FS (5yr)	IGE until 6 yr
13	I739V	✓	✓	+	FS (1yr)	IGE until 8 yr
17	L1123F	✓	A/A/L	-	epilepsy (5mo)	Intractable seizures

Species: corresponding amino acid of $Na_v1.7$ of the mouse, rat and rabbit; Gene family: corresponding amino acid of $Na_v1.1$, $Na_v1.2$, and $Na_v1.3$; ✓, amino acid is identical to human $Na_v1.7$. Family history: -, negative; +, positive. FS, febrile seizures; GTC, generalized tonic-clonic; PC, partial complex; SP, simple partial; GT, generalized tonic; GA, generalized atonic; IGE, idiopathic generalized epilepsy; * family described in Figure 2.

All variants, except proline 149, are conserved in the $Na_v1.7$ gene of mouse, rat and rabbit. Proline 149 is conserved in mouse and rat, and is substituted with alanine in rabbit (Table 2). Less conservation of the mutant $Na_v1.7$ residues is found among the $Na_v1.1$, $Na_v1.2$, and $Na_v1.3$ genes.

A broad variety of neurologic manifestations is observed in patients with mutations in $Na_v1.7$, suggestive of a wide clinical continuum. Illustrating the milder end of the continuum are two probands suffering only of infrequent febrile seizures before six years of age (Table 2: I62V, P149Q). An additional two such patients later developed rare generalized convulsive episodes (associated with generalized epileptiform discharges on EEG) that resolved by eight years of age (Table 2: K655R, I739V). All 21 affected individuals in K4425 experienced

febrile seizures before six years of age (Table 2: N641Y). Eight of these individuals had later afebrile seizures which remitted by the age of 16 in six individuals. Peiffer, *et al.* (1999) *Ann Neurol* 46:671-678). These patients with afebrile seizures that ultimately resolved suggest an intermediate phenotype.

5 Lastly, one proband in our study experienced multiple generalized clonic seizures which were predominantly afebrile, beginning at five months of age. This patient without a family history of seizures progressed to have frequent episodes of status epilepticus and prolonged complex partial seizures by 16 months, and at 5 years old, continues to have mixed seizures (including probable myoclonic and astatic

10 seizures) in spite of resolute therapeutic intervention. This last case represents the severe end of the clinical spectrum, and may be characterized as similar to SMEI (Table 1: L1123F). There is now abundant evidence for an increasing range of epilepsy phenotypes in patients with mutations in $Na_v1.1$ (*see* Nabbout, *et al.* (2003) *Neurology* 60:1961-1967; Fujiwara, *et al.* (2003) *Brain* 126:531-546).

15 Electrophysiological characterization of these unique $Na_v1.7$ mutations may help shed light on the variation in seizure manifestation observed in this group of patients.

To date, $Na_v1.1$ and $Na_v\beta1.1$ are the most commonly mutated genes in the febrile seizure phenotype. However, in an Australian cohort of 36 unrelated

20 GEFS+ samples, mutations in $Nav1.1$ and $Na_v\beta1.1$ account for only 17% of cases (*see* Wallace, *et al.* (2001) *Am J Hum Genet* 68:859-865). In our panel of 32 unrelated febrile seizure cases, only one $Na_v1.1$ mutation, R946H, was identified. $Na_v1.1$ is implicated as a major cause of SMEI or Dravet syndrome (*see* Nabbout, *et al.* (2003) *Neurology* 60:1961-1967; Fujiwara, *et al.* (2003) *Brain* 126:531-546;

25 Claes, *et al.* (2003) *Hum Mutat* 21:615-621). Since, GEFS+, and possibly SMEI, exhibit genetic heterogeneity, there can be a prevalence of $Na_v1.7$ mutations in cohorts of both disorders.

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by

30 reference into this application in order to more fully describe the state of the art to which this invention pertains.

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope

or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being

5 indicated by the following claims.

CLAIMS

We claim:

1. A method of characterizing a nucleic acid sequence that encodes a Na_v1.7 sodium channel alpha subunit, comprising the step of identifying mutations at one or more sites in regions of the nucleic acid sequence that encode an intracellular *N*-terminal region, an extracellular loop in domain I, an intracellular loop between domains I and II, an intracellular loop between domains II and III, an intramembrane region of domain II, or any combination thereof, such identified nucleotides indicating the character of the nucleic acid sequence.
2. The method of claim 1, wherein the mutation is present in the nucleic acid region encoding the intracellular *N*-terminus region of the subunit.
3. The method of claim 2, wherein the mutation encodes amino acid residue 62.
4. The method of claim 3, wherein the encoded amino acid residue is valine.
5. The method of claim 1, wherein the mutation is present in the nucleic acid region encoding the extracellular loop of domain I of the subunit.
6. The method of claim 5, wherein the mutation encodes amino acid residue 149.
7. The method of claim 6, wherein the encoded amino acid residue is glutamine.
8. The method of claim 1, wherein the mutation is present in the nucleic acid region encoding the intracellular loop between domains I and II of the subunit.
9. The method of claim 8, wherein the mutation encodes amino acid residue 641.
10. The method of claim 9, wherein the encoded amino acid residue is tyrosine.
11. The method of claim 8, wherein the mutation encodes amino acid residue 655.
12. The method of claim 11, wherein the encoded amino acid residue is arginine.
13. The method of claim 1, wherein the mutation is present in the nucleic acid region encoding the intracellular loop between domains II and III of the subunit.

14. The method of claim 13, wherein the mutation encodes amino acid residue 1123.
15. The method of claim 14, wherein the encoded amino acid residue is phenylalanine.
16. The method of claim 1, wherein the mutation is present in the nucleic acid region encoding the intramembrane region of domain II of the subunit.
17. The method of claim 16, wherein the mutation encodes amino acid residue 739.
18. The method of claim 17, wherein the encoded amino acid residue is valine.
19. The method of claim 1, wherein the step of identifying the mutations comprises comparing the nucleic acid sequence to a wild-type nucleic acid sequence.
20. The method of claim 19, wherein the wild-type nucleic acid sequence encodes the amino acid sequence of SEQ ID NO: 38.
21. The method of claim 1, wherein the identifying step comprises obtaining a biological sample and testing the sample to identify the nucleotides at the mutations sites of the nucleic acid contained therein.
22. The method of claim 21, wherein the sample is tested by sequencing or probing the nucleic acid.
23. The method of claim 22, wherein the testing step comprises the step of amplifying the nucleic acid contained in the sample.
24. The method of claim 23, wherein the testing step further comprises sequencing the amplified nucleic acid.
25. The method of claim 23, wherein the amplifying step comprises a polymerase chain reaction (PCR).
26. The method of claim 23, wherein the amplifying step comprises contacting the nucleic acid with a primer comprising one or more of the sequences of SEQ ID NOs: 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, and 31.

27. A method for determining a Na_v1.7 haplotype in a human subject comprising identifying one or more nucleotides encoding amino acid residues 62, 149, 641, 655, 739, 1123, or any combination thereof, wherein the nucleotide or nucleotides indicate the haplotype.
28. A method for determining a subject's predisposition to a neurologic disorder associated with a sodium channel mutation comprising comparing the subject's Na_v1.7 haplotype with one or more reference haplotypes that correlate with the neurologic disorder, a similar haplotype in the subject's Na_v1.7 haplotype as compared to the reference haplotype or haplotypes indicating a predisposition to the neurologic disorder.
29. The method of claim 28, wherein the neurologic disorder is a seizure disorder.
30. The method of claim 29, wherein the seizure disorder is a febrile seizure disorder.
31. The method of claim 28, wherein the reference haplotype comprises nucleotides that encode one or more mutations at residue 62, residue 149, residue 641, residue 655, residue 739, or residue 1123 of the encoded amino acid sequence of Na_v1.7.
32. A method of identifying a compound that modulates mutant Na_v1.7 sodium channels comprising:
 - a) contacting with a test compound a cell containing a mutant Na_v1.7 nucleic acid that encodes a mutant Na_v1.7 sodium channel comprising one or more mutations at residue 62, residue 149, residue 641, residue 655, residue 739, or residue 1123;
 - b) detecting Na_v1.7 sodium channel activity; and
 - c) comparing the Na_v1.7 sodium channel activity in the contacted cell with the amount of Na_v1.7 sodium channel activity in a control cell, wherein the control cell is not contacted by the test compound, an increased or decreased Na_v1.7 sodium channel activity in the test cell as compared to the control cell indicating a compound that modulates mutant Na_v1.7 sodium channels.

33. An isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2.
34. An isolated nucleic acid comprising a sequence that hybridizes under stringent conditions to the nucleic acid of claim 33 but not to the nucleic acid sequence that encodes SEQ ID NO: 38.
35. An expression vector comprising the nucleic acid of claim 33 operably linked to an expression control sequence.
36. A cultured cell comprising the vector of claim 35.
37. A method of making a mutant Na_v1.7 sodium channel alpha subunit comprising culturing the cell of claim 36 under conditions allowing expression of the polypeptide encoded by the nucleic acid, wherein the polypeptide comprises a mutant Na_v1.7 sodium channel.
38. An isolated nucleic acid comprising a nucleotide sequence encoding at least 5 residues of the amino acid sequence of SEQ ID NO: 2, wherein one of the amino acid residues comprises a valine in a position that corresponds to position 62 in SEQ ID NO: 2.
39. An isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3.
40. An isolated nucleic acid comprising a sequence that hybridizes under stringent conditions to the nucleic acid of claim 39 but not to the nucleic acid sequence that encodes SEQ ID NO: 38.
41. An expression vector comprising the nucleic acid of claim 39 operably linked to an expression control sequence.
42. A cultured cell comprising the vector of claim 41.
43. A method of making a mutant Na_v1.7 sodium channel alpha subunit comprising culturing the cell of claim 42 under conditions allowing expression of the polypeptide encoded by the nucleic acid, wherein the polypeptide comprises a mutant Na_v1.7 sodium channel.

44. An isolated nucleic acid comprising a nucleotide sequence encoding at least 5 residues of the amino acid sequence of SEQ ID NO: 3, wherein one of the amino acid residues comprises a glutamine in a position that corresponds to position 149 in SEQ ID NO: 3.
45. An isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 4.
46. An isolated nucleic acid comprising a sequence that hybridizes under stringent conditions to the nucleic acid of claim 45 but not to the nucleic acid sequence that encodes SEQ ID NO: 38.
47. An expression vector comprising the nucleic acid of claim 45 operably linked to an expression control sequence.
48. A cultured cell comprising the vector of claim 47.
49. A method of making a mutant Na_v1.7 sodium channel alpha subunit comprising culturing the cell of claim 48 under conditions allowing expression of the polypeptide encoded by the nucleic acid, wherein the polypeptide comprises a mutant Na_v1.7 sodium channel.
50. An isolated nucleic acid comprising a nucleotide sequence encoding at least 5 residues of the amino acid sequence of SEQ ID NO: 4, wherein one of the amino acid residues comprises a tyrosine in a position that corresponds to position 641 in SEQ ID NO: 4.
51. An isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 5.
52. An isolated nucleic acid comprising a sequence that hybridizes under stringent conditions to the nucleic acid of claim 51 but not to the nucleic acid sequence that encodes SEQ ID NO: 38.
53. An expression vector comprising the nucleic acid of claim 51 operably linked to an expression control sequence.
54. A cultured cell comprising the vector of claim 53.

55. A method of making a mutant Na_v1.7 sodium channel alpha subunit comprising culturing the cell of claim 54 under conditions allowing expression of the polypeptide encoded by the nucleic acid, wherein the polypeptide comprises a mutant Na_v1.7 sodium channel.
56. An isolated nucleic acid comprising a nucleotide sequence encoding at least 5 residues of the amino acid sequence of SEQ ID NO: 5, wherein one of the amino acid residues comprises a arginine in a position that corresponds to position 655 in SEQ ID NO: 5.
57. An isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 6.
58. An isolated nucleic acid comprising a sequence that hybridizes under stringent conditions to the nucleic acid of claim 57 but not to the nucleic acid sequence that encodes SEQ ID NO: 38.
59. An expression vector comprising the nucleic acid of claim 57 operably linked to an expression control sequence.
60. A cultured cell comprising the vector of claim 59.
61. A method of making a mutant Na_v1.7 sodium channel alpha subunit comprising culturing the cell of claim 60 under conditions allowing expression of the polypeptide encoded by the nucleic acid, wherein the polypeptide comprises a mutant Na_v1.7 sodium channel.
62. An isolated nucleic acid comprising a nucleotide sequence encoding at least 5 residues of the amino acid sequence of SEQ ID NO: 6, wherein one of the amino acid residues comprises a valine in a position that corresponds to position 739 in SEQ ID NO: 6.
63. An isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 7.
64. An isolated nucleic acid comprising a sequence that hybridizes under stringent conditions to the nucleic acid of claim 63 but not to the nucleic acid sequence that encodes SEQ ID NO: 38.
65. An expression vector comprising the nucleic acid of claim 63 operably linked to an expression control sequence.

66. A cultured cell comprising the vector of claim 65.
67. A method of making a mutant Na_v1.7 sodium channel alpha subunit comprising culturing the cell of claim 67 under conditions allowing expression of the polypeptide encoded by the nucleic acid, wherein the polypeptide comprises a mutant Na_v1.7 sodium channel.
68. An isolated nucleic acid comprising a nucleotide sequence encoding at least 5 residues of the amino acid sequence of SEQ ID NO: 7, wherein one of the amino acid residues comprises a phenylalanine in a position that corresponds to position 1123 in SEQ ID NO: 7.
69. A transgenic mouse comprising cells that encode a mutant Na_v1.7 sodium channel alpha subunit, wherein the mouse exhibits increased seizure activity as compared to the wild-type mouse.
70. An isolated polypeptide comprising SEQ ID NO: 2.
71. An isolated polypeptide comprising SEQ ID NO: 32.
72. An isolated polypeptide comprising SEQ ID NO: 3.
73. An isolated polypeptide comprising SEQ ID NO: 33.
74. An isolated polypeptide comprising SEQ ID NO: 4.
75. An isolated polypeptide comprising SEQ ID NO: 34.
76. An isolated polypeptide comprising SEQ ID NO: 5.
77. An isolated polypeptide comprising SEQ ID NO: 35.
78. An isolated polypeptide comprising SEQ ID NO: 6.
79. An isolated polypeptide comprising SEQ ID NO: 36.
80. An isolated polypeptide comprising SEQ ID NO: 7.
81. An isolated polypeptide comprising SEQ ID NO: 37.
82. A purified antibody that selectively binds to an epitope of a mutant Na_v1.7 sodium channel alpha subunit.
83. The antibody of claim 82, wherein the mutant is an I62V mutant.
84. The antibody of claim 82, wherein the mutant is an P149Q mutant.

ATTORNEY DOCKET NO.: 21101.0048U1

- 85. The antibody of claim 82, wherein the mutant is an N641Y mutant.
- 86. The antibody of claim 82, wherein the mutant is an K655R mutant.
- 87. The antibody of claim 82, wherein the mutant is an I739V mutant.
- 88. The antibody of claim 82, wherein the mutant is an L1123F mutant.

ABSTRACT

Described are mutant Na_v1.7 sodium channel alpha-subunits and nucleic
5 acid sequences encoding such mutants. Further described are methods for
characterizing a nucleic acid sequence that encodes a Na_v1 sodium channel alpha-
subunit, methods for determining a Na_v1.7 haplotype, methods for determining a
subject's predisposition to a neurologic disorder associated with a sodium channel
mutation, and methods of identifying a compound that modulates mutant Na_v1.7
10 sodium channels. Other materials, compositions, articles, devices, and methods
relating to mutant Na_v1.7 sodium channels are also described herein.

SEQUENCE LISTING

<110> Leppert, Mark F.
Singh, Nanda A.

<120> Mutant Sodium Channel Nav1.7 and Methods
Related Thereto

<130> 21101.0048U1

<160> 38

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 5934

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 1

```

atggcaatgt tgcctcccc aggacctcag agctttgtcc atttcacaaa acagtctctt 60
gccctcattg aacaacgcat tgctgaaaga aaatcaaagg aacccaaaga agaaaagaaa 120
gatgatgatg aagaagcccc aaagccaagc agtgacttgg aagctggcaa acaactgccc 180
ttcatctatg gggacattcc tcccggcatg gtgtcagagc ccctggagga cttggacccc 240
tactatgcag acaaaaagac ttcatagta ttgaacaaag ggaaaacaat cttccgttcc 300
aatgccacac ctgctttata tatgctttct cctttcagtc ctctaagaag aatatctatt 360
aagattttag tacactcctt attcagcatg ctcacatgtg gcactattct gacaaactgc 420
atattttatga ccatgaataa cccgccggac tggacaaaaa atgtcgagta cacttttact 480
ggaatatata cttttgaatc acttgtaaaa atccttgcaa gaggtctctg tgtaggagaa 540
ttcacttttc ttctgtgacc gtggaactgg ctggattttg tcgtcattgt ttttgcgtat 600
ttaacagaat ttgtaaacct agccaatgtt tcagctcttc gaactttcag agtattgaga 660
gctttgaaaa ctatttctgt aatcccaggc ctgaagacaa ttgtaggggc tttgatccag 720
tcagtgaaga agctttctga tgcatgatc ctgactgtgt tctgtctgag tgtgtttgca 780
ctaattggac tacagctgtt catgggaaac ctgaagcata aatgttttcg aaattcactt 840
gaaaataatg aaacattaga aagcataatg aataccctag agagtgaaga agactttaga 900
aaatatTTTT attacttggg aggatccaaa gatgctctcc tttgtgggtt cagcacagat 960
tcaggtcagt gtccagaggg gtacacctgt gtgaaaattg gcagaaaccc tgattatggc 1020
tacacgagct ttgacacttt cagctgggcc ttcttagcct tgtttaggct aatgacccaa 1080
gattactggg aaaaccttta ccaacagacg ctgcgtgctg ctggcaaaac ctacatgatc 1140
ttctttgtcg tagtgatttt cctgggctcc ttttatctaa taaacttgat cctggctgtg 1200
gttgccatgg catatgaaga acagaaccag gcaaacattg aagaagctaa acagaaagaa 1260
ttagaatttc aacagatgtt agaccgtctt aaaaagagc aagaagaagc tgaggcaatt 1320
gcagcggcag cggctgaata tacaagtatt aggagaagca gaattatggg cctctcagag 1380
agtctctctg aaacatccaa actgagctct aaaagtgcta aagaagaagc aaacagaaga 1440
aagaaaaaga atcaaaagaa gctctccagt ggagaggaaa agggagatgc tgagaaattg 1500
tcgaaatcag aatcagagga cagcatcaga agaaaaagtt tccaccttgg tgtcgaaggg 1560
cataggcgag cacatgaaaa gaggttgtct acccccaatc agtcaccact cagcattcgt 1620
ggctccttgt tttctgcaag gcgaagcagc agaacaagtc tttttagttt caaaggcaga 1680
ggaagagata taggatctga gactgaattt gccgatgatg agcacagcat ttttggagac 1740
aatgagagca gaaggggctc actgtttgtg cccacagac cccaggagcg acgcagcagt 1800
aacatcagcc aagccagtag gtcccaacca atgctgccgg tgaacgggaa aatgcacagt 1860
gctgtggact gcaacggtgt ggtctccctg gttgatggac gctcagccct catgctcccc 1920
aatggacagc ttctgccaga gggcacgacc aatcaaatac acaagaaaag gcgttgtagt 1980
tcctatctcc tttcagagga tatgctgaat gatcccaacc tcagacagag agcaatgagt 2040
agagcaagca tattaacaaa cactgtggaa gaacttgaag agtccagaca aaaatgtcca 2100
ccttggtggt acagatttgc acacaaattc ttgatctgga attgctctcc atattggata 2160

```

ATTORNEY DOCKET NO. 21101.0048U1

aaattcaaaa	agtgtatcta	ttttattgta	atggatcctt	ttgtagatct	tgcaattacc	2220
atttgcatag	ttttaaacac	atttatttatg	gctatggaac	accacccaat	gactgaggaa	2280
ttcaaaaatg	tacttgctat	aggaaatttg	gtctttactg	gaatccttgc	agctgaaatg	2340
gtattaaaac	tgattgccat	ggatccatat	gagtatcttc	aagtaggctg	gaatattttt	2400
gacagcctta	ttgtgacttt	aagtttagtg	gagctcttcc	tagcagatgt	ggaaggattg	2460
tcagttctgc	gatcattcag	actgctccga	gtcttcaagt	tggcaaaatc	ctggccaaca	2520
ttgaacatgc	tgattaaagat	cattggtaac	tcagtagggg	ctctaggtaa	cctcacctta	2580
gtgttgccca	tcacgtctct	catttttgct	gtggtcggca	tgtagctctt	tggtaagagc	2640
tacaaagaat	gtgtctgcaa	gatcaatgat	gactgtacgc	tcccacgggtg	gcacatgaac	2700
gacttcttcc	actccttccct	gatttgtgtc	cgcgtgctgt	gtggagagtg	gatagagacc	2760
atgtgggact	gtatggagggt	cgtgggtcaa	gctatgtgcc	ttattgttta	catgatggtc	2820
atggtcattg	gaaacctggg	ggctcctaac	ctatttctgg	ccttattatt	gagctcattt	2880
agttcagaca	atcttacagc	aattgaagaa	gacctgatg	caaacaacct	ccagattgca	2940
gtgactagaa	ttaaaaaggg	aataaattat	gtgaaacaaa	ccttacgtga	atattattcta	3000
aaagcatttt	ccaaaaagcc	aaagatttcc	agggagataa	gacaagcaga	agatctgaat	3060
actaagaagg	aaaaactatat	ttctaaccat	acacttgctg	aatgagcaa	aggtcacaat	3120
ttcctcaagg	aaaaagataa	aatcagtggt	tttggaaagca	gcgtggacaa	acacttgatg	3180
gaagacagtg	atgggtcaatc	atattattcac	aatcccagcc	tcacagtgac	agtgcccaatt	3240
gcacctgggg	aatccgattt	ggaaaatatg	aatgctgagg	aacttagcag	tgattcggat	3300
agtgaataca	gcaaagtgag	attaaaccgg	tcaagctcct	cagagtgacg	cacagttgat	3360
aaccttttgc	ctggagaagg	agaagaagca	gaggctgaac	ctatgaattc	cgatgagcca	3420
gaggcctgtt	tcacagatgg	ttgtgtacgg	aggttctcat	gctgccaagt	taacatagag	3480
tcagggaaag	gaaaaatctg	gtggaacatc	aggaaaacct	gctacaagat	tggtgaacac	3540
agttgggttg	aaagcttcat	tgctctcatg	atcctgctca	gcagtggtgc	cctggctttt	3600
gaagatattt	atattgaaag	gaaaaagacc	attaagatta	tcctggagta	tgagacaaag	3660
atcttcactt	acatcttcat	tctggaatg	cttctaaaat	ggatagcata	tggttataaa	3720
acatatattca	ccaatgcctg	gtgttggtg	gatttcttaa	ttgttgatgt	ttctttgggt	3780
actttagtgg	caaacactct	tggtacttca	gatcttggtc	ccattaaatc	ccttcggaca	3840
ctgagagctt	taagacctct	aagagcctta	tctagatttg	aaggaatgag	ggctcgttgtg	3900
aatgcactca	taggagcaat	tccttccatc	atgaatgtgc	tacttgtgtg	tcttatattc	3960
tggtctgat	tcagcatcat	gggagtaaat	ttgtttgctg	gcaagttcta	tgagtgtatt	4020
aacaccacag	atgggtcacg	gtttctctga	agtcaagttc	caaatcgttc	cgaatgtttt	4080
gcccttatga	atgttagtca	aaatgtgcga	tgaaaaaacc	tgaaagtga	ctttgataat	4140
gtcggacttg	gttacctatc	tctgcttcaa	gttgcaactt	ttaagggatg	gacgattatt	4200
atgtatgcag	cagtggtatc	tggtaatgta	gacaagcagc	ccaaatatga	atatagcctc	4260
tacatgtata	tttattttgt	cgtctttatc	atctttgggt	cattcttcac	tttgaacttg	4320
ttcattgggt	tcacatagat	taatttcaac	caacagaaaa	agaagcttgg	aggtcaagac	4380
atctttatga	cagaagaaca	gaagaataac	tataatgcaa	tgaaaaagct	gggggtccaag	4440
aagccacaaa	agccaattcc	tcgaccaggg	aacaaaatcc	aaggatgtat	atttgacctt	4500
gtgacaaatc	aagcctttga	tattagtatc	atggttctta	tctgtctcaa	catggtaacc	4560
atgatggtag	aaaaggaggg	tcaaagtcaa	catatgactg	aagttttata	ttggataaat	4620
gtggttttta	taatcctttt	cactggagaa	tggtgtctaa	aactgatctc	cctcagacac	4680
tactacttca	ctgtaggatg	gaatattttt	gattttgtgg	ttgtgattat	ctccattgta	4740
ggtagtcttc	tagctgattt	gattgaaacg	tattttgtgt	cccctaccct	gttccgagtg	4800
atcctgtctg	ccaggattgg	ccgaatccta	cgtctagtca	aaggagcaaa	ggggatccgc	4860
acgctgctct	ttgctttgat	gatgtccctt	cctgcgttgt	ttaacatcgg	cctcctgctc	4920
ttcctgggtca	tgttcatcta	cgccatcttt	ggaatgtcca	actttgccta	tgttaaaaag	4980
gaagatggaa	ttaatgacat	gttcaatttt	gagacctttg	gcaacagtat	gatttgcctg	5040
ttccaaaatta	caacctctgc	tggtggggat	ggattgtctg	cacctattct	taacagtaag	5100
ccacccgact	gtgacccaaa	aaaagttcat	cctggaaagt	cagttgaagg	agactgtggg	5160
aaacctctg	ttggaatatt	ctactttgtt	agttatatca	tcatactcct	cctgggttgtg	5220
gtgaacatgt	acattgcagt	catactggag	aatttttagtg	ttgccactga	agaaagtact	5280
gaacctctga	gtgaggatga	ctttgagatg	ttctatgagg	tttgggagaa	gtttgatccc	5340
gatgcgaccc	agtttataga	gttctctaaa	ctctctgatt	ttgcagctgc	cctggatcct	5400
cctcttctca	tagcaaaaacc	caacaaagtc	cagctcattg	ccatggatct	gcccatgggt	5460
agtggtgacc	ggatccattg	tcttgacatc	ttatttgctt	ttacaaagcg	tgttttgggt	5520
gagagtgggg	agatggattc	tcttcgttca	cagatggaa	aaaggttcat	gtctgcaaat	5580
ccttccaaag	tgctctatga	accatcaca	accacactaa	aacggaaaca	agaggatgtg	5640
tctgtactgt	tcattcagcg	tgcttataga	cgttaccgct	taaggcaaaa	tgtaaaaaat	5700
atatcaagta	tatacataaa	agatggagac	agagatgatg	atttactcaa	taaaaaagat	5760
atggcttttg	ataatgttaa	tgagaactca	agtccagaaa	aaacagatgc	cacttcatcc	5820

ATTORNEY DOCKET NO. 21101.0048U1

accacctctc caccttcata tgatagtgtg acaaagccag acaaagagaa atatgaacaa 5880
gacagaacag aaaaggaaga caaagggaaa gacagcaagg aaagcaaaaa atag 5934

<210> 2
<211> 1977
<212> PRT
<213> Homo Sapien

<400> 2
Met Ala Met Leu Pro Pro Pro Gly Pro Gln Ser Phe Val His Phe Thr
1 5 10 15
Lys Gln Ser Leu Ala Leu Ile Glu Gln Arg Ile Ala Glu Arg Lys Ser
20 25 30
Lys Glu Pro Lys Glu Glu Lys Lys Asp Asp Asp Glu Glu Ala Pro Lys
35 40 45
Pro Ser Ser Asp Leu Glu Ala Gly Lys Gln Leu Pro Phe Val Tyr Gly
50 55 60
Asp Ile Pro Pro Gly Met Val Ser Glu Pro Leu Glu Asp Leu Asp Pro
65 70 75 80
Tyr Tyr Ala Asp Lys Lys Thr Phe Ile Val Leu Asn Lys Gly Lys Thr
85 90 95
Ile Phe Arg Phe Asn Ala Thr Pro Ala Leu Tyr Met Leu Ser Pro Phe
100 105 110
Ser Pro Leu Arg Arg Ile Ser Ile Lys Ile Leu Val His Ser Leu Phe
115 120 125
Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Ile Phe Met Thr
130 135 140
Met Asn Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr Phe Thr
145 150 155 160
Gly Ile Tyr Thr Phe Glu Ser Leu Val Lys Ile Leu Ala Arg Gly Phe
165 170 175
Cys Val Gly Glu Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp Leu Asp
180 185 190
Phe Val Val Ile Val Phe Ala Tyr Leu Thr Glu Phe Val Asn Leu Gly
195 200 205
Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu Lys Thr
210 215 220
Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala Leu Ile Gln
225 230 235 240
Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val Phe Cys Leu
245 250 255
Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn Leu Lys
260 265 270
His Lys Cys Phe Arg Asn Ser Leu Glu Asn Asn Glu Thr Leu Glu Ser
275 280 285
Ile Met Asn Thr Leu Glu Ser Glu Glu Asp Phe Arg Lys Tyr Phe Tyr
290 295 300
Tyr Leu Glu Gly Ser Lys Asp Ala Leu Leu Cys Gly Phe Ser Thr Asp
305 310 315 320
Ser Gly Gln Cys Pro Glu Gly Tyr Thr Cys Val Lys Ile Gly Arg Asn
325 330 335
Pro Asp Tyr Gly Tyr Thr Ser Phe Asp Thr Phe Ser Trp Ala Phe Leu
340 345 350
Ala Leu Phe Arg Leu Met Thr Gln Asp Tyr Trp Glu Asn Leu Tyr Gln
355 360 365
Gln Thr Leu Arg Ala Ala Gly Lys Thr Tyr Met Ile Phe Phe Val Val
370 375 380

ATTORNEY DOCKET NO. 21101.0048U1

Val	Ile	Phe	Leu	Gly	Ser	Phe	Tyr	Leu	Ile	Asn	Leu	Ile	Leu	Ala	Val	385	390	395	400
Val	Ala	Met	Ala	Tyr	Glu	Glu	Gln	Asn	Gln	Ala	Asn	Ile	Glu	Glu	Ala	405	410	415	
Lys	Gln	Lys	Glu	Leu	Glu	Phe	Gln	Gln	Met	Leu	Asp	Arg	Leu	Lys	Lys	420	425	430	
Glu	Gln	Glu	Glu	Ala	Glu	Ala	Ile	Ala	Ala	Ala	Ala	Ala	Glu	Tyr	Thr	435	440	445	
Ser	Ile	Arg	Arg	Ser	Arg	Ile	Met	Gly	Leu	Ser	Glu	Ser	Ser	Ser	Glu	450	455	460	
Thr	Ser	Lys	Leu	Ser	Ser	Lys	Ser	Ala	Lys	Glu	Arg	Arg	Asn	Arg	Arg	465	470	475	480
Lys	Lys	Lys	Asn	Gln	Lys	Lys	Leu	Ser	Ser	Gly	Glu	Glu	Lys	Gly	Asp	485	490	495	
Ala	Glu	Lys	Leu	Ser	Lys	Ser	Glu	Ser	Glu	Asp	Ser	Ile	Arg	Arg	Lys	500	505	510	
Ser	Phe	His	Leu	Gly	Val	Glu	Gly	His	Arg	Arg	Ala	His	Glu	Lys	Arg	515	520	525	
Leu	Ser	Thr	Pro	Asn	Gln	Ser	Pro	Leu	Ser	Ile	Arg	Gly	Ser	Leu	Phe	530	535	540	
Ser	Ala	Arg	Arg	Ser	Ser	Arg	Thr	Ser	Leu	Phe	Ser	Phe	Lys	Gly	Arg	545	550	555	560
Gly	Arg	Asp	Ile	Gly	Ser	Glu	Thr	Glu	Phe	Ala	Asp	Asp	Glu	His	Ser	565	570	575	
Ile	Phe	Gly	Asp	Asn	Glu	Ser	Arg	Arg	Gly	Ser	Leu	Phe	Val	Pro	His	580	585	590	
Arg	Pro	Gln	Glu	Arg	Arg	Ser	Ser	Asn	Ile	Ser	Gln	Ala	Ser	Arg	Ser	595	600	605	
Pro	Pro	Met	Leu	Pro	Val	Asn	Gly	Lys	Met	His	Ser	Ala	Val	Asp	Cys	610	615	620	
Asn	Gly	Val	Val	Ser	Leu	Val	Asp	Gly	Arg	Ser	Ala	Leu	Met	Leu	Pro	625	630	635	640
Asn	Gly	Gln	Leu	Leu	Pro	Glu	Gly	Thr	Thr	Asn	Gln	Ile	His	Lys	Lys	645	650	655	
Arg	Arg	Cys	Ser	Ser	Tyr	Leu	Leu	Ser	Glu	Asp	Met	Leu	Asn	Asp	Pro	660	665	670	
Asn	Leu	Arg	Gln	Arg	Ala	Met	Ser	Arg	Ala	Ser	Ile	Leu	Thr	Asn	Thr	675	680	685	
Val	Glu	Glu	Leu	Glu	Glu	Ser	Arg	Gln	Lys	Cys	Pro	Pro	Trp	Trp	Tyr	690	695	700	
Arg	Phe	Ala	His	Lys	Phe	Leu	Ile	Trp	Asn	Cys	Ser	Pro	Tyr	Trp	Ile	705	710	715	720
Lys	Phe	Lys	Lys	Cys	Ile	Tyr	Phe	Ile	Val	Met	Asp	Pro	Phe	Val	Asp	725	730	735	
Leu	Ala	Ile	Thr	Ile	Cys	Ile	Val	Leu	Asn	Thr	Leu	Phe	Met	Ala	Met	740	745	750	
Glu	His	His	Pro	Met	Thr	Glu	Glu	Phe	Lys	Asn	Val	Leu	Ala	Ile	Gly	755	760	765	
Asn	Leu	Val	Phe	Thr	Gly	Ile	Phe	Ala	Ala	Glu	Met	Val	Leu	Lys	Leu	770	775	780	
Ile	Ala	Met	Asp	Pro	Tyr	Glu	Tyr	Phe	Gln	Val	Gly	Trp	Asn	Ile	Phe	785	790	795	800
Asp	Ser	Leu	Ile	Val	Thr	Leu	Ser	Leu	Val	Glu	Leu	Phe	Leu	Ala	Asp	805	810	815	
Val	Glu	Gly	Leu	Ser	Val	Leu	Arg	Ser	Phe	Arg	Leu	Leu	Arg	Val	Phe	820	825	830	
Lys	Leu	Ala	Lys	Ser	Trp	Pro	Thr	Leu	Asn	Met	Leu	Ile	Lys	Ile	Ile	835	840	845	
Gly	Asn	Ser	Val	Gly	Ala	Leu	Gly	Asn	Leu	Thr	Leu	Val	Leu	Ala	Ile	850	855	860	

ATTORNEY DOCKET NO. 21101.0048U1

Ile	Val	Phe	Ile	Phe	Ala	Val	Val	Gly	Met	Gln	Leu	Phe	Gly	Lys	Ser	865	870	875	880
Tyr	Lys	Glu	Cys	Val	Cys	Lys	Ile	Asn	Asp	Asp	Cys	Thr	Leu	Pro	Arg	885	890	895	
Trp	His	Met	Asn	Asp	Phe	Phe	His	Ser	Phe	Leu	Ile	Val	Phe	Arg	Val	900	905	910	
Leu	Cys	Gly	Glu	Trp	Ile	Glu	Thr	Met	Trp	Asp	Cys	Met	Glu	Val	Ala	915	920	925	
Gly	Gln	Ala	Met	Cys	Leu	Ile	Val	Tyr	Met	Met	Val	Met	Val	Ile	Gly	930	935	940	
Asn	Leu	Val	Val	Leu	Asn	Leu	Phe	Leu	Ala	Leu	Leu	Leu	Ser	Ser	Phe	945	950	955	960
Ser	Ser	Asp	Asn	Leu	Thr	Ala	Ile	Glu	Glu	Asp	Pro	Asp	Ala	Asn	Asn	965	970		975
Leu	Gln	Ile	Ala	Val	Thr	Arg	Ile	Lys	Lys	Gly	Ile	Asn	Tyr	Val	Lys	980	985	990	
Gln	Thr	Leu	Arg	Glu	Phe	Ile	Leu	Lys	Ala	Phe	Ser	Lys	Lys	Pro	Lys	995	1000	1005	
Ile	Ser	Arg	Glu	Ile	Arg	Gln	Ala	Glu	Asp	Leu	Asn	Thr	Lys	Lys	Glu	1010	1015	1020	
Asn	Tyr	Ile	Ser	Asn	His	Thr	Leu	Ala	Glu	Met	Ser	Lys	Gly	His	Asn	1025	1030	1035	1040
Phe	Leu	Lys	Glu	Lys	Asp	Lys	Ile	Ser	Gly	Phe	Gly	Ser	Ser	Val	Asp	1045	1050		1055
Lys	His	Leu	Met	Glu	Asp	Ser	Asp	Gly	Gln	Ser	Phe	Ile	His	Asn	Pro	1060	1065	1070	
Ser	Leu	Thr	Val	Thr	Val	Pro	Ile	Ala	Pro	Gly	Glu	Ser	Asp	Leu	Glu	1075	1080	1085	
Asn	Met	Asn	Ala	Glu	Glu	Leu	Ser	Ser	Asp	Ser	Asp	Ser	Glu	Tyr	Ser	1090	1095	1100	
Lys	Val	Arg	Leu	Asn	Arg	Ser	Ser	Ser	Ser	Glu	Cys	Ser	Thr	Val	Asp	1105	1110	1115	1120
Asn	Pro	Leu	Pro	Gly	Glu	Gly	Glu	Glu	Ala	Glu	Ala	Glu	Pro	Met	Asn	1125	1130		1135
Ser	Asp	Glu	Pro	Glu	Ala	Cys	Phe	Thr	Asp	Gly	Cys	Val	Arg	Arg	Phe	1140	1145	1150	
Ser	Cys	Cys	Gln	Val	Asn	Ile	Glu	Ser	Gly	Lys	Gly	Lys	Ile	Trp	Trp	1155	1160	1165	
Asn	Ile	Arg	Lys	Thr	Cys	Tyr	Lys	Ile	Val	Glu	His	Ser	Trp	Phe	Glu	1170	1175	1180	
Ser	Phe	Ile	Val	Leu	Met	Ile	Leu	Leu	Ser	Ser	Gly	Ala	Leu	Ala	Phe	1185	1190	1195	1200
Glu	Asp	Ile	Tyr	Ile	Glu	Arg	Lys	Lys	Thr	Ile	Lys	Ile	Ile	Leu	Glu	1205	1210	1215	
Tyr	Ala	Asp	Lys	Ile	Phe	Thr	Tyr	Ile	Phe	Ile	Leu	Glu	Met	Leu	Leu	1220	1225	1230	
Lys	Trp	Ile	Ala	Tyr	Gly	Tyr	Lys	Thr	Tyr	Phe	Thr	Asn	Ala	Trp	Cys	1235	1240	1245	
Trp	Leu	Asp	Phe	Leu	Ile	Val	Asp	Val	Ser	Leu	Val	Thr	Leu	Val	Ala	1250	1255	1260	
Asn	Thr	Leu	Gly	Tyr	Ser	Asp	Leu	Gly	Pro	Ile	Lys	Ser	Leu	Arg	Thr	1265	1270	1275	1280
Leu	Arg	Ala	Leu	Arg	Pro	Leu	Arg	Ala	Leu	Ser	Arg	Phe	Glu	Gly	Met	1285	1290		1295
Arg	Val	Val	Val	Asn	Ala	Leu	Ile	Gly	Ala	Ile	Pro	Ser	Ile	Met	Asn	1300	1305	1310	
Val	Leu	Leu	Val	Cys	Leu	Ile	Phe	Trp	Leu	Ile	Phe	Ser	Ile	Met	Gly	1315	1320	1325	
Val	Asn	Leu	Phe	Ala	Gly	Lys	Phe	Tyr	Glu	Cys	Ile	Asn	Thr	Thr	Asp	1330	1335	1340	

Gly	Ser	Arg	Phe	Pro	Ala	Ser	Gln	Val	Pro	Asn	Arg	Ser	Glu	Cys	Phe	
1345					1350					1355					1360	
Ala	Leu	Met	Asn	Val	Ser	Gln	Asn	Val	Arg	Trp	Lys	Asn	Leu	Lys	Val	
			1365						1370					1375		
Asn	Phe	Asp	Asn	Val	Gly	Leu	Gly	Tyr	Leu	Ser	Leu	Leu	Gln	Val	Ala	
			1380					1385					1390			
Thr	Phe	Lys	Gly	Trp	Thr	Ile	Ile	Met	Tyr	Ala	Ala	Val	Asp	Ser	Val	
		1395					1400					1405				
Asn	Val	Asp	Lys	Gln	Pro	Lys	Tyr	Glu	Tyr	Ser	Leu	Tyr	Met	Tyr	Ile	
	1410					1415					1420					
Tyr	Phe	Val	Val	Phe	Ile	Ile	Phe	Gly	Ser	Phe	Phe	Thr	Leu	Asn	Leu	
1425				1430					1435						1440	
Phe	Ile	Gly	Val	Ile	Ile	Asp	Asn	Phe	Asn	Gln	Gln	Lys	Lys	Lys	Leu	
			1445					1450						1455		
Gly	Gly	Gln	Asp	Ile	Phe	Met	Thr	Glu	Glu	Gln	Lys	Lys	Tyr	Tyr	Asn	
			1460					1465					1470			
Ala	Met	Lys	Lys	Leu	Gly	Ser	Lys	Lys	Pro	Gln	Lys	Pro	Ile	Pro	Arg	
		1475					1480					1485				
Pro	Gly	Asn	Lys	Ile	Gln	Gly	Cys	Ile	Phe	Asp	Leu	Val	Thr	Asn	Gln	
	1490					1495					1500					
Ala	Phe	Asp	Ile	Ser	Ile	Met	Val	Leu	Ile	Cys	Leu	Asn	Met	Val	Thr	
1505				1510					1515						1520	
Met	Met	Val	Glu	Lys	Glu	Gly	Gln	Ser	Gln	His	Met	Thr	Glu	Val	Leu	
			1525						1530					1535		
Tyr	Trp	Ile	Asn	Val	Val	Phe	Ile	Ile	Leu	Phe	Thr	Gly	Glu	Cys	Val	
		1540						1545					1550			
Leu	Lys	Leu	Ile	Ser	Leu	Arg	His	Tyr	Tyr	Phe	Thr	Val	Gly	Trp	Asn	
		1555					1560					1565				
Ile	Phe	Asp	Phe	Val	Val	Val	Ile	Ile	Ser	Ile	Val	Gly	Met	Phe	Leu	
	1570			1575					1580							
Ala	Asp	Leu	Ile	Glu	Thr	Tyr	Phe	Val	Ser	Pro	Thr	Leu	Phe	Arg	Val	
1585				1590					1595						1600	
Ile	Arg	Leu	Ala	Arg	Ile	Gly	Arg	Ile	Leu	Arg	Leu	Val	Lys	Gly	Ala	
			1605					1610						1615		
Lys	Gly	Ile	Arg	Thr	Leu	Leu	Phe	Ala	Leu	Met	Met	Ser	Leu	Pro	Ala	
		1620					1625						1630			
Leu	Phe	Asn	Ile	Gly	Leu	Leu	Leu	Phe	Leu	Val	Met	Phe	Ile	Tyr	Ala	
	1635						1640					1645				
Ile	Phe	Gly	Met	Ser	Asn	Phe	Ala	Tyr	Val	Lys	Lys	Glu	Asp	Gly	Ile	
	1650				1655				1660							
Asn	Asp	Met	Phe	Asn	Phe	Glu	Thr	Phe	Gly	Asn	Ser	Met	Ile	Cys	Leu	
1665				1670				1675								

ATTORNEY DOCKET NO. 21101.0048U1

Ile His Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly
 1825 1830 1835 1840
 Glu Ser Gly Glu Met Asp Ser Leu Arg Ser Gln Met Glu Glu Arg Phe
 1845 1850 1855
 Met Ser Ala Asn Pro Ser Lys Val Ser Tyr Glu Pro Ile Thr Thr Thr
 1860 1865 1870
 Leu Lys Arg Lys Gln Glu Asp Val Ser Ala Thr Val Ile Gln Arg Ala
 1875 1880 1885
 Tyr Arg Arg Tyr Arg Leu Arg Gln Asn Val Lys Asn Ile Ser Ser Ile
 1890 1895 1900
 Tyr Ile Lys Asp Gly Asp Arg Asp Asp Asp Leu Leu Asn Lys Lys Asp
 1905 1910 1915 1920
 Met Ala Phe Asp Asn Val Asn Glu Asn Ser Ser Pro Glu Lys Thr Asp
 1925 1930 1935
 Ala Thr Ser Ser Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys
 1940 1945 1950
 Pro Asp Lys Glu Lys Tyr Glu Gln Asp Arg Thr Glu Lys Glu Asp Lys
 1955 1960 1965
 Gly Lys Asp Ser Lys Glu Ser Lys Lys
 1970 1975

<210> 3
 <211> 1977
 <212> PRT
 <213> Homo Sapien

<400> 3
 Met Ala Met Leu Pro Pro Pro Gly Pro Gln Ser Phe Val His Phe Thr
 1 5 10 15
 Lys Gln Ser Leu Ala Leu Ile Glu Gln Arg Ile Ala Glu Arg Lys Ser
 20 25 30
 Lys Glu Pro Lys Glu Glu Lys Lys Asp Asp Asp Glu Glu Ala Pro Lys
 35 40 45
 Pro Ser Ser Asp Leu Glu Ala Gly Lys Gln Leu Pro Phe Ile Tyr Gly
 50 55 60
 Asp Ile Pro Pro Gly Met Val Ser Glu Pro Leu Glu Asp Leu Asp Pro
 65 70 75 80
 Tyr Tyr Ala Asp Lys Lys Thr Phe Ile Val Leu Asn Lys Gly Lys Thr
 85 90 95
 Ile Phe Arg Phe Asn Ala Thr Pro Ala Leu Tyr Met Leu Ser Pro Phe
 100 105 110
 Ser Pro Leu Arg Arg Ile Ser Ile Lys Ile Leu Val His Ser Leu Phe
 115 120 125
 Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Ile Phe Met Thr
 130 135 140
 Met Asn Asn Pro Gln Asp Trp Thr Lys Asn Val Glu Tyr Thr Phe Thr
 145 150 155 160
 Gly Ile Tyr Thr Phe Glu Ser Leu Val Lys Ile Leu Ala Arg Gly Phe
 165 170 175
 Cys Val Gly Glu Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp Leu Asp
 180 185 190
 Phe Val Val Ile Val Phe Ala Tyr Leu Thr Glu Phe Val Asn Leu Gly
 195 200 205
 Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu Lys Thr
 210 215 220
 Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala Leu Ile Gln
 225 230 235 240
 Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val Phe Cys Leu
 245 250 255

ATTORNEY DOCKET NO. 21101.0048U1

Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn Leu Lys
260 265 270
His Lys Cys Phe Arg Asn Ser Leu Glu Asn Asn Glu Thr Leu Glu Ser
275 280 285
Ile Met Asn Thr Leu Glu Ser Glu Glu Asp Phe Arg Lys Tyr Phe Tyr
290 295 300
Tyr Leu Glu Gly Ser Lys Asp Ala Leu Leu Cys Gly Phe Ser Thr Asp
305 310 315 320
Ser Gly Gln Cys Pro Glu Gly Tyr Thr Cys Val Lys Ile Gly Arg Asn
325 330 335
Pro Asp Tyr Gly Tyr Thr Ser Phe Asp Thr Phe Ser Trp Ala Phe Leu
340 345 350
Ala Leu Phe Arg Leu Met Thr Gln Asp Tyr Trp Glu Asn Leu Tyr Gln
355 360 365
Gln Thr Leu Arg Ala Ala Gly Lys Thr Tyr Met Ile Phe Phe Val Val
370 375 380
Val Ile Phe Leu Gly Ser Phe Tyr Leu Ile Asn Leu Ile Leu Ala Val
385 390 395 400
Val Ala Met Ala Tyr Glu Glu Gln Asn Gln Ala Asn Ile Glu Glu Ala
405 410 415
Lys Gln Lys Glu Leu Glu Phe Gln Gln Met Leu Asp Arg Leu Lys Lys
420 425 430
Glu Gln Glu Glu Ala Glu Ala Ile Ala Ala Ala Ala Glu Tyr Thr
435 440 445
Ser Ile Arg Arg Ser Arg Ile Met Gly Leu Ser Glu Ser Ser Ser Glu
450 455 460
Thr Ser Lys Leu Ser Ser Lys Ser Ala Lys Glu Arg Arg Asn Arg Arg
465 470 475 480
Lys Lys Lys Asn Gln Lys Lys Leu Ser Ser Gly Glu Glu Lys Gly Asp
485 490 495
Ala Glu Lys Leu Ser Lys Ser Glu Ser Glu Asp Ser Ile Arg Arg Lys
500 505 510
Ser Phe His Leu Gly Val Glu Gly His Arg Arg Ala His Glu Lys Arg
515 520 525
Leu Ser Thr Pro Asn Gln Ser Pro Leu Ser Ile Arg Gly Ser Leu Phe
530 535 540
Ser Ala Arg Arg Ser Ser Arg Thr Ser Leu Phe Ser Phe Lys Gly Arg
545 550 555 560
Gly Arg Asp Ile Gly Ser Glu Thr Glu Phe Ala Asp Asp Glu His Ser
565 570 575
Ile Phe Gly Asp Asn Glu Ser Arg Arg Gly Ser Leu Phe Val Pro His
580 585 590
Arg Pro Gln Glu Arg Arg Ser Ser Asn Ile Ser Gln Ala Ser Arg Ser
595 600 605
Pro Pro Met Leu Pro Val Asn Gly Lys Met His Ser Ala Val Asp Cys
610 615 620
Asn Gly Val Val Ser Leu Val Asp Gly Arg Ser Ala Leu Met Leu Pro
625 630 635 640
Asn Gly Gln Leu Leu Pro Glu Gly Thr Thr Asn Gln Ile His Lys Lys
645 650 655
Arg Arg Cys Ser Ser Tyr Leu Leu Ser Glu Asp Met Leu Asn Asp Pro
660 665 670
Asn Leu Arg Gln Arg Ala Met Ser Arg Ala Ser Ile Leu Thr Asn Thr
675 680 685
Val Glu Glu Leu Glu Glu Ser Arg Gln Lys Cys Pro Pro Trp Trp Tyr
690 695 700
Arg Phe Ala His Lys Phe Leu Ile Trp Asn Cys Ser Pro Tyr Trp Ile
705 710 715 720
Lys Phe Lys Lys Cys Ile Tyr Phe Ile Val Met Asp Pro Phe Val Asp
725 730 735

ATTORNEY DOCKET NO. 21101.0048U1

Leu	Ala	Ile	Thr	Ile	Cys	Ile	Val	Leu	Asn	Thr	Leu	Phe	Met	Ala	Met		
			740						745				750				
Glu	His	His	Pro	Met	Thr	Glu	Glu	Phe	Lys	Asn	Val	Leu	Ala	Ile	Gly		
		755					760					765					
Asn	Leu	Val	Phe	Thr	Gly	Ile	Phe	Ala	Ala	Glu	Met	Val	Leu	Lys	Leu		
	770				775						780						
Ile	Ala	Met	Asp	Pro	Tyr	Glu	Tyr	Phe	Gln	Val	Gly	Trp	Asn	Ile	Phe		
785					790					795					800		
Asp	Ser	Leu	Ile	Val	Thr	Leu	Ser	Leu	Val	Glu	Leu	Phe	Leu	Ala	Asp		
			805						810					815			
Val	Glu	Gly	Leu	Ser	Val	Leu	Arg	Ser	Phe	Arg	Leu	Leu	Arg	Val	Phe		
			820					825					830				
Lys	Leu	Ala	Lys	Ser	Trp	Pro	Thr	Leu	Asn	Met	Leu	Ile	Lys	Ile	Ile		
	835					840						845					
Gly	Asn	Ser	Val	Gly	Ala	Leu	Gly	Asn	Leu	Thr	Leu	Val	Leu	Ala	Ile		
	850					855					860						
Ile	Val	Phe	Ile	Phe	Ala	Val	Val	Gly	Met	Gln	Leu	Phe	Gly	Lys	Ser		
865				870					875						880		
Tyr	Lys	Glu	Cys	Val	Cys	Lys	Ile	Asn	Asp	Asp	Cys	Thr	Leu	Pro	Arg		
			885					890						895			
Trp	His	Met	Asn	Asp	Phe	Phe	His	Ser	Phe	Leu	Ile	Val	Phe	Arg	Val		
		900						905					910				
Leu	Cys	Gly	Glu	Trp	Ile	Glu	Thr	Met	Trp	Asp	Cys	Met	Glu	Val	Ala		
	915					920						925					
Gly	Gln	Ala	Met	Cys	Leu	Ile	Val	Tyr	Met	Met	Val	Met	Val	Ile	Gly		
	930					935					940						
Asn	Leu	Val	Val	Leu	Asn	Leu	Phe	Leu	Ala	Leu	Leu	Leu	Ser	Ser	Phe		
945				950					955						960		
Ser	Ser	Asp	Asn	Leu	Thr	Ala	Ile	Glu	Glu	Asp	Pro	Asp	Ala	Asn	Asn		
			965						970					975			
Leu	Gln	Ile	Ala	Val	Thr	Arg	Ile	Lys	Lys	Gly	Ile	Asn	Tyr	Val	Lys		
	980							985					990				
Gln	Thr	Leu	Arg	Glu	Phe	Ile	Leu	Lys	Ala	Phe	Ser	Lys	Lys	Pro	Lys		
	995							1000					1005				
Ile	Ser	Arg	Glu	Ile	Arg	Gln	Ala	Glu	Asp	Leu	Asn	Thr	Lys	Lys	Glu		
	1010					1015						1020					
Asn	Tyr	Ile	Ser	Asn	His	Thr	Leu	Ala	Glu	Met	Ser	Lys	Gly	His	Asn		
1025				1030					1035						1040		
Phe	Leu	Lys	Glu	Lys	Asp	Lys	Ile	Ser	Gly	Phe	Gly	Ser	Ser	Val	Asp		
			1045						1050					1055			
Lys	His	Leu	Met	Glu	Asp	Ser	Asp	Gly	Gln	Ser	Phe	Ile	His	Asn	Pro		
	1060							1065					1070				
Ser	Leu	Thr	Val	Thr	Val	Pro	Ile	Ala	Pro	Gly	Glu	Ser	Asp	Leu	Glu		
	1075						1080						1085				
Asn	Met	Asn	Ala	Glu	Glu	Leu	Ser	Ser	Asp	Ser	Asp	Ser	Glu	Tyr	Ser		
	1090					1095					1100						
Lys	Val	Arg	Leu	Asn	Arg	Ser	Ser	Ser	Ser	Glu	Cys	Ser	Thr	Val	Asp		
	1105				1110					1115					1120		
Asn	Pro	Leu	Pro	Gly	Glu	Gly	Glu	Glu	Ala	Glu	Ala	Glu	Pro	Met	Asn		
			1125						1130					1135			
Ser	Asp	Glu	Pro	Glu	Ala	Cys	Phe	Thr	Asp	Gly	Cys	Val	Arg	Arg	Phe		
		1140						1145					1150				
Ser	Cys	Cys	Gln	Val	Asn	Ile	Glu	Ser	Gly	Lys	Gly	Lys	Ile	Trp	Trp		
	1155						1160					1165					
Asn	Ile	Arg	Lys	Thr	Cys	Tyr	Lys	Ile	Val	Glu	His	Ser	Trp	Phe	Glu		
	1170					1175					1180						
Ser	Phe	Ile	Val	Leu	Met	Ile	Leu	Leu	Ser	Ser	Gly	Ala	Leu	Ala	Phe		
	1185				1190					1195					1200		
Glu	Asp	Ile	Tyr	Ile	Glu	Arg	Lys	Lys	Thr	Ile	Lys	Ile	Ile	Leu	Glu		
			1205						1210					1215			

ATTORNEY DOCKET NO. 21101.0048U1

Tyr Ala Asp Lys Ile Phe Thr Tyr Ile Phe Ile Leu Glu Met Leu Leu
 1220 1225 1230
 Lys Trp Ile Ala Tyr Gly Tyr Lys Thr Tyr Phe Thr Asn Ala Trp Cys
 1235 1240 1245
 Trp Leu Asp Phe Leu Ile Val Asp Val Ser Leu Val Thr Leu Val Ala
 1250 1255 1260
 Asn Thr Leu Gly Tyr Ser Asp Leu Gly Pro Ile Lys Ser Leu Arg Thr
 1265 1270 1275 1280
 Leu Arg Ala Leu Arg Pro Leu Arg Ala Leu Ser Arg Phe Glu Gly Met
 1285 1290 1295
 Arg Val Val Val Asn Ala Leu Ile Gly Ala Ile Pro Ser Ile Met Asn
 1300 1305 1310
 Val Leu Leu Val Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile Met Gly
 1315 1320 1325
 Val Asn Leu Phe Ala Gly Lys Phe Tyr Glu Cys Ile Asn Thr Thr Asp
 1330 1335 1340
 Gly Ser Arg Phe Pro Ala Ser Gln Val Pro Asn Arg Ser Glu Cys Phe
 1345 1350 1355 1360
 Ala Leu Met Asn Val Ser Gln Asn Val Arg Trp Lys Asn Leu Lys Val
 1365 1370 1375
 Asn Phe Asp Asn Val Gly Leu Gly Tyr Leu Ser Leu Leu Gln Val Ala
 1380 1385 1390
 Thr Phe Lys Gly Trp Thr Ile Ile Met Tyr Ala Ala Val Asp Ser Val
 1395 1400 1405
 Asn Val Asp Lys Gln Pro Lys Tyr Glu Tyr Ser Leu Tyr Met Tyr Ile
 1410 1415 1420
 Tyr Phe Val Val Phe Ile Ile Phe Gly Ser Phe Phe Thr Leu Asn Leu
 1425 1430 1435 1440
 Phe Ile Gly Val Ile Ile Asp Asn Phe Asn Gln Gln Lys Lys Lys Leu
 1445 1450 1455
 Gly Gly Gln Asp Ile Phe Met Thr Glu Glu Gln Lys Lys Tyr Tyr Asn
 1460 1465 1470
 Ala Met Lys Lys Leu Gly Ser Lys Lys Pro Gln Lys Pro Ile Pro Arg
 1475 1480 1485
 Pro Gly Asn Lys Ile Gln Gly Cys Ile Phe Asp Leu Val Thr Asn Gln
 1490 1495 1500
 Ala Phe Asp Ile Ser Ile Met Val Leu Ile Cys Leu Asn Met Val Thr
 1505 1510 1515 1520
 Met Met Val Glu Lys Glu Gly Gln Ser Gln His Met Thr Glu Val Leu
 1525 1530 1535
 Tyr Trp Ile Asn Val Val Phe Ile Ile Leu Phe Thr Gly Glu Cys Val
 1540 1545 1550
 Leu Lys Leu Ile Ser Leu Arg His Tyr Tyr Phe Thr Val Gly Trp Asn
 1555 1560 1565
 Ile Phe Asp Phe Val Val Val Ile Ser Ile Val Gly Met Phe Leu
 1570 1575 1580
 Ala Asp Leu Ile Glu Thr Tyr Phe Val Ser Pro Thr Leu Phe Arg Val
 1585 1590 1595 1600
 Ile Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg Leu Val Lys Gly Ala
 1605 1610 1615
 Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu Met Met Ser Leu Pro Ala
 1620 1625 1630
 Leu Phe Asn Ile Gly Leu Leu Leu Phe Leu Val Met Phe Ile Tyr Ala
 1635 1640 1645
 Ile Phe Gly Met Ser Asn Phe Ala Tyr Val Lys Lys Glu Asp Gly Ile
 1650 1655 1660
 Asn Asp Met Phe Asn Phe Glu Thr Phe Gly Asn Ser Met Ile Cys Leu
 1665 1670 1675 1680
 Phe Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly Leu Leu Ala Pro Ile
 1685 1690 1695

ATTORNEY DOCKET NO. 21101.0048U1

Leu Asn Ser Lys Pro Pro Asp Cys Asp Pro Lys Lys Val His Pro Gly
 1700 1705 1710
 Ser Ser Val Glu Gly Asp Cys Gly Asn Pro Ser Val Gly Ile Phe Tyr
 1715 1720 1725
 Phe Val Ser Tyr Ile Ile Ile Ser Phe Leu Val Val Val Asn Met Tyr
 1730 1735 1740
 Ile Ala Val Ile Leu Glu Asn Phe Ser Val Ala Thr Glu Glu Ser Thr
 1745 1750 1755 1760
 Glu Pro Leu Ser Glu Asp Asp Phe Glu Met Phe Tyr Glu Val Trp Glu
 1765 1770 1775
 Lys Phe Asp Pro Asp Ala Thr Gln Phe Ile Glu Phe Ser Lys Leu Ser
 1780 1785 1790
 Asp Phe Ala Ala Ala Leu Asp Pro Pro Leu Leu Ile Ala Lys Pro Asn
 1795 1800 1805
 Lys Val Gln Leu Ile Ala Met Asp Leu Pro Met Val Ser Gly Asp Arg
 1810 1815 1820
 Ile His Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly
 1825 1830 1835 1840
 Glu Ser Gly Glu Met Asp Ser Leu Arg Ser Gln Met Glu Glu Arg Phe
 1845 1850 1855
 Met Ser Ala Asn Pro Ser Lys Val Ser Tyr Glu Pro Ile Thr Thr Thr
 1860 1865 1870
 Leu Lys Arg Lys Gln Glu Asp Val Ser Ala Thr Val Ile Gln Arg Ala
 1875 1880 1885
 Tyr Arg Arg Tyr Arg Leu Arg Gln Asn Val Lys Asn Ile Ser Ser Ile
 1890 1895 1900
 Tyr Ile Lys Asp Gly Asp Arg Asp Asp Asp Leu Leu Asn Lys Lys Asp
 1905 1910 1915 1920
 Met Ala Phe Asp Asn Val Asn Glu Asn Ser Ser Pro Glu Lys Thr Asp
 1925 1930 1935
 Ala Thr Ser Ser Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys
 1940 1945 1950
 Pro Asp Lys Glu Lys Tyr Glu Gln Asp Arg Thr Glu Lys Glu Asp Lys
 1955 1960 1965
 Gly Lys Asp Ser Lys Glu Ser Lys Lys
 1970 1975

<210> 4
 <211> 1977
 <212> PRT
 <213> Homo Sapien

<400> 4
 Met Ala Met Leu Pro Pro Pro Gly Pro Gln Ser Phe Val His Phe Thr
 1 5 10 15
 Lys Gln Ser Leu Ala Leu Ile Glu Gln Arg Ile Ala Glu Arg Lys Ser
 20 25 30
 Lys Glu Pro Lys Glu Glu Lys Lys Asp Asp Asp Glu Glu Ala Pro Lys
 35 40 45
 Pro Ser Ser Asp Leu Glu Ala Gly Lys Gln Leu Pro Phe Ile Tyr Gly
 50 55 60
 Asp Ile Pro Pro Gly Met Val Ser Glu Pro Leu Glu Asp Leu Asp Pro
 65 70 75 80
 Tyr Tyr Ala Asp Lys Lys Thr Phe Ile Val Leu Asn Lys Gly Lys Thr
 85 90 95
 Ile Phe Arg Phe Asn Ala Thr Pro Ala Leu Tyr Met Leu Ser Pro Phe
 100 105 110
 Ser Pro Leu Arg Arg Ile Ser Ile Lys Ile Leu Val His Ser Leu Phe
 115 120 125

ATTORNEY DOCKET NO. 21101.0048U1

Ser	Met	Leu	Ile	Met	Cys	Thr	Ile	Leu	Thr	Asn	Cys	Ile	Phe	Met	Thr	130	135	140
Met	Asn	Asn	Pro	Pro	Asp	Trp	Thr	Lys	Asn	Val	Glu	Tyr	Thr	Phe	Thr	145	150	155
Gly	Ile	Tyr	Thr	Phe	Glu	Ser	Leu	Val	Lys	Ile	Leu	Ala	Arg	Gly	Phe	165	170	175
Cys	Val	Gly	Glu	Phe	Thr	Phe	Leu	Arg	Asp	Pro	Trp	Asn	Trp	Leu	Asp	180	185	190
Phe	Val	Val	Ile	Val	Phe	Ala	Tyr	Leu	Thr	Glu	Phe	Val	Asn	Leu	Gly	195	200	205
Asn	Val	Ser	Ala	Leu	Arg	Thr	Phe	Arg	Val	Leu	Arg	Ala	Leu	Lys	Thr	210	215	220
Ile	Ser	Val	Ile	Pro	Gly	Leu	Lys	Thr	Ile	Val	Gly	Ala	Leu	Ile	Gln	225	230	235
Ser	Val	Lys	Lys	Leu	Ser	Asp	Val	Met	Ile	Leu	Thr	Val	Phe	Cys	Leu	245	250	255
Ser	Val	Phe	Ala	Leu	Ile	Gly	Leu	Gln	Leu	Phe	Met	Gly	Asn	Leu	Lys	260	265	270
His	Lys	Cys	Phe	Arg	Asn	Ser	Leu	Glu	Asn	Asn	Glu	Thr	Leu	Glu	Ser	275	280	285
Ile	Met	Asn	Thr	Leu	Glu	Ser	Glu	Glu	Asp	Phe	Arg	Lys	Tyr	Phe	Tyr	290	295	300
Tyr	Leu	Glu	Gly	Ser	Lys	Asp	Ala	Leu	Leu	Cys	Gly	Phe	Ser	Thr	Asp	305	310	315
Ser	Gly	Gln	Cys	Pro	Glu	Gly	Tyr	Thr	Cys	Val	Lys	Ile	Gly	Arg	Asn	325	330	335
Pro	Asp	Tyr	Gly	Tyr	Thr	Ser	Phe	Asp	Thr	Phe	Ser	Trp	Ala	Phe	Leu	340	345	350
Ala	Leu	Phe	Arg	Leu	Met	Thr	Gln	Asp	Tyr	Trp	Glu	Asn	Leu	Tyr	Gln	355	360	365
Gln	Thr	Leu	Arg	Ala	Ala	Gly	Lys	Thr	Tyr	Met	Ile	Phe	Phe	Val	Val	370	375	380
Val	Ile	Phe	Leu	Gly	Ser	Phe	Tyr	Leu	Ile	Asn	Leu	Ile	Leu	Ala	Val	385	390	395
Val	Ala	Met	Ala	Tyr	Glu	Glu	Gln	Asn	Gln	Ala	Asn	Ile	Glu	Glu	Ala	405	410	415
Lys	Gln	Lys	Glu	Leu	Glu	Phe	Gln	Gln	Met	Leu	Asp	Arg	Leu	Lys	Lys	420	425	430
Glu	Gln	Glu	Glu	Ala	Glu	Ala	Ile	Ala	Ala	Ala	Ala	Ala	Glu	Tyr	Thr	435	440	445
Ser	Ile	Arg	Arg	Ser	Arg	Ile	Met	Gly	Leu	Ser	Glu	Ser	Ser	Ser	Glu	450	455	460
Thr	Ser	Lys	Leu	Ser	Ser	Lys	Ser	Ala	Lys	Glu	Arg	Arg	Asn	Arg	Arg	465	470	475
Lys	Lys	Lys	Asn	Gln	Lys	Lys	Leu	Ser	Ser	Gly	Glu	Glu	Lys	Gly	Asp	485	490	495
Ala	Glu	Lys	Leu	Ser	Lys	Ser	Glu	Ser	Glu	Asp	Ser	Ile	Arg	Arg	Lys	500	505	510
Ser	Phe	His	Leu	Gly	Val	Glu	Gly	His	Arg	Arg	Ala	His	Glu	Lys	Arg	515	520	525
Leu	Ser	Thr	Pro	Asn	Gln	Ser	Pro	Leu	Ser	Ile	Arg	Gly	Ser	Leu	Phe	530	535	540
Ser	Ala	Arg	Arg	Ser	Ser	Arg	Thr	Ser	Leu	Phe	Ser	Phe	Lys	Gly	Arg	545	550	555
Gly	Arg	Asp	Ile	Gly	Ser	Glu	Thr	Glu	Phe	Ala	Asp	Asp	Glu	His	Ser	565	570	575
Ile	Phe	Gly	Asp	Asn	Glu	Ser	Arg	Arg	Gly	Ser	Leu	Phe	Val	Pro	His	580	585	590
Arg	Pro	Gln	Glu	Arg	Arg	Ser	Ser	Asn	Ile	Ser	Gln	Ala	Ser	Arg	Ser	595	600	605

ATTORNEY DOCKET NO. 21101.0048U1

Pro	Pro	Met	Leu	Pro	Val	Asn	Gly	Lys	Met	His	Ser	Ala	Val	Asp	Cys
610						615					620				
Asn	Gly	Val	Val	Ser	Leu	Val	Asp	Gly	Arg	Ser	Ala	Leu	Met	Leu	Pro
625					630					635					640
Tyr	Gly	Gln	Leu	Leu	Pro	Glu	Gly	Thr	Thr	Asn	Gln	Ile	His	Lys	Lys
				645						650				655	
Arg	Arg	Cys	Ser	Ser	Tyr	Leu	Leu	Ser	Glu	Asp	Met	Leu	Asn	Asp	Pro
			660					665				670			
Asn	Leu	Arg	Gln	Arg	Ala	Met	Ser	Arg	Ala	Ser	Ile	Leu	Thr	Asn	Thr
		675				680						685			
Val	Glu	Glu	Leu	Glu	Glu	Ser	Arg	Gln	Lys	Cys	Pro	Pro	Trp	Trp	Tyr
	690					695					700				
Arg	Phe	Ala	His	Lys	Phe	Leu	Ile	Trp	Asn	Cys	Ser	Pro	Tyr	Trp	Ile
705					710				715						720
Lys	Phe	Lys	Lys	Cys	Ile	Tyr	Phe	Ile	Val	Met	Asp	Pro	Phe	Val	Asp
				725					730					735	
Leu	Ala	Ile	Thr	Ile	Cys	Ile	Val	Leu	Asn	Thr	Leu	Phe	Met	Ala	Met
			740					745					750		
Glu	His	His	Pro	Met	Thr	Glu	Glu	Phe	Lys	Asn	Val	Leu	Ala	Ile	Gly
		755				760						765			
Asn	Leu	Val	Phe	Thr	Gly	Ile	Phe	Ala	Ala	Glu	Met	Val	Leu	Lys	Leu
	770				775						780				
Ile	Ala	Met	Asp	Pro	Tyr	Glu	Tyr	Phe	Gln	Val	Gly	Trp	Asn	Ile	Phe
785					790				795						800
Asp	Ser	Leu	Ile	Val	Thr	Leu	Ser	Leu	Val	Glu	Leu	Phe	Leu	Ala	Asp
				805					810					815	
Val	Glu	Gly	Leu	Ser	Val	Leu	Arg	Ser	Phe	Arg	Leu	Leu	Arg	Val	Phe
			820					825					830		
Lys	Leu	Ala	Lys	Ser	Trp	Pro	Thr	Leu	Asn	Met	Leu	Ile	Lys	Ile	Ile
		835					840					845			
Gly	Asn	Ser	Val	Gly	Ala	Leu	Gly	Asn	Leu	Thr	Leu	Val	Leu	Ala	Ile
	850					855					860				
Ile	Val	Phe	Ile	Phe	Ala	Val	Val	Gly	Met	Gln	Leu	Phe	Gly	Lys	Ser
865					870					875					880
Tyr	Lys	Glu	Cys	Val	Cys	Lys	Ile	Asn	Asp	Cys	Thr	Leu	Pro	Arg	
				885					890					895	
Trp	His	Met	Asn	Asp	Phe	Phe	His	Ser	Phe	Leu	Ile	Val	Phe	Arg	Val
			900					905					910		
Leu	Cys	Gly	Glu	Trp	Ile	Glu	Thr	Met	Trp	Asp	Cys	Met	Glu	Val	Ala
		915					920						925		
Gly	Gln	Ala	Met	Cys	Leu	Ile	Val	Tyr	Met	Met	Val	Met	Val	Ile	Gly
	930					935					940				
Asn	Leu	Val	Val	Leu	Asn	Leu	Phe	Leu	Ala	Leu	Leu	Leu	Ser	Ser	Phe
945					950					955					960
Ser	Ser	Asp	Asn	Leu	Thr	Ala	Ile	Glu	Glu	Asp	Pro	Asp	Ala	Asn	Asn
				965					970					975	
Leu	Gln	Ile	Ala	Val	Thr	Arg	Ile	Lys	Lys	Gly	Ile	Asn	Tyr	Val	Lys
			980					985					990		
Gln	Thr	Leu	Arg	Glu	Phe	Ile	Leu	Lys	Ala	Phe	Ser	Lys	Lys	Pro	Lys
		995					1000					1005			
Ile	Ser	Arg	Glu	Ile	Arg	Gln	Ala	Glu	Asp	Leu	Asn	Thr	Lys	Lys	Glu
	1010					1015					1020				
Asn	Tyr	Ile	Ser	Asn	His	Thr	Leu	Ala	Glu	Met	Ser	Lys	Gly	His	Asn
1025					1030					1035					1040
Phe	Leu	Lys	Glu	Lys	Asp	Lys	Ile	Ser	Gly	Phe	Gly	Ser	Ser	Val	Asp
				1045					1050					1055	
Lys	His	Leu	Met	Glu	Asp	Ser	Asp	Gly	Gln	Ser	Phe	Ile	His	Asn	Pro
			1060					1065					1070		
Ser	Leu	Thr	Val	Thr	Val	Pro	Ile	Ala	Pro	Gly	Glu	Ser	Asp	Leu	Glu
		1075					1080					1085			

ATTORNEY DOCKET NO. 21101.0048U1

Asn Met Asn Ala Glu Glu Leu Ser Ser Asp Ser Asp Ser Glu Tyr Ser	1090	1095	1100
Lys Val Arg Leu Asn Arg Ser Ser Ser Ser Glu Cys Ser Thr Val Asp	1105	1110	1115
Asn Pro Leu Pro Gly Glu Gly Glu Glu Ala Glu Ala Glu Pro Met Asn	1125	1130	1135
Ser Asp Glu Pro Glu Ala Cys Phe Thr Asp Gly Cys Val Arg Arg Phe	1140	1145	1150
Ser Cys Cys Gln Val Asn Ile Glu Ser Gly Lys Gly Lys Ile Trp Trp	1155	1160	1165
Asn Ile Arg Lys Thr Cys Tyr Lys Ile Val Glu His Ser Trp Phe Glu	1170	1175	1180
Ser Phe Ile Val Leu Met Ile Leu Leu Ser Ser Gly Ala Leu Ala Phe	1185	1190	1195
Glu Asp Ile Tyr Ile Glu Arg Lys Lys Thr Ile Lys Ile Ile Leu Glu	1205	1210	1215
Tyr Ala Asp Lys Ile Phe Thr Tyr Ile Phe Ile Leu Glu Met Leu Leu	1220	1225	1230
Lys Trp Ile Ala Tyr Gly Tyr Lys Thr Tyr Phe Thr Asn Ala Trp Cys	1235	1240	1245
Trp Leu Asp Phe Leu Ile Val Asp Val Ser Leu Val Thr Leu Val Ala	1250	1255	1260
Asn Thr Leu Gly Tyr Ser Asp Leu Gly Pro Ile Lys Ser Leu Arg Thr	1265	1270	1275
Leu Arg Ala Leu Arg Pro Leu Arg Ala Leu Ser Arg Phe Glu Gly Met	1285	1290	1295
Arg Val Val Val Asn Ala Leu Ile Gly Ala Ile Pro Ser Ile Met Asn	1300	1305	1310
Val Leu Leu Val Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile Met Gly	1315	1320	1325
Val Asn Leu Phe Ala Gly Lys Phe Tyr Glu Cys Ile Asn Thr Thr Asp	1330	1335	1340
Gly Ser Arg Phe Pro Ala Ser Gln Val Pro Asn Arg Ser Glu Cys Phe	1345	1350	1355
Ala Leu Met Asn Val Ser Gln Asn Val Arg Trp Lys Asn Leu Lys Val	1365	1370	1375
Asn Phe Asp Asn Val Gly Leu Gly Tyr Leu Ser Leu Leu Gln Val Ala	1380	1385	1390
Thr Phe Lys Gly Trp Thr Ile Ile Met Tyr Ala Ala Val Asp Ser Val	1395	1400	1405
Asn Val Asp Lys Gln Pro Lys Tyr Glu Tyr Ser Leu Tyr Met Tyr Ile	1410	1415	1420
Tyr Phe Val Val Phe Ile Ile Phe Gly Ser Phe Phe Thr Leu Asn Leu	1425	1430	1435
Phe Ile Gly Val Ile Ile Asp Asn Phe Asn Gln Gln Lys Lys Lys Leu	1445	1450	1455
Gly Gly Gln Asp Ile Phe Met Thr Glu Glu Gln Lys Lys Tyr Tyr Asn	1460	1465	1470
Ala Met Lys Lys Leu Gly Ser Lys Lys Pro Gln Lys Pro Ile Pro Arg	1475	1480	1485
Pro Gly Asn Lys Ile Gln Gly Cys Ile Phe Asp Leu Val Thr Asn Gln	1490	1495	1500
Ala Phe Asp Ile Ser Ile Met Val Leu Ile Cys Leu Asn Met Val Thr	1505	1510	1515
Met Met Val Glu Lys Glu Gly Gln Ser Gln His Met Thr Glu Val Leu	1525	1530	1535
Tyr Trp Ile Asn Val Val Phe Ile Ile Leu Phe Thr Gly Glu Cys Val	1540	1545	1550
Leu Lys Leu Ile Ser Leu Arg His Tyr Tyr Phe Thr Val Gly Trp Asn	1555	1560	1565

ATTORNEY DOCKET NO. 21101.0048U1

Ile Phe Asp Phe Val Val Val Ile Ile Ser Ile Val Gly Met Phe Leu
1570 1575 1580
Ala Asp Leu Ile Glu Thr Tyr Phe Val Ser Pro Thr Leu Phe Arg Val
1585 1590 1595 1600
Ile Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg Leu Val Lys Gly Ala
1605 1610 1615
Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu Met Met Ser Leu Pro Ala
1620 1625 1630
Leu Phe Asn Ile Gly Leu Leu Leu Phe Leu Val Met Phe Ile Tyr Ala
1635 1640 1645
Ile Phe Gly Met Ser Asn Phe Ala Tyr Val Lys Lys Glu Asp Gly Ile
1650 1655 1660
Asn Asp Met Phe Asn Phe Glu Thr Phe Gly Asn Ser Met Ile Cys Leu
1665 1670 1675 1680
Phe Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly Leu Leu Ala Pro Ile
1685 1690 1695
Leu Asn Ser Lys Pro Pro Asp Cys Asp Pro Lys Lys Val His Pro Gly
1700 1705 1710
Ser Ser Val Glu Gly Asp Cys Gly Asn Pro Ser Val Gly Ile Phe Tyr
1715 1720 1725
Phe Val Ser Tyr Ile Ile Ile Ser Phe Leu Val Val Val Asn Met Tyr
1730 1735 1740
Ile Ala Val Ile Leu Glu Asn Phe Ser Val Ala Thr Glu Glu Ser Thr
1745 1750 1755 1760
Glu Pro Leu Ser Glu Asp Asp Phe Glu Met Phe Tyr Glu Val Trp Glu
1765 1770 1775
Lys Phe Asp Pro Asp Ala Thr Gln Phe Ile Glu Phe Ser Lys Leu Ser
1780 1785 1790
Asp Phe Ala Ala Ala Leu Asp Pro Pro Leu Leu Ile Ala Lys Pro Asn
1795 1800 1805
Lys Val Gln Leu Ile Ala Met Asp Leu Pro Met Val Ser Gly Asp Arg
1810 1815 1820
Ile His Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly
1825 1830 1835 1840
Glu Ser Gly Glu Met Asp Ser Leu Arg Ser Gln Met Glu Glu Arg Phe
1845 1850 1855
Met Ser Ala Asn Pro Ser Lys Val Ser Tyr Glu Pro Ile Thr Thr Thr
1860 1865 1870
Leu Lys Arg Lys Gln Glu Asp Val Ser Ala Thr Val Ile Gln Arg Ala
1875 1880 1885
Tyr Arg Arg Tyr Arg Leu Arg Gln Asn Val Lys Asn Ile Ser Ser Ile
1890 1895 1900
Tyr Ile Lys Asp Gly Asp Arg Asp Asp Asp Leu Leu Asn Lys Lys Asp
1905 1910 1915 1920
Met Ala Phe Asp Asn Val Asn Glu Asn Ser Ser Pro Glu Lys Thr Asp
1925 1930 1935
Ala Thr Ser Ser Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys
1940 1945 1950
Pro Asp Lys Glu Lys Tyr Glu Gln Asp Arg Thr Glu Lys Glu Asp Lys
1955 1960 1965
Gly Lys Asp Ser Lys Glu Ser Lys Lys
1970 1975

<210> 5
<211> 1977
<212> PRT
<213> Homo Sapien

<400> 5

ATTORNEY DOCKET NO. 21101.0048U1

Met	Ala	Met	Leu	Pro	Pro	Pro	Gly	Pro	Gln	Ser	Phe	Val	His	Phe	Thr
1				5				10					15		
Lys	Gln	Ser	Leu	Ala	Leu	Ile	Glu	Gln	Arg	Ile	Ala	Glu	Arg	Lys	Ser
			20					25					30		
Lys	Glu	Pro	Lys	Glu	Glu	Lys	Lys	Asp	Asp	Asp	Glu	Glu	Ala	Pro	Lys
		35					40					45			
Pro	Ser	Ser	Asp	Leu	Glu	Ala	Gly	Lys	Gln	Leu	Pro	Phe	Ile	Tyr	Gly
		50				55					60				
Asp	Ile	Pro	Pro	Gly	Met	Val	Ser	Glu	Pro	Leu	Glu	Asp	Leu	Asp	Pro
65				70					75					80	
Tyr	Tyr	Ala	Asp	Lys	Lys	Thr	Phe	Ile	Val	Leu	Asn	Lys	Gly	Lys	Thr
			85					90					95		
Ile	Phe	Arg	Phe	Asn	Ala	Thr	Pro	Ala	Leu	Tyr	Met	Leu	Ser	Pro	Phe
			100					105					110		
Ser	Pro	Leu	Arg	Arg	Ile	Ser	Ile	Lys	Ile	Leu	Val	His	Ser	Leu	Phe
		115					120					125			
Ser	Met	Leu	Ile	Met	Cys	Thr	Ile	Leu	Thr	Asn	Cys	Ile	Phe	Met	Thr
		130				135					140				
Met	Asn	Asn	Pro	Pro	Asp	Trp	Thr	Lys	Asn	Val	Glu	Tyr	Thr	Phe	Thr
145					150				155					160	
Gly	Ile	Tyr	Thr	Phe	Glu	Ser	Leu	Val	Lys	Ile	Leu	Ala	Arg	Gly	Phe
				165				170						175	
Cys	Val	Gly	Glu	Phe	Thr	Phe	Leu	Arg	Asp	Pro	Trp	Asn	Trp	Leu	Asp
			180					185					190		
Phe	Val	Val	Ile	Val	Phe	Ala	Tyr	Leu	Thr	Glu	Phe	Val	Asn	Leu	Gly
		195						200				205			
Asn	Val	Ser	Ala	Leu	Arg	Thr	Phe	Arg	Val	Leu	Arg	Ala	Leu	Lys	Thr
		210				215					220				
Ile	Ser	Val	Ile	Pro	Gly	Leu	Lys	Thr	Ile	Val	Gly	Ala	Leu	Ile	Gln
225					230					235				240	
Ser	Val	Lys	Lys	Leu	Ser	Asp	Val	Met	Ile	Leu	Thr	Val	Phe	Cys	Leu
			245					250						255	
Ser	Val	Phe	Ala	Leu	Ile	Gly	Leu	Gln	Leu	Phe	Met	Gly	Asn	Leu	Lys
			260					265					270		
His	Lys	Cys	Phe	Arg	Asn	Ser	Leu	Glu	Asn	Asn	Glu	Thr	Leu	Glu	Ser
		275					280					285			
Ile	Met	Asn	Thr	Leu	Glu	Ser	Glu	Glu	Asp	Phe	Arg	Lys	Tyr	Phe	Tyr
		290				295					300				
Tyr	Leu	Glu	Gly	Ser	Lys	Asp	Ala	Leu	Leu	Cys	Gly	Phe	Ser	Thr	Asp
305					310					315				320	
Ser	Gly	Gln	Cys	Pro	Glu	Gly	Tyr	Thr	Cys	Val	Lys	Ile	Gly	Arg	Asn
			325						330					335	
Pro	Asp	Tyr	Gly	Tyr	Thr	Ser	Phe	Asp	Thr	Phe	Ser	Trp	Ala	Phe	Leu
			340					345					350		
Ala	Leu	Phe	Arg	Leu	Met	Thr	Gln	Asp	Tyr	Trp	Glu	Asn	Leu	Tyr	Gln
		355						360					365		
Gln	Thr	Leu	Arg	Ala	Ala	Gly	Lys	Thr	Tyr	Met	Ile	Phe	Phe	Val	Val
		370				375					380				
Val	Ile	Phe	Leu	Gly	Ser	Phe	Tyr	Leu	Ile	Asn	Leu	Ile	Leu	Ala	Val
385					390					395				400	
Val	Ala	Met	Ala	Tyr	Glu	Glu	Gln	Asn	Gln	Ala	Asn	Ile	Glu	Glu	Ala
			405						410					415	
Lys	Gln	Lys	Glu	Leu	Glu	Phe	Gln	Gln	Met	Leu	Asp	Arg	Leu	Lys	Lys
			420					425					430		
Glu	Gln	Glu	Glu	Ala	Glu	Ala	Ile	Ala	Ala	Ala	Ala	Ala	Glu	Tyr	Thr
			435					440					445		
Ser	Ile	Arg	Arg	Ser	Arg	Ile	Met	Gly	Leu	Ser	Glu	Ser	Ser	Ser	Glu
		450				455					460				
Thr	Ser	Lys	Leu	Ser	Ser	Lys	Ser	Ala	Lys	Glu	Arg	Arg	Asn	Arg	Arg
465					470					475					480

ATTORNEY DOCKET NO. 21101.0048U1

Lys Lys Lys Asn Gln Lys Lys Leu Ser Ser Gly Glu Glu Lys Gly Asp
 485 490 495
 Ala Glu Lys Leu Ser Lys Ser Glu Ser Glu Asp Ser Ile Arg Arg Lys
 500 505 510
 Ser Phe His Leu Gly Val Glu Gly His Arg Arg Ala His Glu Lys Arg
 515 520 525
 Leu Ser Thr Pro Asn Gln Ser Pro Leu Ser Ile Arg Gly Ser Leu Phe
 530 535 540
 Ser Ala Arg Arg Ser Ser Arg Thr Ser Leu Phe Ser Phe Lys Gly Arg
 545 550 555 560
 Gly Arg Asp Ile Gly Ser Glu Thr Glu Phe Ala Asp Asp Glu His Ser
 565 570 575
 Ile Phe Gly Asp Asn Glu Ser Arg Arg Gly Ser Leu Phe Val Pro His
 580 585 590
 Arg Pro Gln Glu Arg Arg Ser Ser Asn Ile Ser Gln Ala Ser Arg Ser
 595 600 605
 Pro Pro Met Leu Pro Val Asn Gly Lys Met His Ser Ala Val Asp Cys
 610 615 620
 Asn Gly Val Val Ser Leu Val Asp Gly Arg Ser Ala Leu Met Leu Pro
 625 630 635 640
 Asn Gly Gln Leu Leu Pro Glu Gly Thr Thr Asn Gln Ile His Arg Lys
 645 650 655
 Arg Arg Cys Ser Ser Tyr Leu Leu Ser Glu Asp Met Leu Asn Asp Pro
 660 665 670
 Asn Leu Arg Gln Arg Ala Met Ser Arg Ala Ser Ile Leu Thr Asn Thr
 675 680 685
 Val Glu Glu Leu Glu Glu Ser Arg Gln Lys Cys Pro Pro Trp Trp Tyr
 690 695 700
 Arg Phe Ala His Lys Phe Leu Ile Trp Asn Cys Ser Pro Tyr Trp Ile
 705 710 715 720
 Lys Phe Lys Lys Cys Ile Tyr Phe Ile Val Met Asp Pro Phe Val Asp
 725 730 735
 Leu Ala Ile Thr Ile Cys Ile Val Leu Asn Thr Leu Phe Met Ala Met
 740 745 750
 Glu His His Pro Met Thr Glu Glu Phe Lys Asn Val Leu Ala Ile Gly
 755 760 765
 Asn Leu Val Phe Thr Gly Ile Phe Ala Ala Glu Met Val Leu Lys Leu
 770 775 780
 Ile Ala Met Asp Pro Tyr Glu Tyr Phe Gln Val Gly Trp Asn Ile Phe
 785 790 795 800
 Asp Ser Leu Ile Val Thr Leu Ser Leu Val Glu Leu Phe Leu Ala Asp
 805 810 815
 Val Glu Gly Leu Ser Val Leu Arg Ser Phe Arg Leu Leu Arg Val Phe
 820 825 830
 Lys Leu Ala Lys Ser Trp Pro Thr Leu Asn Met Leu Ile Lys Ile Ile
 835 840 845
 Gly Asn Ser Val Gly Ala Leu Gly Asn Leu Thr Leu Val Leu Ala Ile
 850 855 860
 Ile Val Phe Ile Phe Ala Val Val Gly Met Gln Leu Phe Gly Lys Ser
 865 870 875 880
 Tyr Lys Glu Cys Val Cys Lys Ile Asn Asp Asp Cys Thr Leu Pro Arg
 885 890 895
 Trp His Met Asn Asp Phe Phe His Ser Phe Leu Ile Val Phe Arg Val
 900 905 910
 Leu Cys Gly Glu Trp Ile Glu Thr Met Trp Asp Cys Met Glu Val Ala
 915 920 925
 Gly Gln Ala Met Cys Leu Ile Val Tyr Met Met Val Met Val Ile Gly
 930 935 940
 Asn Leu Val Val Leu Asn Leu Phe Leu Ala Leu Leu Ser Ser Phe
 945 950 955 960

ATTORNEY DOCKET NO. 21101.0048U1

Ser	Ser	Asp	Asn	Leu	Thr	Ala	Ile	Glu	Glu	Asp	Pro	Asp	Ala	Asn	Asn	965	970	975
Leu	Gln	Ile	Ala	Val	Thr	Arg	Ile	Lys	Lys	Gly	Ile	Asn	Tyr	Val	Lys	980	985	990
Gln	Thr	Leu	Arg	Glu	Phe	Ile	Leu	Lys	Ala	Phe	Ser	Lys	Lys	Pro	Lys	995	1000	1005
Ile	Ser	Arg	Glu	Ile	Arg	Gln	Ala	Glu	Asp	Leu	Asn	Thr	Lys	Lys	Glu	1010	1015	1020
Asn	Tyr	Ile	Ser	Asn	His	Thr	Leu	Ala	Glu	Met	Ser	Lys	Gly	His	Asn	1025	1030	1035
Phe	Leu	Lys	Glu	Lys	Asp	Lys	Ile	Ser	Gly	Phe	Gly	Ser	Ser	Val	Asp	1045	1050	1055
Lys	His	Leu	Met	Glu	Asp	Ser	Asp	Gly	Gln	Ser	Phe	Ile	His	Asn	Pro	1060	1065	1070
Ser	Leu	Thr	Val	Thr	Val	Pro	Ile	Ala	Pro	Gly	Glu	Ser	Asp	Leu	Glu	1075	1080	1085
Asn	Met	Asn	Ala	Glu	Glu	Leu	Ser	Ser	Asp	Ser	Asp	Ser	Glu	Tyr	Ser	1090	1095	1100
Lys	Val	Arg	Leu	Asn	Arg	Ser	Ser	Ser	Ser	Glu	Cys	Ser	Thr	Val	Asp	1105	1110	1115
Asn	Pro	Leu	Pro	Gly	Glu	Gly	Glu	Glu	Ala	Glu	Ala	Glu	Pro	Met	Asn	1125	1130	1135
Ser	Asp	Glu	Pro	Glu	Ala	Cys	Phe	Thr	Asp	Gly	Cys	Val	Arg	Arg	Phe	1140	1145	1150
Ser	Cys	Cys	Gln	Val	Asn	Ile	Glu	Ser	Gly	Lys	Gly	Lys	Ile	Trp	Trp	1155	1160	1165
Asn	Ile	Arg	Lys	Thr	Cys	Tyr	Lys	Ile	Val	Glu	His	Ser	Trp	Phe	Glu	1170	1175	1180
Ser	Phe	Ile	Val	Leu	Met	Ile	Leu	Leu	Ser	Ser	Gly	Ala	Leu	Ala	Phe	1185	1190	1195
Glu	Asp	Ile	Tyr	Ile	Glu	Arg	Lys	Lys	Thr	Ile	Lys	Ile	Ile	Leu	Glu	1205	1210	1215
Tyr	Ala	Asp	Lys	Ile	Phe	Thr	Tyr	Ile	Phe	Ile	Leu	Glu	Met	Leu	Leu	1220	1225	1230
Lys	Trp	Ile	Ala	Tyr	Gly	Tyr	Lys	Thr	Tyr	Phe	Thr	Asn	Ala	Trp	Cys	1235	1240	1245
Trp	Leu	Asp	Phe	Leu	Ile	Val	Asp	Val	Ser	Leu	Val	Thr	Leu	Val	Ala	1250	1255	1260
Asn	Thr	Leu	Gly	Tyr	Ser	Asp	Leu	Gly	Pro	Ile	Lys	Ser	Leu	Arg	Thr	1265	1270	1275
Leu	Arg	Ala	Leu	Arg	Pro	Leu	Arg	Ala	Leu	Ser	Arg	Phe	Glu	Gly	Met	1285	1290	1295
Arg	Val	Val	Val	Asn	Ala	Leu	Ile	Gly	Ala	Ile	Pro	Ser	Ile	Met	Asn	1300	1305	1310
Val	Leu	Leu	Val	Cys	Leu	Ile	Phe	Trp	Leu	Ile	Phe	Ser	Ile	Met	Gly	1315	1320	1325
Val	Asn	Leu	Phe	Ala	Gly	Lys	Phe	Tyr	Glu	Cys	Ile	Asn	Thr	Thr	Asp	1330	1335	1340
Gly	Ser	Arg	Phe	Pro	Ala	Ser	Gln	Val	Pro	Asn	Arg	Ser	Glu	Cys	Phe	1345	1350	1355
Ala	Leu	Met	Asn	Val	Ser	Gln	Asn	Val	Arg	Trp	Lys	Asn	Leu	Lys	Val	1365	1370	1375
Asn	Phe	Asp	Asn	Val	Gly	Leu	Gly	Tyr	Leu	Ser	Leu	Leu	Gln	Val	Ala	1380	1385	1390
Thr	Phe	Lys	Gly	Trp	Thr	Ile	Ile	Met	Tyr	Ala	Ala	Val	Asp	Ser	Val	1395	1400	1405
Asn	Val	Asp	Lys	Gln	Pro	Lys	Tyr	Glu	Tyr	Ser	Leu	Tyr	Met	Tyr	Ile	1410	1415	1420
Tyr	Phe	Val	Val	Phe	Ile	Ile	Phe	Gly	Ser	Phe	Phe	Thr	Leu	Asn	Leu	1425	1430	1435

ATTORNEY DOCKET NO. 21101.0048U1

Phe Ile Gly Val Ile Ile Asp Asn Phe Asn Gln Gln Lys Lys Lys Leu
 1445 1450 1455
 Gly Gly Gln Asp Ile Phe Met Thr Glu Glu Gln Lys Lys Tyr Tyr Asn
 1460 1465 1470
 Ala Met Lys Lys Leu Gly Ser Lys Lys Pro Gln Lys Pro Ile Pro Arg
 1475 1480 1485
 Pro Gly Asn Lys Ile Gln Gly Cys Ile Phe Asp Leu Val Thr Asn Gln
 1490 1495 1500
 Ala Phe Asp Ile Ser Ile Met Val Leu Ile Cys Leu Asn Met Val Thr
 1505 1510 1515 1520
 Met Met Val Glu Lys Glu Gly Gln Ser Gln His Met Thr Glu Val Leu
 1525 1530 1535
 Tyr Trp Ile Asn Val Val Phe Ile Ile Leu Phe Thr Gly Glu Cys Val
 1540 1545 1550
 Leu Lys Leu Ile Ser Leu Arg His Tyr Tyr Phe Thr Val Gly Trp Asn
 1555 1560 1565
 Ile Phe Asp Phe Val Val Val Ile Ile Ser Ile Val Gly Met Phe Leu
 1570 1575 1580
 Ala Asp Leu Ile Glu Thr Tyr Phe Val Ser Pro Thr Leu Phe Arg Val
 1585 1590 1595 1600
 Ile Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg Leu Val Lys Gly Ala
 1605 1610 1615
 Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu Met Met Ser Leu Pro Ala
 1620 1625 1630
 Leu Phe Asn Ile Gly Leu Leu Leu Phe Leu Val Met Phe Ile Tyr Ala
 1635 1640 1645
 Ile Phe Gly Met Ser Asn Phe Ala Tyr Val Lys Lys Glu Asp Gly Ile
 1650 1655 1660
 Asn Asp Met Phe Asn Phe Glu Thr Phe Gly Asn Ser Met Ile Cys Leu
 1665 1670 1675 1680
 Phe Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly Leu Leu Ala Pro Ile
 1685 1690 1695
 Leu Asn Ser Lys Pro Pro Asp Cys Asp Pro Lys Lys Val His Pro Gly
 1700 1705 1710
 Ser Ser Val Glu Gly Asp Cys Gly Asn Pro Ser Val Gly Ile Phe Tyr
 1715 1720 1725
 Phe Val Ser Tyr Ile Ile Ile Ser Phe Leu Val Val Val Asn Met Tyr
 1730 1735 1740
 Ile Ala Val Ile Leu Glu Asn Phe Ser Val Ala Thr Glu Glu Ser Thr
 1745 1750 1755 1760
 Glu Pro Leu Ser Glu Asp Asp Phe Glu Met Phe Tyr Glu Val Trp Glu
 1765 1770 1775
 Lys Phe Asp Pro Asp Ala Thr Gln Phe Ile Glu Phe Ser Lys Leu Ser
 1780 1785 1790
 Asp Phe Ala Ala Ala Leu Asp Pro Pro Leu Leu Ile Ala Lys Pro Asn
 1795 1800 1805
 Lys Val Gln Leu Ile Ala Met Asp Leu Pro Met Val Ser Gly Asp Arg
 1810 1815 1820
 Ile His Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly
 1825 1830 1835 1840
 Glu Ser Gly Glu Met Asp Ser Leu Arg Ser Gln Met Glu Glu Arg Phe
 1845 1850 1855
 Met Ser Ala Asn Pro Ser Lys Val Ser Tyr Glu Pro Ile Thr Thr Thr
 1860 1865 1870
 Leu Lys Arg Lys Gln Glu Asp Val Ser Ala Thr Val Ile Gln Arg Ala
 1875 1880 1885
 Tyr Arg Arg Tyr Arg Leu Arg Gln Asn Val Lys Asn Ile Ser Ser Ile
 1890 1895 1900
 Tyr Ile Lys Asp Gly Asp Arg Asp Asp Asp Leu Leu Asn Lys Lys Asp
 1905 1910 1915 1920

ATTORNEY DOCKET NO. 21101.0048U1

Met Ala Phe Asp Asn Val Asn Glu Asn Ser Ser Pro Glu Lys Thr Asp
 1925 1930 1935
 Ala Thr Ser Ser Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys
 1940 1945 1950
 Pro Asp Lys Glu Lys Tyr Glu Gln Asp Arg Thr Glu Lys Glu Asp Lys
 1955 1960 1965
 Gly Lys Asp Ser Lys Glu Ser Lys Lys
 1970 1975

<210> 6
 <211> 1977
 <212> PRT
 <213> Homo Sapien

<400> 6
 Met Ala Met Leu Pro Pro Pro Gly Pro Gln Ser Phe Val His Phe Thr
 1 5 10 15
 Lys Gln Ser Leu Ala Leu Ile Glu Gln Arg Ile Ala Glu Arg Lys Ser
 20 25 30
 Lys Glu Pro Lys Glu Glu Lys Lys Asp Asp Asp Glu Glu Ala Pro Lys
 35 40 45
 Pro Ser Ser Asp Leu Glu Ala Gly Lys Gln Leu Pro Phe Ile Tyr Gly
 50 55 60
 Asp Ile Pro Pro Gly Met Val Ser Glu Pro Leu Glu Asp Leu Asp Pro
 65 70 75 80
 Tyr Tyr Ala Asp Lys Lys Thr Phe Ile Val Leu Asn Lys Gly Lys Thr
 85 90 95
 Ile Phe Arg Phe Asn Ala Thr Pro Ala Leu Tyr Met Leu Ser Pro Phe
 100 105 110
 Ser Pro Leu Arg Arg Ile Ser Ile Lys Ile Leu Val His Ser Leu Phe
 115 120 125
 Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Ile Phe Met Thr
 130 135 140
 Met Asn Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr Phe Thr
 145 150 155 160
 Gly Ile Tyr Thr Phe Glu Ser Leu Val Lys Ile Leu Ala Arg Gly Phe
 165 170 175
 Cys Val Gly Glu Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp Leu Asp
 180 185 190
 Phe Val Val Ile Val Phe Ala Tyr Leu Thr Glu Phe Val Asn Leu Gly
 195 200 205
 Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu Lys Thr
 210 215 220
 Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala Leu Ile Gln
 225 230 235 240
 Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val Phe Cys Leu
 245 250 255
 Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn Leu Lys
 260 265 270
 His Lys Cys Phe Arg Asn Ser Leu Glu Asn Asn Glu Thr Leu Glu Ser
 275 280 285
 Ile Met Asn Thr Leu Glu Ser Glu Glu Asp Phe Arg Lys Tyr Phe Tyr
 290 295 300
 Tyr Leu Glu Gly Ser Lys Asp Ala Leu Leu Cys Gly Phe Ser Thr Asp
 305 310 315 320
 Ser Gly Gln Cys Pro Glu Gly Tyr Thr Cys Val Lys Ile Gly Arg Asn
 325 330 335
 Pro Asp Tyr Gly Tyr Thr Ser Phe Asp Thr Phe Ser Trp Ala Phe Leu
 340 345 350

ATTORNEY DOCKET NO. 21101.0048U1

Ala	Leu	Phe	Arg	Leu	Met	Thr	Gln	Asp	Tyr	Trp	Glu	Asn	Leu	Tyr	Gln
	355						360					365			
Gln	Thr	Leu	Arg	Ala	Ala	Gly	Lys	Thr	Tyr	Met	Ile	Phe	Phe	Val	Val
	370					375					380				
Val	Ile	Phe	Leu	Gly	Ser	Phe	Tyr	Leu	Ile	Asn	Leu	Ile	Leu	Ala	Val
385					390					395				400	
Val	Ala	Met	Ala	Tyr	Glu	Gln	Asn	Gln	Ala	Asn	Ile	Glu	Glu	Ala	
			405					410					415		
Lys	Gln	Lys	Glu	Leu	Glu	Phe	Gln	Gln	Met	Leu	Asp	Arg	Leu	Lys	Lys
		420					425					430			
Glu	Gln	Glu	Glu	Ala	Glu	Ala	Ile	Ala	Ala	Ala	Ala	Ala	Glu	Tyr	Thr
	435					440						445			
Ser	Ile	Arg	Arg	Ser	Arg	Ile	Met	Gly	Leu	Ser	Glu	Ser	Ser	Ser	Glu
450					455					460					
Thr	Ser	Lys	Leu	Ser	Ser	Lys	Ser	Ala	Lys	Glu	Arg	Arg	Asn	Arg	Arg
465					470					475				480	
Lys	Lys	Lys	Asn	Gln	Lys	Lys	Leu	Ser	Ser	Gly	Glu	Glu	Lys	Gly	Asp
			485					490					495		
Ala	Glu	Lys	Leu	Ser	Lys	Ser	Glu	Ser	Glu	Asp	Ser	Ile	Arg	Arg	Lys
		500					505					510			
Ser	Phe	His	Leu	Gly	Val	Glu	Gly	His	Arg	Arg	Ala	His	Glu	Lys	Arg
	515					520						525			
Leu	Ser	Thr	Pro	Asn	Gln	Ser	Pro	Leu	Ser	Ile	Arg	Gly	Ser	Leu	Phe
530					535					540					
Ser	Ala	Arg	Arg	Ser	Ser	Arg	Thr	Ser	Leu	Phe	Ser	Phe	Lys	Gly	Arg
545					550				555					560	
Gly	Arg	Asp	Ile	Gly	Ser	Glu	Thr	Glu	Phe	Ala	Asp	Asp	Glu	His	Ser
			565					570					575		
Ile	Phe	Gly	Asp	Asn	Glu	Ser	Arg	Arg	Gly	Ser	Leu	Phe	Val	Pro	His
		580					585						590		
Arg	Pro	Gln	Glu	Arg	Arg	Ser	Ser	Asn	Ile	Ser	Gln	Ala	Ser	Arg	Ser
	595					600						605			
Pro	Pro	Met	Leu	Pro	Val	Asn	Gly	Lys	Met	His	Ser	Ala	Val	Asp	Cys
610					615						620				
Asn	Gly	Val	Val	Ser	Leu	Val	Asp	Gly	Arg	Ser	Ala	Leu	Met	Leu	Pro
625					630				635					640	
Asn	Gly	Gln	Leu	Leu	Pro	Glu	Gly	Thr	Thr	Asn	Gln	Ile	His	Lys	Lys
			645					650					655		
Arg	Arg	Cys	Ser	Ser	Tyr	Leu	Leu	Ser	Glu	Asp	Met	Leu	Asn	Asp	Pro
			660				665					670			
Asn	Leu	Arg	Gln	Arg	Ala	Met	Ser	Arg	Ala	Ser	Ile	Leu	Thr	Asn	Thr
	675				680							685			
Val	Glu	Glu	Leu	Glu	Glu	Ser	Arg	Gln	Lys	Cys	Pro	Pro	Trp	Trp	Tyr
	690				695						700				
Arg	Phe	Ala	His	Lys	Phe	Leu	Ile	Trp	Asn	Cys	Ser	Pro	Tyr	Trp	Ile
705					710				715					720	
Lys	Phe	Lys	Lys	Cys	Ile	Tyr	Phe	Ile	Val	Met	Asp	Pro	Phe	Val	Asp
			725					730					735		
Leu	Ala	Val	Thr	Ile	Cys	Ile	Val	Leu	Asn	Thr	Leu	Phe	Met	Ala	Met
			740				745					750			
Glu	His	His	Pro	Met	Thr	Glu	Glu	Phe	Lys	Asn	Val	Leu	Ala	Ile	Gly
	755					760						765			
Asn	Leu	Val	Phe	Thr	Gly	Ile	Phe	Ala	Ala	Glu	Met	Val	Leu	Lys	Leu
	770				775						780				
Ile	Ala	Met	Asp	Pro	Tyr	Glu	Tyr	Phe	Gln	Val	Gly	Trp	Asn	Ile	Phe
785					790				795					800	
Asp	Ser	Leu	Ile	Val	Thr	Leu	Ser	Leu	Val	Glu	Leu	Phe	Leu	Ala	Asp
			805					810					815		
Val	Glu	Gly	Leu	Ser	Val	Leu	Arg	Ser	Phe	Arg	Leu	Leu	Arg	Val	Phe
		820					825					830			

ATTORNEY DOCKET NO. 21101.0048U1

Lys	Leu	Ala	Lys	Ser	Trp	Pro	Thr	Leu	Asn	Met	Leu	Ile	Lys	Ile	Ile
	835						840					845			
Gly	Asn	Ser	Val	Gly	Ala	Leu	Gly	Asn	Leu	Thr	Leu	Val	Leu	Ala	Ile
	850					855					860				
Ile	Val	Phe	Ile	Phe	Ala	Val	Val	Gly	Met	Gln	Leu	Phe	Gly	Lys	Ser
	865				870					875					880
Tyr	Lys	Glu	Cys	Val	Cys	Lys	Ile	Asn	Asp	Asp	Cys	Thr	Leu	Pro	Arg
				885					890					895	
Trp	His	Met	Asn	Asp	Phe	Phe	His	Ser	Phe	Leu	Ile	Val	Phe	Arg	Val
			900					905					910		
Leu	Cys	Gly	Glu	Trp	Ile	Glu	Thr	Met	Trp	Asp	Cys	Met	Glu	Val	Ala
		915					920					925			
Gly	Gln	Ala	Met	Cys	Leu	Ile	Val	Tyr	Met	Met	Val	Met	Val	Ile	Gly
	930					935					940				
Asn	Leu	Val	Val	Leu	Asn	Leu	Phe	Leu	Ala	Leu	Leu	Leu	Ser	Ser	Phe
	945				950					955					960
Ser	Ser	Asp	Asn	Leu	Thr	Ala	Ile	Glu	Glu	Asp	Pro	Asp	Ala	Asn	Asn
				965					970					975	
Leu	Gln	Ile	Ala	Val	Thr	Arg	Ile	Lys	Lys	Gly	Ile	Asn	Tyr	Val	Lys
		980						985					990		
Gln	Thr	Leu	Arg	Glu	Phe	Ile	Leu	Lys	Ala	Phe	Ser	Lys	Lys	Pro	Lys
	995						1000					1005			
Ile	Ser	Arg	Glu	Ile	Arg	Gln	Ala	Glu	Asp	Leu	Asn	Thr	Lys	Lys	Glu
	1010					1015					1020				
Asn	Tyr	Ile	Ser	Asn	His	Thr	Leu	Ala	Glu	Met	Ser	Lys	Gly	His	Asn
	1025				1030					1035					1040
Phe	Leu	Lys	Glu	Lys	Asp	Lys	Ile	Ser	Gly	Phe	Gly	Ser	Ser	Val	Asp
				1045					1050					1055	
Lys	His	Leu	Met	Glu	Asp	Ser	Asp	Gly	Gln	Ser	Phe	Ile	His	Asn	Pro
		1060						1065					1070		
Ser	Leu	Thr	Val	Thr	Val	Pro	Ile	Ala	Pro	Gly	Glu	Ser	Asp	Leu	Glu
	1075						1080					1085			
Asn	Met	Asn	Ala	Glu	Glu	Leu	Ser	Ser	Asp	Ser	Asp	Ser	Glu	Tyr	Ser
	1090					1095					1100				
Lys	Val	Arg	Leu	Asn	Arg	Ser	Ser	Ser	Ser	Glu	Cys	Ser	Thr	Val	Asp
	1105				1110					1115					1120
Asn	Pro	Leu	Pro	Gly	Glu	Gly	Glu	Glu	Ala	Glu	Ala	Glu	Pro	Met	Asn
				1125					1130					1135	
Ser	Asp	Glu	Pro	Glu	Ala	Cys	Phe	Thr	Asp	Gly	Cys	Val	Arg	Arg	Phe
			1140					1145					1150		
Ser	Cys	Cys	Gln	Val	Asn	Ile	Glu	Ser	Gly	Lys	Gly	Lys	Ile	Trp	Trp
		1155					1160					1165			
Asn	Ile	Arg	Lys	Thr	Cys	Tyr	Lys	Ile	Val	Glu	His	Ser	Trp	Phe	Glu
	1170					1175					1180				
Ser	Phe	Ile	Val	Leu	Met	Ile	Leu	Leu	Ser	Ser	Gly	Ala	Leu	Ala	Phe
	1185				1190				1195						1200
Glu	Asp	Ile	Tyr	Ile	Glu	Arg	Lys	Lys	Thr	Ile	Lys	Ile	Ile	Leu	Glu
				1205					1210					1215	
Tyr	Ala	Asp	Lys	Ile	Phe	Thr	Tyr	Ile	Phe	Ile	Leu	Glu	Met	Leu	Leu
			1220					1225					1230		
Lys	Trp	Ile	Ala	Tyr	Gly	Tyr	Lys	Thr	Tyr	Phe	Thr	Asn	Ala	Trp	Cys
	1235						1240					1245			
Trp	Leu	Asp	Phe	Leu	Ile	Val	Asp	Val	Ser	Leu	Val	Thr	Leu	Val	Ala
	1250					1255					1260				
Asn	Thr	Leu	Gly	Tyr	Ser	Asp	Leu	Gly	Pro	Ile	Lys	Ser	Leu	Arg	Thr
	1265				1270				1275						1280
Leu	Arg	Ala	Leu	Arg	Pro	Leu	Arg	Ala	Leu	Ser	Arg	Phe	Glu	Gly	Met
				1285					1290					1295	
Arg	Val	Val	Val	Asn	Ala	Leu	Ile	Gly	Ala	Ile	Pro	Ser	Ile	Met	Asn
			1300					1305					1310		

ATTORNEY DOCKET NO. 21101.0048U1

Val Leu Leu Val Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile Met Gly
1315 1320 1325
Val Asn Leu Phe Ala Gly Lys Phe Tyr Glu Cys Ile Asn Thr Thr Asp
1330 1335 1340
Gly Ser Arg Phe Pro Ala Ser Gln Val Pro Asn Arg Ser Glu Cys Phe
1345 1350 1355 1360
Ala Leu Met Asn Val Ser Gln Asn Val Arg Trp Lys Asn Leu Lys Val
1365 1370 1375
Asn Phe Asp Asn Val Gly Leu Gly Tyr Leu Ser Leu Leu Gln Val Ala
1380 1385 1390
Thr Phe Lys Gly Trp Thr Ile Ile Met Tyr Ala Ala Val Asp Ser Val
1395 1400 1405
Asn Val Asp Lys Gln Pro Lys Tyr Glu Tyr Ser Leu Tyr Met Tyr Ile
1410 1415 1420
Tyr Phe Val Val Phe Ile Ile Phe Gly Ser Phe Phe Thr Leu Asn Leu
1425 1430 1435 1440
Phe Ile Gly Val Ile Ile Asp Asn Phe Asn Gln Gln Lys Lys Lys Leu
1445 1450 1455
Gly Gly Gln Asp Ile Phe Met Thr Glu Glu Gln Lys Lys Tyr Tyr Asn
1460 1465 1470
Ala Met Lys Lys Leu Gly Ser Lys Lys Pro Gln Lys Pro Ile Pro Arg
1475 1480 1485
Pro Gly Asn Lys Ile Gln Gly Cys Ile Phe Asp Leu Val Thr Asn Gln
1490 1495 1500
Ala Phe Asp Ile Ser Ile Met Val Leu Ile Cys Leu Asn Met Val Thr
1505 1510 1515 1520
Met Met Val Glu Lys Glu Gly Gln Ser Gln His Met Thr Glu Val Leu
1525 1530 1535
Tyr Trp Ile Asn Val Val Phe Ile Ile Leu Phe Thr Gly Glu Cys Val
1540 1545 1550
Leu Lys Leu Ile Ser Leu Arg His Tyr Tyr Phe Thr Val Gly Trp Asn
1555 1560 1565
Ile Phe Asp Phe Val Val Val Ile Ile Ser Ile Val Gly Met Phe Leu
1570 1575 1580
Ala Asp Leu Ile Glu Thr Tyr Phe Val Ser Pro Thr Leu Phe Arg Val
1585 1590 1595 1600
Ile Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg Leu Val Lys Gly Ala
1605 1610 1615
Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu Met Met Ser Leu Pro Ala
1620 1625 1630
Leu Phe Asn Ile Gly Leu Leu Leu Phe Leu Val Met Phe Ile Tyr Ala
1635 1640 1645
Ile Phe Gly Met Ser Asn Phe Ala Tyr Val Lys Lys Glu Asp Gly Ile
1650 1655 1660
Asn Asp Met Phe Asn Phe Glu Thr Phe Gly Asn Ser Met Ile Cys Leu
1665 1670 1675 1680
Phe Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly Leu Leu Ala Pro Ile
1685 1690 1695
Leu Asn Ser Lys Pro Pro Asp Cys Asp Pro Lys Lys Val His Pro Gly
1700 1705 1710
Ser Ser Val Glu Gly Asp Cys Gly Asn Pro Ser Val Gly Ile Phe Tyr
1715 1720 1725
Phe Val Ser Tyr Ile Ile Ile Ser Phe Leu Val Val Val Asn Met Tyr
1730 1735 1740
Ile Ala Val Ile Leu Glu Asn Phe Ser Val Ala Thr Glu Glu Ser Thr
1745 1750 1755 1760
Glu Pro Leu Ser Glu Asp Asp Phe Glu Met Phe Tyr Glu Val Trp Glu
1765 1770 1775
Lys Phe Asp Pro Asp Ala Thr Gln Phe Ile Glu Phe Ser Lys Leu Ser
1780 1785 1790

ATTORNEY DOCKET NO. 21101.0048U1

Asp Phe Ala Ala Ala Leu Asp Pro Pro Leu Leu Ile Ala Lys Pro Asn
 1795 1800 1805
 Lys Val Gln Leu Ile Ala Met Asp Leu Pro Met Val Ser Gly Asp Arg
 1810 1815 1820
 Ile His Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly
 1825 1830 1835 1840
 Glu Ser Gly Glu Met Asp Ser Leu Arg Ser Gln Met Glu Glu Arg Phe
 1845 1850 1855
 Met Ser Ala Asn Pro Ser Lys Val Ser Tyr Glu Pro Ile Thr Thr Thr
 1860 1865 1870
 Leu Lys Arg Lys Gln Glu Asp Val Ser Ala Thr Val Ile Gln Arg Ala
 1875 1880 1885
 Tyr Arg Arg Tyr Arg Leu Arg Gln Asn Val Lys Asn Ile Ser Ser Ile
 1890 1895 1900
 Tyr Ile Lys Asp Gly Asp Arg Asp Asp Asp Leu Leu Asn Lys Lys Asp
 1905 1910 1915 1920
 Met Ala Phe Asp Asn Val Asn Glu Asn Ser Ser Pro Glu Lys Thr Asp
 1925 1930 1935
 Ala Thr Ser Ser Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys
 1940 1945 1950
 Pro Asp Lys Glu Lys Tyr Glu Gln Asp Arg Thr Glu Lys Glu Asp Lys
 1955 1960 1965
 Gly Lys Asp Ser Lys Glu Ser Lys Lys
 1970 1975

<210> 7
 <211> 1977
 <212> PRT
 <213> Homo Sapien

<400> 7
 Met Ala Met Leu Pro Pro Gly Pro Gln Ser Phe Val His Phe Thr
 1 5 10 15
 Lys Gln Ser Leu Ala Leu Ile Glu Gln Arg Ile Ala Glu Arg Lys Ser
 20 25 30
 Lys Glu Pro Lys Glu Glu Lys Lys Asp Asp Asp Glu Glu Ala Pro Lys
 35 40 45
 Pro Ser Ser Asp Leu Glu Ala Gly Lys Gln Leu Pro Phe Ile Tyr Gly
 50 55 60
 Asp Ile Pro Pro Gly Met Val Ser Glu Pro Leu Glu Asp Leu Asp Pro
 65 70 75 80
 Tyr Tyr Ala Asp Lys Lys Thr Phe Ile Val Leu Asn Lys Gly Lys Thr
 85 90 95
 Ile Phe Arg Phe Asn Ala Thr Pro Ala Leu Tyr Met Leu Ser Pro Phe
 100 105 110
 Ser Pro Leu Arg Arg Ile Ser Ile Lys Ile Leu Val His Ser Leu Phe
 115 120 125
 Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Ile Phe Met Thr
 130 135 140
 Met Asn Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr Phe Thr
 145 150 155 160
 Gly Ile Tyr Thr Phe Glu Ser Leu Val Lys Ile Leu Ala Arg Gly Phe
 165 170 175
 Cys Val Gly Glu Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp Leu Asp
 180 185 190
 Phe Val Val Ile Val Phe Ala Tyr Leu Thr Glu Phe Val Asn Leu Gly
 195 200 205
 Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu Lys Thr
 210 215 220

ATTORNEY DOCKET NO. 21101.0048U1

Ile	Ser	Val	Ile	Pro	Gly	Leu	Lys	Thr	Ile	Val	Gly	Ala	Leu	Ile	Gln	225	230	235	240
Ser	Val	Lys	Lys	Leu	Ser	Asp	Val	Met	Ile	Leu	Thr	Val	Phe	Cys	Leu	245	250	255	
Ser	Val	Phe	Ala	Leu	Ile	Gly	Leu	Gln	Leu	Phe	Met	Gly	Asn	Leu	Lys	260	265	270	
His	Lys	Cys	Phe	Arg	Asn	Ser	Leu	Glu	Asn	Asn	Glu	Thr	Leu	Glu	Ser	275	280	285	
Ile	Met	Asn	Thr	Leu	Glu	Ser	Glu	Glu	Asp	Phe	Arg	Lys	Tyr	Phe	Tyr	290	295	300	
Tyr	Leu	Glu	Gly	Ser	Lys	Asp	Ala	Leu	Leu	Cys	Gly	Phe	Ser	Thr	Asp	305	310	315	320
Ser	Gly	Gln	Cys	Pro	Glu	Gly	Tyr	Thr	Cys	Val	Lys	Ile	Gly	Arg	Asn	325	330	335	
Pro	Asp	Tyr	Gly	Tyr	Thr	Ser	Phe	Asp	Thr	Phe	Ser	Trp	Ala	Phe	Leu	340	345	350	
Ala	Leu	Phe	Arg	Leu	Met	Thr	Gln	Asp	Tyr	Trp	Glu	Asn	Leu	Tyr	Gln	355	360	365	
Gln	Thr	Leu	Arg	Ala	Ala	Gly	Lys	Thr	Tyr	Met	Ile	Phe	Phe	Val	Val	370	375	380	
Val	Ile	Phe	Leu	Gly	Ser	Phe	Tyr	Leu	Ile	Asn	Leu	Ile	Leu	Ala	Val	385	390	395	400
Val	Ala	Met	Ala	Tyr	Glu	Glu	Gln	Asn	Gln	Ala	Asn	Ile	Glu	Glu	Ala	405	410	415	
Lys	Gln	Lys	Glu	Leu	Glu	Phe	Gln	Gln	Met	Leu	Asp	Arg	Leu	Lys	Lys	420	425	430	
Glu	Gln	Glu	Glu	Ala	Glu	Ala	Ile	Ala	Ala	Ala	Ala	Ala	Glu	Tyr	Thr	435	440	445	
Ser	Ile	Arg	Arg	Ser	Arg	Ile	Met	Gly	Leu	Ser	Glu	Ser	Ser	Ser	Glu	450	455	460	
Thr	Ser	Lys	Leu	Ser	Ser	Lys	Ser	Ala	Lys	Glu	Arg	Arg	Asn	Arg	Arg	465	470	475	480
Lys	Lys	Lys	Asn	Gln	Lys	Lys	Leu	Ser	Ser	Gly	Glu	Glu	Lys	Gly	Asp	485	490	495	
Ala	Glu	Lys	Leu	Ser	Lys	Ser	Glu	Ser	Glu	Asp	Ser	Ile	Arg	Arg	Lys	500	505	510	
Ser	Phe	His	Leu	Gly	Val	Glu	Gly	His	Arg	Arg	Ala	His	Glu	Lys	Arg	515	520	525	
Leu	Ser	Thr	Pro	Asn	Gln	Ser	Pro	Leu	Ser	Ile	Arg	Gly	Ser	Leu	Phe	530	535	540	
Ser	Ala	Arg	Arg	Ser	Ser	Arg	Thr	Ser	Leu	Phe	Ser	Phe	Lys	Gly	Arg	545	550	555	560
Gly	Arg	Asp	Ile	Gly	Ser	Glu	Thr	Glu	Phe	Ala	Asp	Asp	Glu	His	Ser	565	570	575	
Ile	Phe	Gly	Asp	Asn	Glu	Ser	Arg	Arg	Gly	Ser	Leu	Phe	Val	Pro	His	580	585	590	
Arg	Pro	Gln	Glu	Arg	Arg	Ser	Ser	Asn	Ile	Ser	Gln	Ala	Ser	Arg	Ser	595	600	605	
Pro	Pro	Met	Leu	Pro	Val	Asn	Gly	Lys	Met	His	Ser	Ala	Val	Asp	Cys	610	615	620	
Asn	Gly	Val	Val	Ser	Leu	Val	Asp	Gly	Arg	Ser	Ala	Leu	Met	Leu	Pro	625	630	635	640
Asn	Gly	Gln	Leu	Leu	Pro	Glu	Gly	Thr	Thr	Asn	Gln	Ile	His	Lys	Lys	645	650	655	
Arg	Arg	Cys	Ser	Ser	Tyr	Leu	Leu	Ser	Glu	Asp	Met	Leu	Asn	Asp	Pro	660	665	670	
Asn	Leu	Arg	Gln	Arg	Ala	Met	Ser	Arg	Ala	Ser	Ile	Leu	Thr	Asn	Thr	675	680	685	
Val	Glu	Glu	Leu	Glu	Glu	Ser	Arg	Gln	Lys	Cys	Pro	Pro	Trp	Trp	Tyr	690	695	700	

ATTORNEY DOCKET NO. 21101.0048U1

Arg	Phe	Ala	His	Lys	Phe	Leu	Ile	Trp	Asn	Cys	Ser	Pro	Tyr	Trp	Ile	705	710	715	720
Lys	Phe	Lys	Lys	Cys	Ile	Tyr	Phe	Ile	Val	Met	Asp	Pro	Phe	Val	Asp	725	730	735	
Leu	Ala	Ile	Thr	Ile	Cys	Ile	Val	Leu	Asn	Thr	Leu	Phe	Met	Ala	Met	740	745	750	
Glu	His	His	Pro	Met	Thr	Glu	Glu	Phe	Lys	Asn	Val	Leu	Ala	Ile	Gly	755	760	765	
Asn	Leu	Val	Phe	Thr	Gly	Ile	Phe	Ala	Ala	Glu	Met	Val	Leu	Lys	Leu	770	775	780	
Ile	Ala	Met	Asp	Pro	Tyr	Glu	Tyr	Phe	Gln	Val	Gly	Trp	Asn	Ile	Phe	785	790	795	800
Asp	Ser	Leu	Ile	Val	Thr	Leu	Ser	Leu	Val	Glu	Leu	Phe	Leu	Ala	Asp	805	810	815	
Val	Glu	Gly	Leu	Ser	Val	Leu	Arg	Ser	Phe	Arg	Leu	Leu	Arg	Val	Phe	820	825	830	
Lys	Leu	Ala	Lys	Ser	Trp	Pro	Thr	Leu	Asn	Met	Leu	Ile	Lys	Ile	Ile	835	840	845	
Gly	Asn	Ser	Val	Gly	Ala	Leu	Gly	Asn	Leu	Thr	Leu	Val	Leu	Ala	Ile	850	855	860	
Ile	Val	Phe	Ile	Phe	Ala	Val	Val	Gly	Met	Gln	Leu	Phe	Gly	Lys	Ser	865	870	875	880
Tyr	Lys	Glu	Cys	Val	Cys	Lys	Ile	Asn	Asp	Asp	Cys	Thr	Leu	Pro	Arg	885	890	895	
Trp	His	Met	Asn	Asp	Phe	Phe	His	Ser	Phe	Leu	Ile	Val	Phe	Arg	Val	900	905	910	
Leu	Cys	Gly	Glu	Trp	Ile	Glu	Thr	Met	Trp	Asp	Cys	Met	Glu	Val	Ala	915	920	925	
Gly	Gln	Ala	Met	Cys	Leu	Ile	Val	Tyr	Met	Met	Val	Met	Val	Ile	Gly	930	935	940	
Asn	Leu	Val	Val	Leu	Asn	Leu	Phe	Leu	Ala	Leu	Leu	Ser	Ser	Phe		945	950	955	960
Ser	Ser	Asp	Asn	Leu	Thr	Ala	Ile	Glu	Glu	Asp	Pro	Asp	Ala	Asn	Asn	965	970	975	
Leu	Gln	Ile	Ala	Val	Thr	Arg	Ile	Lys	Lys	Gly	Ile	Asn	Tyr	Val	Lys	980	985	990	
Gln	Thr	Leu	Arg	Glu	Phe	Ile	Leu	Lys	Ala	Phe	Ser	Lys	Lys	Pro	Lys	995	1000	1005	
Ile	Ser	Arg	Glu	Ile	Arg	Gln	Ala	Glu	Asp	Leu	Asn	Thr	Lys	Lys	Glu	1010	1015	1020	
Asn	Tyr	Ile	Ser	Asn	His	Thr	Leu	Ala	Glu	Met	Ser	Lys	Gly	His	Asn	1025	1030	1035	1040
Phe	Leu	Lys	Glu	Lys	Asp	Lys	Ile	Ser	Gly	Phe	Gly	Ser	Ser	Val	Asp	1045	1050	1055	
Lys	His	Leu	Met	Glu	Asp	Ser	Asp	Gly	Gln	Ser	Phe	Ile	His	Asn	Pro	1060	1065	1070	
Ser	Leu	Thr	Val	Thr	Val	Pro	Ile	Ala	Pro	Gly	Glu	Ser	Asp	Leu	Glu	1075	1080	1085	
Asn	Met	Asn	Ala	Glu	Glu	Leu	Ser	Ser	Asp	Ser	Asp	Ser	Glu	Tyr	Ser	1090	1095	1100	
Lys	Val	Arg	Leu	Asn	Arg	Ser	Ser	Ser	Ser	Glu	Cys	Ser	Thr	Val	Asp	1105	1110	1115	1120
Asn	Pro	Phe	Pro	Gly	Glu	Gly	Glu	Glu	Ala	Glu	Ala	Glu	Pro	Met	Asn	1125	1130	1135	
Ser	Asp	Glu	Pro	Glu	Ala	Cys	Phe	Thr	Asp	Gly	Cys	Val	Arg	Arg	Phe	1140	1145	1150	
Ser	Cys	Cys	Gln	Val	Asn	Ile	Glu	Ser	Gly	Lys	Gly	Lys	Ile	Trp	Trp	1155	1160	1165	
Asn	Ile	Arg	Lys	Thr	Cys	Tyr	Lys	Ile	Val	Glu	His	Ser	Trp	Phe	Glu	1170	1175	1180	

ATTORNEY DOCKET NO. 21101.0048U1

Ser Phe Ile Val Leu Met Ile Leu Leu Ser Ser Gly Ala Leu Ala Phe
1185 1190 1195 1200
Glu Asp Ile Tyr Ile Glu Arg Lys Lys Thr Ile Lys Ile Ile Leu Glu
1205 1210 1215
Tyr Ala Asp Lys Ile Phe Thr Tyr Ile Phe Ile Leu Glu Met Leu Leu
1220 1225 1230
Lys Trp Ile Ala Tyr Gly Tyr Lys Thr Tyr Phe Thr Asn Ala Trp Cys
1235 1240 1245
Trp Leu Asp Phe Leu Ile Val Asp Val Ser Leu Val Thr Leu Val Ala
1250 1255 1260
Asn Thr Leu Gly Tyr Ser Asp Leu Gly Pro Ile Lys Ser Leu Arg Thr
1265 1270 1275 1280
Leu Arg Ala Leu Arg Pro Leu Arg Ala Leu Ser Arg Phe Glu Gly Met
1285 1290 1295
Arg Val Val Val Asn Ala Leu Ile Gly Ala Ile Pro Ser Ile Met Asn
1300 1305 1310
Val Leu Leu Val Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile Met Gly
1315 1320 1325
Val Asn Leu Phe Ala Gly Lys Phe Tyr Glu Cys Ile Asn Thr Thr Asp
1330 1335 1340
Gly Ser Arg Phe Pro Ala Ser Gln Val Pro Asn Arg Ser Glu Cys Phe
1345 1350 1355 1360
Ala Leu Met Asn Val Ser Gln Asn Val Arg Trp Lys Asn Leu Lys Val
1365 1370 1375
Asn Phe Asp Asn Val Gly Leu Gly Tyr Leu Ser Leu Leu Gln Val Ala
1380 1385 1390
Thr Phe Lys Gly Trp Thr Ile Ile Met Tyr Ala Ala Val Asp Ser Val
1395 1400 1405
Asn Val Asp Lys Gln Pro Lys Tyr Glu Tyr Ser Leu Tyr Met Tyr Ile
1410 1415 1420
Tyr Phe Val Val Phe Ile Ile Phe Gly Ser Phe Phe Thr Leu Asn Leu
1425 1430 1435 1440
Phe Ile Gly Val Ile Ile Asp Asn Phe Asn Gln Gln Lys Lys Lys Leu
1445 1450 1455
Gly Gly Gln Asp Ile Phe Met Thr Glu Glu Gln Lys Lys Tyr Tyr Asn
1460 1465 1470
Ala Met Lys Lys Leu Gly Ser Lys Lys Pro Gln Lys Pro Ile Pro Arg
1475 1480 1485
Pro Gly Asn Lys Ile Gln Gly Cys Ile Phe Asp Leu Val Thr Asn Gln
1490 1495 1500
Ala Phe Asp Ile Ser Ile Met Val Leu Ile Cys Leu Asn Met Val Thr
1505 1510 1515 1520
Met Met Val Glu Lys Glu Gly Gln Ser Gln His Met Thr Glu Val Leu
1525 1530 1535
Tyr Trp Ile Asn Val Val Phe Ile Ile Leu Phe Thr Gly Glu Cys Val
1540 1545 1550
Leu Lys Leu Ile Ser Leu Arg His Tyr Tyr Phe Thr Val Gly Trp Asn
1555 1560 1565
Ile Phe Asp Phe Val Val Val Ile Ile Ser Ile Val Gly Met Phe Leu
1570 1575 1580
Ala Asp Leu Ile Glu Thr Tyr Phe Val Ser Pro Thr Leu Phe Arg Val
1585 1590 1595 1600
Ile Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg Leu Val Lys Gly Ala
1605 1610 1615
Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu Met Met Ser Leu Pro Ala
1620 1625 1630
Leu Phe Asn Ile Gly Leu Leu Leu Phe Leu Val Met Phe Ile Tyr Ala
1635 1640 1645
Ile Phe Gly Met Ser Asn Phe Ala Tyr Val Lys Lys Glu Asp Gly Ile
1650 1655 1660

ATTORNEY DOCKET NO. 21101.0048U1

Asn Asp Met Phe Asn Phe Glu Thr Phe Gly Asn Ser Met Ile Cys Leu
1665 1670 1675 1680
Phe Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly Leu Leu Ala Pro Ile
1685 1690 1695
Leu Asn Ser Lys Pro Pro Asp Cys Asp Pro Lys Lys Val His Pro Gly
1700 1705 1710
Ser Ser Val Glu Gly Asp Cys Gly Asn Pro Ser Val Gly Ile Phe Tyr
1715 1720 1725
Phe Val Ser Tyr Ile Ile Ile Ser Phe Leu Val Val Val Asn Met Tyr
1730 1735 1740
Ile Ala Val Ile Leu Glu Asn Phe Ser Val Ala Thr Glu Glu Ser Thr
1745 1750 1755 1760
Glu Pro Leu Ser Glu Asp Asp Phe Glu Met Phe Tyr Glu Val Trp Glu
1765 1770 1775
Lys Phe Asp Pro Asp Ala Thr Gln Phe Ile Glu Phe Ser Lys Leu Ser
1780 1785 1790
Asp Phe Ala Ala Ala Leu Asp Pro Pro Leu Leu Ile Ala Lys Pro Asn
1795 1800 1805
Lys Val Gln Leu Ile Ala Met Asp Leu Pro Met Val Ser Gly Asp Arg
1810 1815 1820
Ile His Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly
1825 1830 1835 1840
Glu Ser Gly Glu Met Asp Ser Leu Arg Ser Gln Met Glu Glu Arg Phe
1845 1850 1855
Met Ser Ala Asn Pro Ser Lys Val Ser Tyr Glu Pro Ile Thr Thr Thr
1860 1865 1870
Leu Lys Arg Lys Gln Glu Asp Val Ser Ala Thr Val Ile Gln Arg Ala
1875 1880 1885
Tyr Arg Arg Tyr Arg Leu Arg Gln Asn Val Lys Asn Ile Ser Ser Ile
1890 1895 1900
Tyr Ile Lys Asp Gly Asp Arg Asp Asp Asp Leu Leu Asn Lys Lys Asp
1905 1910 1915 1920
Met Ala Phe Asp Asn Val Asn Glu Asn Ser Ser Pro Glu Lys Thr Asp
1925 1930 1935
Ala Thr Ser Ser Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys
1940 1945 1950
Pro Asp Lys Glu Lys Tyr Glu Gln Asp Arg Thr Glu Lys Glu Asp Lys
1955 1960 1965
Gly Lys Asp Ser Lys Glu Ser Lys Lys
1970 1975

<210> 8

<211> 5934

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 8

atgggcaatgt tgcctccccc aggacctcag agctttgtcc atttcacaaa acagtctctt 60
gccctcattg aacaacgcat tgctgaaaga aaatcaaagg aacccaaaga agaaaagaaa 120
gatgatgatg aagaagcccc aaagccaagc agtgacttgg aagctggcaa acaactgccc 180
ttcgtctatg gggacattcc tcccgcatg gtgtcagagc ccctggagga cttggacccc 240
tactatgcag acaaaaagac ttatcatagta ttgaacaaag ggaaaacaat cttccgtttc 300
aatgccacac ctgctttata tatgctttct cctttcagtc ctctaagaag aatatctatt 360
aagattttag tacactcctt attcagcatg ctcacatgt gcactattct gacaaactgc 420
atatattatga ccatgaataa cccgccggac tggacaaaa atgtcgagta cacttttact 480
ggaatatata cttttgaatc acttgtaaaa atccttgcaa gaggttctg ttaggagaa 540

ATTORNEY DOCKET NO. 21101.0048U1

ttcacttttc	ttcgtgaccc	gtggaactgg	ctggattttg	tcgtcattgt	ttttgcgtat	600
ttaacagaat	ttgtaaacct	aggcaatggt	tcagctcttc	gaactttcag	agtattgaga	660
gctttgaaaa	ctattttctgt	aatcccaggc	ctgaagacaa	ttgtaggggc	tttgatccag	720
tcagtgaaga	agctttctga	tgatcatgat	ctgactgtgt	tctgtctgag	tggttttgca	780
ctaattggac	tacagctggt	catgggaaac	ctgaagcata	aatgttttcg	aaattcactt	840
gaaaaaatg	aaacattaga	aagcataatg	aataccctag	agagtgaaga	agacttttaga	900
aaatattttt	attacttgga	aggatccaaa	gatgctctcc	tttgtgggtt	cagcacagat	960
tcaggtcagt	gtccagaggg	gtacacctgt	gtgaaaattg	gcagaaaccc	tgattatggc	1020
tacacgagct	ttgacacttt	cagctggggc	ttcttagcct	tgtttaggct	aatgacccaa	1080
gattactggg	aaaaccttta	ccaacagacg	ctgcgtgctg	ctggcaaaac	ctacatgatc	1140
ttctttgtcg	tagtgatttt	cctgggctcc	ttttatctaa	taaaacttgat	cctggctgtg	1200
gttgccatgg	catatgaaga	acagaaccag	gcaaaccattg	aagaagctaa	acagaaagaa	1260
ttagaatttc	aacagatggt	agaccgtctt	aaaaaagagc	aagaagaagc	tgaggcaatt	1320
gcagcggcag	cggctgaata	tacaagtatt	aggagaagca	gaattatggg	cctctcagag	1380
agttcttctg	aaacatccaa	actgagctct	aaaagtgtct	aagaagaag	aaacagaaga	1440
aagaaaaaga	atcaaaagaa	gctctccagt	ggagagggaa	agggagatgc	tgagaaattg	1500
tcgaaatcag	aatcagagga	cagcatcaga	agaaaaagtt	tccaccttgg	tgctgaaggg	1560
catagggcag	cacatgaaaa	gaggttgtct	acccccaatc	agtcaccact	cagcattcgt	1620
ggctccttgt	tttctgcaag	gcgaagcagc	agaacaagtc	tttttagttt	caaaggcaga	1680
ggaagagata	taggatctga	gactgaattt	gccgatgatg	agcacagcat	ttttggagac	1740
aatgagagca	gaaggggctc	actgttttgt	ccccacagac	cccaggagcg	acgcagcagt	1800
aacatcagcc	aagccagtag	gtccccacca	atgctgcccg	tgacgggaa	aatgcacagt	1860
gctgtggact	gcaacggtgt	ggtctccctg	gttgatggac	gctcagccct	catgctcccc	1920
aatggacagc	ttctgccaga	gggcacgacc	aatcaaatac	acaagaaaag	gcgttgtagt	1980
tcctatctcc	tttcagagga	tatgctgaat	gatcccaacc	tcagacagag	agcaatgagt	2040
agagcaagca	tattaacaaa	cactgtggaa	gaacttgaag	agtcagaca	aaaatgtcca	2100
ccttggtggt	acagatttgc	acacaaattc	ttgatctgga	attgctctcc	atattggata	2160
aaattcaaaa	agtgtatcta	ttttattgta	atggatcctt	ttgtagatct	tgcaattacc	2220
atttgcatag	ttttaaacac	attatttatg	gctatggaac	accacccaat	gactgaggaa	2280
ttcaaaaatg	tacttgctat	aggaaaattg	gtctttactg	gaatctttgc	agctgaaatg	2340
gtatttaaac	gatttgccat	ggatccatat	gagtatttcc	aagtaggctg	gaatattttt	2400
gacagcctta	ttgtgacttt	aagttagtg	gagctcttcc	tagcagatgt	ggaaggattg	2460
tcagtctctg	gatcattcag	actgctccga	gtcttcaagt	tggaacaaac	ctggccaaca	2520
ttgaacatgc	tgattaagat	catttggtaac	tcagtagggg	ctctaggtaa	cctcacctta	2580
gtgttgggcca	tcactgctct	catttttgc	gtggtcggca	tgagctctct	tggttaagagc	2640
tacaaaagat	gtgtctgcaa	gatcaatgat	gactgtacgc	tcccacgggt	gcacatgaac	2700
gacttcttcc	actccttcc	gatttgtgtc	cgctgtctgt	gtggagagtg	gatagagacc	2760
atgtgggact	gtatggaggt	cgctggtcaa	gctatgtgcc	ttattgttta	catgatggtc	2820
atggtcattg	gaaacctggt	ggtcctaacc	ctatttcttg	ccttattatt	gagctcattt	2880
agttcagaca	atcttcacag	aattgaagaa	gacctgatg	caaacaacct	ccagattgca	2940
gtgactagaa	ttaaaaaggg	aataaattat	gtgaaacaaa	ccttacgtga	atttattcta	3000
aaagcatttt	ccaaaaagcc	aaagatttcc	agggagataa	gacaagcaga	agatctgaat	3060
actaagaagg	aaaactatat	ttctaaccat	acacttgctg	aaatgagcaa	aggtcacaa	3120
ttcctcaagg	aaaaagataa	aatcagtggg	tttgggaagca	gcgtggacaa	acacttgatg	3180
gaagacagtg	atgggtcaatc	atttattcac	aatcccagcc	tcacagtga	agtgccaatt	3240
gcacctgggg	aatccgattt	ggaaaatatg	aatgctgagg	aacttagcag	tgattcggat	3300
agtgaataca	gcaaagtgag	attaaaccgg	tcaagctcct	cagagtgcag	cacagtgtat	3360
aaccttttgc	ctggagaagg	agaagaagca	gaggctgaac	ctatgaattc	cgatgagcca	3420
gaggcctggt	tcacagatgg	ttgtgtacgg	aggttctcat	gctgccaagt	taacatagag	3480
tcagggaaag	gaaaaatctg	gtggaacatc	aggaaaacct	gctacaagat	tggtgaacac	3540
agttgggttg	aaagcttcat	tgctctcatg	atcctgctca	gcagtgggtc	cctggctttt	3600
gaagatattt	atattgaaag	gaaaaagacc	attaaagatta	tcctggagta	tgagacaaag	3660
atcttcactt	acatcttcat	tctggaaatg	cttctaaaa	ggatagcata	tggttataaa	3720
acatatattca	ccaatgcctg	gtgttgctg	gatttcttaa	ttgttgatgt	ttctttgggt	3780
acttttagtg	caaacactct	tggtacttca	gatcttggcc	ccattaaatc	ccttcggaca	3840
ctgagagctt	taagacctct	aagagcctta	tctagatttg	aaggaaatgag	ggctcgttgtg	3900
aatgcactca	taggagcaat	tccttccatc	atgaatgtgc	tacttgtgtg	tcttatattc	3960
tggtgatgat	tcagatcat	gggagtaaat	ttgtttgctg	gcaagttcta	tgagtgtatt	4020
aacaccacag	atgggtcacg	gtttcctgca	agtcaggttc	caaactcggtc	cgaatgtttt	4080
gcccttatga	atgttagtca	aaatgtgcga	tggaacaaac	tgaaagtga	ccttgataat	4140
gtcggacttg	gttacctatc	tctgcttcaa	gttgcaactt	ttaagggatg	gacgattatt	4200

ATTORNEY DOCKET NO. 21101.0048U1

```

atgtatgcag cagtggattc tgtaaatgta gacaagcagc ccaaatatga atatagcctc 4260
tacatgtata tttattttgt cgtctttatc atctttgggt cattcttcac tttgaacttg 4320
ttcattgggtg tcatcataga taatttcaac caacagaaaa agaagcttgg aggtcaagac 4380
atctttatga cagaagaaca gaagaaatac tataatgcaa tgaaaaagct ggggtccaag 4440
aagccacaaa agccaattcc tcgaccaggg aacaaaatcc aaggatgtat atttgaccta 4500
gtgacaaatc aagcctttga tattagtatc atgggttcta tctgtctcaa catggtaacc 4560
atgatggtag aaaaggaggg tcaaagtcaa catatgactg aagttttata ttggataaat 4620
gtgggtttta taatcctttt cactggagaa tgtgtgctaa aactgatctc cctcagacac 4680
tactacttca ctgtaggatg gaatattttt gattttgtgg ttgtgattat ctccattgta 4740
gggtatgtttc tagctgattt gattgaaacg tattttgtgt cccctaccct gttccgagtg 4800
atccgtcttg ccaggattgg ccgaatccta cgtctagtca aaggagcaaa ggggatccgc 4860
acgctgctct ttgctttgat gatgtccctt cctgcgttgt ttaacatcgg cctcctgctc 4920
ttcctggtea tgttcattca cgccatcttt ggaatgtcca actttgccta tgttaaaaag 4980
gaagatggaa ttaatgacat gttcaatttt gagaccttg gcaacagtat gatttgcctg 5040
ttccaaatta caacctctgc tggctgggat ggattgctag cacctattct taacagtaag 5100
ccaccgact gtgacccaaa aaaagttcat cctggaagtt cagtgaagg agactgtgg 5160
aacccatctg ttggaatatt ctactttgtt agttatatca tcatatcctt cctgggttg 5220
gtgaacatgt acattgcagt catactggag aatttttagt ttgccactga agaaagtact 5280
gaacctctga gtgaggatga ctttgagatg ttctatgagg ttggggagaa gtttgatccc 5340
gatgcgaccc agtttataga gttctctaaa ctctctgatt ttgcagctgc cctggatcct 5400
cctcttctca tagcaaaacc caacaaagtc cagctcattg ccatggatct gcccatgggt 5460
agtggtagcc ggtaccattg tcttgacatc ttatttgcct ttacaaagcg tgttttgggt 5520
gagagtgggg agatggattc tcttcgttca cagatggaag aaaggttcat gtctgcaaat 5580
ccttccaaag tgtctatga acccatcaca accacactaa aacggaaaca agaggatgtg 5640
tctgctactg tcattcagcg tgcttataga cgttaccgct taaggcaaaa tgtcaaaaat 5700
atatcaagta tatacataaa agatggagac agagatgatg atttactcaa taaaaaagat 5760
atggcttttg ataatgttaa tgagaactca agtccagaaa aaacagatgc cacttcattc 5820
accacctctc caccttcata tgatagtgtg acaaagccag acaaagagaa atatgaacaa 5880
gacagaacag aaaaggaaga caaagggaaa gacagcaagg aaagcaaaaa atag 5934

```

<210> 9

<211> 5934

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 9

```

atggcaatgt tgcctccccc aggacctcag agctttgtcc atttcacaaa acagtctctt 60
gccctcattg aacaacgcct tgctgaaaga aaatcaaagg aacccaaaga agaaaagaaa 120
gatgatgatg aagaagcccc aaagccaagc agtgacttgg aagctggcaa acaactgccc 180
ttcatctatg gggacattcc tcccgcatg gtgtcagagc ccctggagga cttggacccc 240
tactatgcag acaaaaagac ttctatagta ttgaacaaag ggaaaacaat ctccggtttc 300
aatgccacac ctgctttata tatgctttct cctttcagtc ctctaagaag aatatctatt 360
aagattttag tacactcctt attcagcatg ctcatcatgt gcactattct gacaaactgc 420
atatttatga ccatgaataa cccgcaggac tggaccaaaa atgtcgagta cacttttact 480
ggaatatata cttttgaatc acttgtaaaa atccttgcaa gaggtctctg tgtaggagaa 540
ttcacttttc ttctgtaccc gtggaactgg ctggattttg tcgtcattgt ttttgcgtat 600
ttaacagaat ttgtaaacct aggcaatgtt tcagctcttc gaactttcag agtattgaga 660
gctttgaaaa ctatttctgt aatcccaggc ctgaagacaa ttgtaggggc ttgatccag 720
tcagtgaaga agctttctga tgctcatgat ctgactgtgt tctgtctgag tgtgtttgca 780
ctaattggac tacagctgtt catgggaaac ctgaagcata aatgttttcg aaattcactt 840
gaaaataatg aaacattaga aagcataatg aataccctag agagtgaaga agactttaga 900
aaatattttt attacttggg aggatccaaa gatgctctcc tttgtggttt cagcacagat 960
tcaggtcagt gtcagagggg gtacacctgt gtgaaaattg gcagaaaccc tgattatggc 1020
tacacgagct ttgacacttt cagctgggcc ttcttagcct tgtttaggct aatgacccaa 1080
gattactggg aaaaccttta ccaacagacg ctgcgtgctg ctggcaaaac ctacatgatc 1140

```

ATTORNEY DOCKET NO. 21101.0048U1

ttctttgtcg	tagtgatttt	cctgggctcc	ttttatctaa	taaacttgat	cctggctgtg	1200
gttgccatgg	catatgaaga	acagaaccag	gcaaaccattg	aagaagctaa	acagaaagaa	1260
ttagaatttc	aacagatggt	agaccgtctt	aaaaaagagc	aagaagaagc	tgaggcaatt	1320
gcagcggcag	cggctgaata	tacaagtatt	aggagaagca	gaattatggg	cctctcagag	1380
agttcttctg	aaacatccaa	actgagctct	aaaagtgtcta	aagaaagaag	aaacagaaga	1440
aagaaaaaga	atcaaaagaa	gctctccagt	ggagagggaaa	agggagatgc	tgagaaattg	1500
tcgaaatcag	aatcagagga	cagcatcaga	agaaaaagtt	tccaccttgg	tgtcgaagg	1560
cataggcgag	cacatgaaaa	gaggttgtct	acccccaatc	agtcaccact	cagcattcgt	1620
ggctccttgt	tttctgcaag	gcgaagcagc	agaacaagtc	tttttagttt	caaaggcaga	1680
ggaagagata	taggatctga	gactgaattt	gccgatgatg	agcacagcat	ttttggagac	1740
aatgagagca	gaaggggctc	actgtttgtg	ccccacagac	cccgaggagcg	acgcagcagt	1800
aacatcagcc	aagccagtag	gtccccacca	atgctgcggg	tgaacgggaa	aatgcacag	1860
gctgtggact	gcaacggtgt	ggtctccctg	gttgatggac	gctcagccct	catgctcccc	1920
aatggacagc	ttctgccaga	gggcacgacc	aatcaaatac	acaagaaaag	gcgtttagt	1980
tcctatctcc	tttcagagga	tatgctgaat	gatcccaacc	tcagacagag	agcaatgagt	2040
agagcaagca	tattaacaaa	cactgtggaa	gaacttgaag	agtccagaca	aaaatgtcca	2100
ccttggtggg	acagatttgc	acacaaattc	ttgatctgga	attgctctcc	atattggata	2160
aaattcaaaa	agtgtatcta	ttttattgta	atggatcctt	ttgtagatct	tgcaattacc	2220
atttgcatag	ttttaaacac	attatttatg	gctatggaac	accacccaat	gactgaggaa	2280
ttcaaaaatg	tacttgctat	aggaaatttg	gtctttactg	gaatctttgc	agctgaaatg	2340
gtattaaac	tattgtccat	ggatccatat	gagtatttcc	aagtaggctg	gaatattttt	2400
gacagcctta	ttgtgacttt	aagttttagt	gagctcttcc	tagcagatgt	ggaaggattg	2460
tcagtctcgc	gatcattcag	actgctccga	gtcttcaagt	tgccaaaatc	ctggccaaca	2520
ttgaacatgc	tgattaagat	cattggtaac	tcagtagggg	ctctaggtaa	cctcacctta	2580
gtgttgccca	tcacgtctct	catttttgc	gtggctggca	tcagactctt	tggttaagagc	2640
tacaaagaat	gtgtctgcaa	gatcaatgat	gactgtacgc	tcccacgggtg	gcacatgaac	2700
gacttcttcc	actccttcc	gattgtgttc	cgcgtgctgt	gtggagagt	gatagagacc	2760
atgtgggact	gtatggaggt	cgtgtgtcaa	gctatgtgcc	ttattgttta	catgatggtc	2820
atggtcattg	gaaacctgg	ggctcctaaac	ctatttctgg	ccttattatt	gagctcattt	2880
agttcagaca	atcttacagc	aattgaagaa	gacctgatg	caaacaacct	ccagattgca	2940
gtgactagaa	ttaaaaagg	aataaattat	gtgaaacaaa	ccttacgtga	atattattcta	3000
aaagcatttt	ccaaaaagcc	aaagatttcc	agggagataa	gacaagcaga	agatctgaat	3060
actaagaagg	aaaactatat	ttctaaccat	acacttgctg	aaatgagcaa	aggtcacat	3120
ttcctcaagg	aaaaagataa	aatcagtggt	tttggaaagca	gcgtggacaa	acacttgatg	3180
gaagacagtg	atggtcaatc	atttattcac	aatcccagcc	tcacagtgc	agtgccaatt	3240
gcacctgggg	aatccgattt	ggaaaatatg	aatgctgagg	aacttagcag	tgattcggat	3300
agtgaataca	gcaaagttag	attaaaccgg	tcaagctcct	cagagtgcag	cacagttagt	3360
aaccttttgc	ctggagaagg	agaagaagca	gaggctgaac	ctatgaattc	cgatgagcca	3420
gaggcctgtt	tcacagatgg	ttgtgtacgg	aggttctcat	gctgccaaat	taacatagag	3480
tcaggggaaa	gaaaaatctg	gtggaacatc	aggaaaacct	gctacaagat	tggtgaacac	3540
agttgggttg	aaagcttcat	tgctctcatg	atcctgctca	gcagtgggtg	cctggctttt	3600
gaagatattt	atattgaaag	gaaaaagacc	attaagatta	tcctggagta	tgagacaaag	3660
atcttcaact	acatcttcat	tctggaaatg	cttctaaaa	ggatagcata	tggttataaa	3720
acatatttca	ccaatgcctg	gtgttggtcg	gatttcctaa	ttgttgatgt	ttctttgggt	3780
actttagtg	caaacactct	tggtactca	gatcttgccc	ccattaaatc	ccttcggaca	3840
ctgagagctt	taagacctct	aagagcctta	tctagatttg	aaggaatgag	ggctcgttg	3900
aatgcactca	taggagcaat	tccttccatc	atgaatgtgc	tacttggtg	tcttatattc	3960
tggctgatat	tcagcatcat	gggagtaaat	ttgtttgctg	gcaagttcta	tgagtgtatt	4020
aacaccacag	atgggtcacg	gtttcctgca	agtcaggctc	caaatcgctc	cgaatgtttt	4080
gcccttatga	atgttagtca	aaatgtgcga	tggaacaaac	tgaaagtga	ctttgataat	4140
gtcggacttg	gttacctatc	tctgcttcaa	gttgcaactt	ttaagggatg	gacgattatt	4200
atgtatgcag	cagtggattc	tgtaaatgta	gacaagcagc	ccaaatatga	atatagcctc	4260
tacatgtata	tttattttgt	cgtctttatc	atctttgggt	cattcttctc	tttgaacttg	4320
ttcatttggt	tcattcataga	taatttcaac	caacagaaaa	agaagcttgg	aggtcaagac	4380
atctttatga	cagaagaaca	gaagaaatac	tataatgcaa	tgaaaaagct	ggggtccaag	4440
aagccacaaa	agccaattcc	tcgaccagg	aacaaaatcc	aaggatgtat	atgtgacct	4500
gtgacaaatc	aagcctttga	tatttagtatc	atggttctta	tctgtctcaa	catggttaacc	4560
atgatggtag	aaaaggagg	tcaaagtcaa	catatgactg	aagttttata	ttggataaat	4620
gtggttttta	taactctttt	cactggagaa	tggtgtctaa	aactgatctc	cctcagacac	4680
tactacttca	ctgtaggatg	gaatattttt	gattttgtgg	ttgtgattat	ctccattgta	4740
ggatgtttc	tagctgattt	gattgaaacg	tattttgtgt	cccctaccct	gttccgagtg	4800

ATTORNEY DOCKET NO. 21101.0048U1

```

atccgtcttg ccaggattgg ccgaatccta cgtctagtca aaggagcaaa ggggatccgc 4860
acgetgctct ttgctttgat gatgtccctt cctgcgttgt ttaacatcgg cctcctgctc 4920
ttcctggtea tgttcatacta cgccatcttt ggaatgtcca actttgccta tgttaaaaag 4980
gaagatggaa ttaatgacat gttcaatttt gagacctttg gcaacagtat gatttgcctg 5040
ttccaaatta caacctctgc tggctgggat ggattgctag cacctattct taacagtaag 5100
ccaccgact gtgacccaaa aaaagttcat cctggaagtt cagttgaagg agactgtggt 5160
aaccatctg ttggaatatt ctactttgtt agttatatca tcatacctt cctggttgtg 5220
gtgaacatgt acattgcagt catactggag aatttttagt ttgccactga agaaagtact 5280
gaacctctga gtgaggatga ctttgagatg ttctatgagg ttggggagaa gtttgatccc 5340
gatgcgaccc agtttataga gttctctaaa ctctctgatt ttgcagctgc cctggatcct 5400
cctcttctca tagcaaaacc caacaaagtc cagctcattg ccatggatct gcccatggtt 5460
agtgggtgacc ggatccattg tcttgacatc ttatttgctt ttacaaagcg tgttttgggt 5520
gagagtgggg agatggattc tcttcgttca cagatggaag aaaggttcat gtctgcaaat 5580
ccttccaaag tgcctatga acccatcaca accacactaa aacggaaaca agaggatgtg 5640
tctgctactg tcatccagcg tgcttataga cgttaccgct taaggcaaaa tgtcaaaaat 5700
atatcaagta tatacataaa agatggagac agagatgatg atttactcaa taaaaaagat 5760
atggcttttg ataagttaa tgagaactca agtcagaaaa aaacagatgc cacttcattc 5820
accacctctc caccttcata tgatagtgtg acaaagccag acaaagagaa atatgaacaa 5880
gacagaacag aaaaggaaga caaagggaaa gacagcaagg aaagcaaaaa atag 5934

```

<210> 10

<211> 5934

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 10

```

atggcaatgt tgccctcccc aggacctcag agctttgtcc atttcacaaa acagtctctt 60
gccctcattg aacaacgcat tgctgaaaga aaatcaaagg aacccaaaga agaaaagaaa 120
gatgatgatg aagaagcccc aaagccaagc agtgacttgg aagctggcaa acaactgccc 180
ttcatctatg gggacattcc tcccgcatg gtgtcagagc cctggagga cttggacccc 240
tactatgcag acaaaaagac ttctatagta ttgaacaaag ggaaaacaat cttccgtttc 300
aatgccacac ctgctttata tatgctttct cctttcagtc ctctaagaag aatatctatt 360
aagattttag tacactcctt attcagcatg ctcatcatgt gcactattct gacaaactgc 420
atatttatga ccatgaataa cccgccggac tggacaaaaa atgtcagata cacttttact 480
ggaatatata cttttgaatc acttgtaaaa atccttgcaa gaggtctctg tgtaggagaa 540
ttcaactttt ttcgtgaccc gtggaactgg ctggattttg tcgtcattgt ttttgcgtat 600
ttaacagaat ttgtaaacct aggcaatggt tcagctcttc gaactttcag agtattgaga 660
gctttgaaaa ctattttctgt aatcccagc ctgaagacaa ttgtaggggc tttgatccag 720
tcagtgaaga agctttctga tgtcatgac ctgactgtgt tctgtctgag tgtgtttgca 780
ctaattggac tacagctggt catgggaaac ctgaagcata aatgttttcg aaattcactt 840
gaaaataatg aaacattaga aagcataatg aataccctag agagtgaaga agactttaga 900
aaatatTTTT attacttggg aggatccaaa gatgctctcc tttgtggttt cagcacagat 960
tcaggctcagt gtccagaggg gtacacctgt gtgaaaattg gcagaaaccc tgattatggc 1020
tacacgagct ttgacacttt cagctgggccc ttcttagcct tgtttaggct aatgacccaa 1080
gattactggg aaaaccttta ccaacagacg ctgcgtgctg ctggcaaaac ctacatgac 1140
ttctttgtcg tagtgatttt cctgggctcc ttttatctaa taaacttgat cctggctgtg 1200
gttgccatgg catatgaaga acagaaccag gcaaacattg aagaagctaa acagaaagaa 1260
ttagaatttc aacagatggt agaccgtctt aaaaaagagc aagaagaagc tgaggcaatt 1320
gcagcggcag cggctgaata tacaagtatt aggagaagca gaattatggg cctctcagag 1380
agtctctctg aaacatccaa actgagctct aaaagtgtc aagaagaag aaacagaaga 1440
aagaaaaaga atcaaaagaa gctctccagt ggagaggaaa agggagatgc tgagaaattg 1500
tcgaaatcag aatcagagga cagcatcaga agaaaaagtt tccaccttgg tgtcgaaggg 1560
cataggcgag cacatgaaaa gagttgtct accccaatc agtcaccact cagcattcgt 1620
ggctccttgt tttctgcaag gcgaagcagc agaacaagtc tttttagttt caaaggcaga 1680
ggaagagata taggatctga gactgaattt gccgatgatg agcacagcat ttttggagac 1740

```

ATTORNEY DOCKET NO. 21101.0048U1

aatgagagca	gaaggggctc	actgttttgt	ccccacagac	cccaggagcg	acgcagcagt	1800
aacatcagcc	aagccagtag	gtccccacca	atgctgccgg	tgaacgggaa	aatgcacagt	1860
gctgtggact	gcaacgggtg	ggctctccctg	gttgatggac	gctcagccct	catgctcccc	1920
tatggacagc	ttctgccaga	gggcacgacc	aatcaaatac	acaagaaaag	gcgttgtagt	1980
tcctatctcc	tttcagagga	tatgctgaat	gatcccaacc	tcagacagag	agcaatgagt	2040
agagcaagca	tattaacaaa	cactgtggaa	gaacttgaag	agtccagaca	aaaaatgtcca	2100
ccttggtggg	acagatttgc	acacaaattc	ttgatctgga	attgctctcc	atattggata	2160
aaattcaaaa	agtgtatcta	ttttattgta	atggatccctt	ttgtagatct	tgcaattacc	2220
atttgcatag	ttttaaacac	attattttatg	gctatggaac	accaccaat	gactgaggaa	2280
ttcaaaaatg	tacttgctat	aggaaatttgc	gtctttactg	gaatctttgc	agctgaaatg	2340
gtattaaaaa	tgattgccat	ggatccatat	gagtatctcc	aagtaggctg	gaatattttt	2400
gacagcctta	ttgtgacttt	aagtttagtg	gagctctttc	tagcagatgt	ggaaggattg	2460
tcagtctctg	gatcattcag	actgctccga	gtcttcaagt	tggaacaaatc	ctggccaaca	2520
ttgaacatgc	tgattaagat	cattggtaac	tcagtagggg	ctctaggtaa	cctcacctta	2580
gtgttgccca	tcacgtctct	catttttgc	gtggctggca	tgagctctct	tggttaagagc	2640
tacaaagaat	gtgctgcaa	gatcaatgat	gactgtacgc	tcccacgggtg	gcacatgaac	2700
gacttcttcc	actccttcc	gattgtgttc	cgctgtctgt	gtggagagtg	gatagagacc	2760
atgtgggact	gtatggagggt	cgctgggtcaa	gctatgtgcc	ttattgttta	catgatgggtc	2820
atgggtcattg	gaaacctggg	ggctcctaaac	ctatttctgg	ccttattatt	gagctcattt	2880
agttcagaca	atcttacagc	aattgaagaa	gacctgtatg	caaacacact	ccagattgca	2940
gtgataagaa	ttaaaaaggg	aataaattat	gtgaaacaaa	ccttacgtga	atttattcta	3000
aaagcatttt	ccaaaaagcc	aaagatttcc	agggagataa	gacaagcaga	agatctgaat	3060
actaagaagg	aaaactatat	ttctaaccat	acactgtctg	aaatgagcaa	aggtcacaa	3120
ttcctcaagg	aaaaagataa	aatcagtggt	tttggaagca	gcgtggacaa	acacttgatg	3180
gaagacagtg	atgggtcaatc	atttattcac	aatcccagcc	tcacagtgc	agtgcacatt	3240
gcacctgggg	aatccgattt	ggaaaatatg	aatgctgagg	aacttagcag	tgattcggat	3300
agtgaataca	gcaaaagtga	attaaaccgg	tcaagctcct	cagagtgcag	cacagttgat	3360
aacctcttgc	ctggagaagg	agaagaagca	gaggctgaac	ctatgaattc	cgatgagcca	3420
gaggcctgtt	tcacagatgg	ttgtgtacgg	agggttctcat	gctgccaagt	taacatagag	3480
tcagggaagg	gaaaaatctg	gtggaacatc	aggaaaacct	gctacaagat	tggtgaacac	3540
agttggtttg	aaagcttcat	tgctctcatg	atcctgtcca	gcagtgggtc	cctggctttt	3600
gaagatattt	atattgaaag	gaaaaagacc	attaagatta	tcctggagta	tcagacaaag	3660
atcttcaact	acatcttcat	tctggaaatg	cttctaaaat	ggatagcata	tggttataaa	3720
acatatttca	ccaatgcctg	gtgttggtcg	gatttcttaa	ttgttgatgt	ttctttgggt	3780
actttagtgg	caaacactct	tggtactcca	gatcttgccc	ccattaaatc	ccttcggaca	3840
ctgagagctt	taagacctct	aagagcctta	tctagatttg	aaggaaatgag	ggctcgttgtg	3900
aatgcactca	taggagcaat	tccttccatc	atgaatgtgc	tacttggtg	tcttatattc	3960
tggtctgat	tcagcatcat	gggagtaaat	ttgtttgctg	gcaagttcta	tgagtgtatt	4020
aacaccacag	atgggtcacg	gtttcctgca	agtcaggctc	caaatcgctc	cgaatgtttt	4080
gccttctatga	gtttagtcca	aaatgtgcga	tggaacaaac	tgaaagtga	ctttgataat	4140
gtcggacttg	gttacctatc	tctgcttcaa	gttgcaactt	ttaagggatg	gacgattatt	4200
atgtatgcag	cagtggattc	tggtaatgta	gacaagcagc	ccaaatatga	atatagcctc	4260
tacatgtata	tttattttgt	cgtctttatc	atctttgggt	cattcttcac	tttgaacttg	4320
ttcattgggt	tcacataga	taatttcaac	caacagaaaa	agaagcttgg	aggtcaagac	4380
atctttatga	cagaagaaca	gaagaaatac	tataatgcaa	tgaaaaagct	ggggtccaag	4440
aagccacaaa	agccaattcc	tcgaccaggg	aacaaaatcc	aaggatgtat	atttgacctt	4500
gtgacaaatc	aagcctttga	tattagtatc	atgggtctta	tctgtctcaa	catggtaacc	4560
atgatggtag	aaaaggaggg	tcaaagtcaa	catatgactg	aagttttata	ttggataaat	4620
gtgggtttta	taatcctttt	cactggagaa	tgtgtgctaa	aactgatctc	cctcagacac	4680
tactacttca	ctgtaggatg	gaatattttt	gattttgtgg	ttgtgattat	ctccattgtt	4740
ggatgtttc	tagctgattt	gattgaaacg	tattttgtgt	ccctaccct	gttccgagtg	4800
atccgtcttg	ccaggattgg	ccgaatccta	cgtctagtca	aaggagcaaa	ggggatccgc	4860
acgctgctct	ttgctttgat	gatgtccctt	cctgcgttgt	ttaacatcgg	cctcctgctc	4920
ttcctggcca	tgttcactca	cgccatcttt	ggaatgtcca	actttgccta	tgtaaaaaag	4980
gaagatggaa	ttaatgacat	gttcaatttt	gagacctttg	gcaacagtat	gatttgcttg	5040
ttccaaatta	caacctctgc	tggtggggat	ggattgctag	cacctattct	taacagtaag	5100
ccaccggact	gtgacccaaa	aaaagttcat	cctggaagtt	cagttgaagg	agactgtggt	5160
aacctcatctg	ttggaatatt	ctactttgtt	agttatatca	tcatatcctt	cctgggttgtg	5220
gtgaacatgt	acattgcagt	catactggag	aatttttagtg	ttgccactga	agaaagtact	5280
gaacctctga	gtgaggatga	ctttgagatg	ttctatgagg	tttgggagaa	gtttgatccc	5340
gatgcgaccc	agtttataga	gttctctaaa	ctctctgatt	ttgcagctgc	cctggatcct	5400

ATTORNEY DOCKET NO. 21101.0048U1

```
cctcttctca tagcaaaacc caacaaagtc cagctcattg ccatggatct gcccatgggt 5460
agtgggtgacc ggatccattg tcttgacatc ttatttgctt ttacaaagcg tgttttgggt 5520
gagagtgggg agatggattc tcttcgttca cagatggaag aaagggttcac gtctgcaaat 5580
ccttccaaag tgccttatga acccatcaca accacactaa aacggaaaca agaggatgtg 5640
tctgctactg tcattcagcg tgcttataga cgttaccgct taaggcaaaa tgtcaaaaat 5700
atatcaagta tatacataaa agatggagac agagatgatg atttactcaa taaaaaagat 5760
atggcttttg ataagttaa tgagaactca agtccagaaa aaacagatgc cacttcattc 5820
accacctctc caccttcata tgatagtgtg acaaagccag acaaagagaa atatgaacaa 5880
gacagaacag aaaaggaaga caaagggaag gacagcaagg aaagcaaaaa atag 5934
```

<210> 11

<211> 5934

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 11

```
atggcaatgt tgctccccc aggacctcag agctttgtcc atttcacaaa acagtctctt 60
gccctcattg aacaacgcat tgctgaaaga aaatcaaagg aacccaaaga agaaaagaaa 120
gatgatgatg aagaagcccc aaagccaagc agtgacttgg aagctggcaa acaactgccc 180
ttcatctatg gggacattcc tcccggcatg gtgtcagagc cctggagga cttggacccc 240
tactatgcag acaaaaagac tttcatagta ttgaacaaag ggaaaacaat cttccgtttc 300
aatgccacac ctgctttata tatgctttct cctttcagtc ctctaagaag aatatctatt 360
aagattttag tacactcctt attcagcatg ctcatcatgt gcactattct gacaaactgc 420
atatttatga ccatgaataa cccgccggac tggaccaaaa atgtcagta cacttttact 480
ggaaatatata cttttgaatc acttgtaaaa atccttgcaa gaggtctctg tgtaggagaa 540
ttcacttttc ttctgtgacc gtggaactgg ctggattttg tegtattgt ttttgctat 600
ttaacagaat ttgtaaacct aggcaatgtt tcagctcttc gaactttcag agtattgaga 660
gctttgaaaa ctatttctgt aatcccaggc ctgaagacaa ttgtaggggc tttgatccag 720
tcagtgaaga agctttctga tgtcatgac ctgactgtgt tctgtctgag tgtgtttgca 780
ctaattggac tacagctgtt catgggaaac ctgaagcata aatgttttcg aaattcactt 840
gaaaaaatg aaacattaga aagcataatg aataccctag agagtgaaga agactttaga 900
aaatattttt attacttgga aggatccaaa gatgctctcc tttgtggttt cagcacagat 960
tcaggtcagt gtccagaggg gtacacctgt gtgaaaattg gcagaaaccc tgattatggc 1020
tacacgagct ttgacacttt cagctgggcc ttcttagcct tgtttaggct aatgacccaa 1080
gattactggg aaaaccttta ccaacagacg ctgctgtctg ctggcaaaac ctacatgatc 1140
ttctttgtcg tagtgatttt cctgggctcc ttttatctaa taaacttgat cctggctgtg 1200
gttgccatgg catatgaaga acagaaccag gcaaacattg aagaagctaa acagaaagaa 1260
ttagaatttc aacagatgtt agaccgtctt aaaaaagagc aagaagaagc tgaggcaatt 1320
gcagcggcag cggctgaata tacaagtatt aggagaagca gaattatggg cctctcagag 1380
agtctctctg aaacatccaa actgagctct aaaaagtcta aagaaagaag aaacagaaga 1440
aagaaaaaga atcaaaagaa gctctccagt ggagaggaaa agggagatgc tgagaaattg 1500
tcgaaatcag aatcagagga cagcatcaga agaaaaagtt tccaccttgg tgtcgaagg 1560
cataggcgag cacatgaaaa gaggttgtct accccaatc agtcaccact cagcatctgt 1620
ggctccttgt tttctgcaag gcgaagcagc agaacaagtc tttttagttt caaaggcaga 1680
ggaagagata taggatctga gactgaattt gccgatgatg agcacagcat ttttggagac 1740
aatgagagca gaaggggctc actgttttgt cccacagac cccaggagcg acgcagcagt 1800
aacatcagcc aagccagtag gtccccacca atgctgccgg tgaacgggaa aatgcacagt 1860
gctgtggact gcaacggtgt ggtctccctg ttgatggag gctcagccct catgctccc 1920
aatggacagc ttctgccaga gggcacgacc aatcaaatac acaggaaaag gcgttgtagt 1980
tcctatctcc tttcagagga tatgctgaat gatcccaacc tcagacagag agcaatgagt 2040
agagcaagca tattaacaaa cactgtggaa gaacttgaag agtcagaca aaaatgtcca 2100
ccttgggtgt acagatttgc acacaaattc ttgatctgga attgctctcc atattggata 2160
aaattcaaaa agtgatact ttttattgta atggatcctt ttgtagatct tgcaattacc 2220
atgtgcatag ttttaaacac attatttatg gctatggaac accaccaat gactgaggaa 2280
ttcaaaaatg tacttgctat aggaaatttg gtctttactg gaatctttgc agctgaaatg 2340
```


ATTORNEY DOCKET NO. 21101.0048U1

gtattaaaac	tgattgccat	ggatccatat	gagtatattcc	aagtaggctg	gaatattttt	2400
gacagcctta	ttgtgacttt	aagtttagtg	gagctctttc	tagcagatgt	ggaaggattg	2460
tcagttctgc	gatcattcag	actgctccga	gtcttcaagt	tggcaaaatc	ctggccaaca	2520
ttgaacatgc	tgattaagat	cattggtaac	tcagtagggg	ctctaggtaa	cctcacctta	2580
gtgttggcca	tcacgtctct	catttttgct	gtggctcgga	tgcagctctt	tggtaagagc	2640
tacaaagaat	gtgtctgcaa	gatcaatgat	gactgtacgc	tcccacgggtg	gcacatgaac	2700
gacttcttcc	actccttcc	gattgtgttc	cgctgtctgt	gtggagagt	gatagagacc	2760
atgtgggaact	gtatggagg	cgctgggtcaa	gctatgtgcc	ttattgttta	catgatggc	2820
atggtcattg	gaaacctggt	ggctcctaaac	ctatttctgg	ccttattatt	gagctcattt	2880
agttcagaca	atcttacagc	aattgaagaa	gacctgatg	caacaacct	ccagattgca	2940
gtgactagaa	ttaaaaaggg	aataaattat	gtgaaacaaa	ccttacgtga	atttattcta	3000
aaagcatttt	ccaaaaagcc	aaagatttcc	agggagataa	gacaagcaga	agatctgaat	3060
actaagaagg	aaaactatat	ttctaaccat	acacttgctg	aatgagcaa	aggtcacaat	3120
ttcctcaagg	aaaaagataa	aatcagtggt	tttggaaagca	gcgtggacaa	acacttgatg	3180
gaagacagt	atggtcaatc	atttattcac	aatcccagcc	tcacagtga	agtgccaatt	3240
gcacctgggg	aatccgattt	ggaaaaatag	aatgctgagg	aacttagcag	tgattcggat	3300
agtgaataca	gcaaaagtga	attaaaccgg	tcaagctcct	cagagtgcag	cacagttgat	3360
aaccttttgc	ctggagaagg	agaagaagca	gaggctgaac	ctatgaattc	cgatgagcca	3420
gaggcctgtt	tcacagatgg	ttgtgtacgg	aggttctcat	gctgccaagt	taacatagag	3480
tcagggaag	gaaaaatctg	gtggaaacatc	aggaaaacct	gctacaagat	tggtgaacac	3540
agttggtttg	aaagcttcat	tgctctcatg	atcctgctca	gcagtgggtg	cctggccttt	3600
gaagatattt	atattgaaag	gaaaaagacc	attaagatta	tcctggagta	tcagacaaag	3660
atcttcactt	acatcttcat	tctggaaatg	cttctaaaat	ggatagcata	tggttataaa	3720
acatatttca	ccaatgcctg	gtgttggtg	gatttccctaa	ttgttgatgt	ttctttgggt	3780
actttagtgg	caaacactct	tggtactca	gatcttgccc	ccattaaatc	ccttcggaca	3840
ctgagagctt	taagacctct	aagagcctta	tctagatttg	aaggaaatgag	ggctggtgtg	3900
aatgcactca	taggagcaat	tccttccatc	atgaatgtgc	tacttgtgtg	tttatattc	3960
tggctgatat	tcagcatcat	gggagtaaat	ttgtttgctg	gcaagttcta	tgagtgtatt	4020
aacaccacag	atgggtcacg	gtttcctgca	agtcaagttc	caaatcggtc	cgaatgtttt	4080
gcccttatga	atgttagtca	aaatgtgcga	tggaaaaacc	tgaaagtga	ccttgataat	4140
gtcggacttg	gttacctatc	tctgcttcaa	gttgcaactt	ttaaaggatg	gacgattatt	4200
atgtatgcag	cagtggattc	tgtaaatgta	gacaagcagc	ccaaatatga	atatagcctc	4260
tacatgtata	ttatttttgt	cgctctttatc	atctttgggt	cattcttcac	tttgaacttg	4320
ttcattgggtg	tcacataga	taatttcaac	caacagaaaa	agaagcttgg	aggccaagac	4380
atctttatga	gaagaagaaca	gaagaataac	tataatgcaa	tgaaaaagct	ggggccaag	4440
aagccacaaa	agccaatttc	tcgaccagg	aacaaaatcc	aaggatgtat	atttgaccta	4500
gtgacaaatc	aagcctttga	tattagatc	atggttctta	tctgtctcaa	catggtaacc	4560
atgatggtag	aaaaggagg	tcaaagtcaa	catatgactg	aaagtttata	ttggataaat	4620
gtggttttta	taatcctttt	cactggagaa	tgtgtgctaa	aactgatctc	cctcagacac	4680
tactacttca	ctgtaggatg	gaatatattt	gtgtgtgtgg	ttgtgattat	ctccattgta	4740
ggtatgtttc	tagctgattt	gattgaaacg	tattttgtgt	ccctaccct	gttccgagt	4800
atccgtcttg	ccaggattgg	ccgaatccta	cgctagtca	aaggagcaaa	ggggatccgc	4860
acgtgctct	ttgctttgat	gatgtccctt	cctgcgttgt	ttacatcgg	cctcctgctc	4920
ttcctggta	tgctcatcta	cgccatcttt	ggaatgtoca	actttgccta	tgtaaaaaag	4980
gaagatggaa	ttaatgacat	gttcaatttt	gagacctttg	gcaacagtat	gatttgcctg	5040
ttccaaatta	caacctctgc	tggtcgggat	ggattgctag	cacctattct	taacagtaag	5100
ccacccgact	gtgacccaaa	aaaagttcat	cctggaagtt	cagttgaagg	agactgtggt	5160
aacctcatctg	ttggaatatt	ctactttgtt	agttatatca	tcatatcctt	cctggttgtg	5220
gtgaacatgt	acattgcagt	catactggag	aatttttagtg	ttgccactga	agaaagtact	5280
gaacctctga	gtgaggatga	ctttgagatg	ttctatgagg	tttgggagaa	gtttgatccc	5340
gatgcgaccc	agtttataga	gttctctaaa	ctctctgatt	ttgcagctgc	cctggatcct	5400
cctctttctca	tagcaaaacc	caacaaagtc	cagctcattg	ccatggatct	gccccatggt	5460
agtgtgacc	ggatccattg	tcttgacatc	ttatttgctt	ttacaaagcg	tgttttgggt	5520
gagagtgggg	agatggattc	tcttcgttca	cagatggaag	aaaggttcac	gtctgcaaat	5580
ccttccaaag	tgctctatga	acctatcaca	accacactaa	aacggaaaca	agaggatgtg	5640
tctgtactg	tcattcagcg	tgcttataga	cgttaccgct	taaggcaaaa	tgtcaaaaat	5700
atatcaagta	tatacataaa	agatggagac	agagatgatg	atttactcaa	taaaaaagat	5760
atggcttttg	ataggttaa	tgagaactca	agtcagaaa	aaacagatgc	cacttcaccc	5820
accacctctc	caacctcata	tgatagtgtc	acaaagccag	acaaagagaa	atatgaacaa	5880
gacagaacag	aaaaggaaga	caaagggaaa	gacagcaagg	aaagcaaaaa	atag	5934

<210> 12
 <211> 5934
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:/note =
 synthetic construct

<400> 12
 atggcaatgt tgcctccccc aggacctcag agctttgtcc atttcacaaa acagtctctt 60
 gccctcattg aacaacgcat tgctgaaaga aaatcaaagg aacccaaaga agaaaagaaa 120
 gatgatgatg aagaagcccc aaagccaagc agtgacttgg aagctggcaa acaactgccc 180
 ttcatctatg gggacattcc tcccgcatg gtgtcagagc ccctggagga cttggacccc 240
 tactatgcag acaaaaagac ttcatagta ttgaacaaag ggaaaacaat cttccgtttc 300
 aatgccacac ctgctttata tatgctttct cctttcagtc ctctaagaag aatatctatt 360
 aagatttttag tacactcctt attcagcatg ctcatcatgt gcactattct gacaaactgc 420
 atattttatga ccatgaataa cccgccggac tggacaaaa atgtcgagta cacttttact 480
 ggaatatata cttttgaatc acttgtaaaa atccttgcaa gaggttcttg tgtaggagaa 540
 ttactttttc ttctgtgacc gtggaactgg ctggattttg tcgtcattgt ttttgctgat 600
 ttaacagaat ttgtaaacct aggcaatgtt tcagctcttc gaactttcag agtattgaga 660
 gctttgaaaa ctattttctgt aatcccaggc ctgaagacaa ttgtaggggc tttgatccag 720
 tcagtgaaga agctttctga tgtcatgac ctgactgtgt tctgtctgag tgtgtttgca 780
 ctaattggac tacagctgtt catgggaaac ctgaagcata aatgttttcg aaattcactt 840
 gaaaaaatatg aaacattaga aagcataatg aataccctag agagtgaaga agactttaga 900
 aaatattttt attacttgga aggatccaaa gatgctctcc tttgtggttt cagcacagat 960
 tcaggtcagt gtccagaggg gtacacctgt gtgaaaattg gcagaaaccc tgattatggc 1020
 tacacgagct ttgacacttt cagctgggcc ttcttagcct tgtttaggct aatgacccaa 1080
 gattactggg aaaaccttta ccaacagacg ctgctgtctg ctggcaaaac ctacatgac 1140
 ttctttgtcg tagtgatttt cctgggctcc ttttatctaa taaacttgat cctggctgtg 1200
 gttgccatgg catatgaaga acagaaccag gcaaacattg aagaagctaa acagaaagaa 1260
 ttgaatttc aacagatgtt agaccgtctt aaaaaagagc aagaagaagc tgaggcaatt 1320
 gcagcggcag cygctgaata tacaagtatt aggagaagca gaattatggg cctctcagag 1380
 agttcttctg aaacatccaa actgagctct aaaagtgtc aagaagaag aaacagaaga 1440
 aagaaaaaga atcaaaagaa gctctccagt ggagaggaaa agggagatgc tgagaaattg 1500
 tcgaaatcag aatcagagga cagcatcaga agaaaaagt tccaccttg tgtcgaaggg 1560
 catagggcag cacatgaaaa gaggtgtct accccaatc agtcaccact cagcattcgt 1620
 ggctccttgt tttctgcaag gcgaagcagc agaacaagtc tttttagttt caaaggcaga 1680
 ggaagagata taggatctga gactgaattt gccgatgat agcacagcat ttttgagac 1740
 aatgagagca gaaggggctc actgtttgtg cccacagac ccaggagcg acgcagcagt 1800
 aacatcagcc aagccagtag gtccccacca atgtgcggg tgaacgggaa aatgcacagt 1860
 gctgtggact gcaacgggtg ggtctccctg gttgatggac gctcagccct catgctcccc 1920
 aatggacagc ttctgccaga gggcacgacc aatcaaatac acaagaaaag gcgtttagt 1980
 tcctatctcc ttccagagga tatgctgaat gatcccaacc tcagacagag agcaatgagt 2040
 agagcaagca tattaacaaa cactgtggaa gaacttgaag agtcagaca aaaatgtcca 2100
 ccttgggtgg acagatttgc acacaaattc ttgatctgga attgctctcc atattggata 2160
 aaattcaaaa agtgtatcta ttttattgta ttggatcctt ttgtagatct tgcagttacc 2220
 atttgcatag ttttaaacac attatttatg gctatggaac accaccaat gactgaggaa 2280
 ttcaaaaatg tacttgetat aggaaatttg gtctttactg gaatctttgc agctgaaatg 2340
 gtattaaaac tgattgccat ggatccatat gagtatttcc aagtaggctg gaatattttt 2400
 gacagcctta ttgtgacttt aagtttagtg gagctcttcc tagcagatgt ggaaggattg 2460
 tcagttctgc gatcattcag actgctccga gtcttcaagt tggcaaaatc ctggccaaca 2520
 ttgaacatgc tgattaagat catttgtaac tcagtagggg ctctaggtaa cctcacctta 2580
 gtgttgccca tcatcgtctt catttttgct gtggtcggca tgcagctctt tggtaagagc 2640
 tacaagaat gtgtctgcaa gatcaatgat gactgtacgc tcccacgggtg gcacatgaac 2700
 gactctctcc actccttctt gattgtgttc cgcgtgctgt gtggagagtgt gatagagacc 2760
 atgtgggact gtatggaggt cgctgggtcaa gctatgtgcc ttattgttta catgatggtc 2820
 atggtcattg gaaacctggt ggtcctaacc ctatttctgg ccttattatt gagctcattt 2880

ATTORNEY DOCKET NO. 21101.0048U1

```

agttcagaca atcttacagc aattgaagaa gaccctgatg caaacaacct ccagattgca 2940
gtgactagaa ttaaaaaggg aataaattat gtgaaacaaa ccttacgtga atttattcta 3000
aaagcatttt ccaaaaagcc aaagatttcc agggagataa gacaagcaga agatctgaat 3060
actaagaagg aaaactatat ttctaaccat acacttgctg aaatgagcaa aggtcacaa 3120
ttcctcaagg aaaaagataa aatcagtggt tttggaagca gcgtggacaa acacttgatg 3180
gaagacagtg atggtaaatc atttattcac aatcccagcc tcacagtgc acgtgccaatt 3240
gcacctgggg aatccgattt ggaaaatatg aatgctgagg aacttagcag tgattcggat 3300
agtgaataga gcaaaagtga attaaaccgg tcaagctcct cagagtgcag cacagttgat 3360
aaccccttgc ctggagaagg agaagaagca gaggctgaac ctatgaattc cgatgagcca 3420
gaggcctggt tcacagatgg ttgtgtacgg aggttctcat gctgccaaagt taacatagag 3480
tcagggaagg gaaaaatctg gtggaacatc aggaaaacct gctacaagat tgttgaacac 3540
agttggtttg aaagcttcat tgcctcatg atcctgctca gcagtgggtg cctggctttt 3600
gaagatattt atattgaaag gaaaaagacc attaaagatta tcctggagta tgcagacaag 3660
atcttccactt acatcttcat tctggaaatg cttctaaaat ggatagcata tggttataaa 3720
acatatttca ccaatgcctg gtgttggctg gatttccctaa ttgttgatgt ttctttggtt 3780
actttagtgg caaacactct tggctactca gatcttgccc ccattaaatc ccttcggaca 3840
ctgagagctt taagacctct aagagcctta tctagatttg aaggaaatgag ggtcgtttgt 3900
aatgcactca taggagcaat tcttccatc atgaatgtgc tacttgtgtg tcttatattc 3960
tggctgatat tcagcatcat gggagtaaat ttgtttgctg gcaagttcta tgagtgtatt 4020
aacaccacag atgggtcacg gtttccctga agtcaagttc caaatcgctc cgaatgtttt 4080
gcccttatga atgttagtca aaatgtgcga tggaaaaacc tgaaagtga ctttgataat 4140
gtcggacttg gttacctatc tctgcttcaa gttgcaactt ttaagggatg gacgattatt 4200
atgtatgcag cagtggatct tgttaatgta gacaagcagc ccaaataatga atatagcctc 4260
tacatgtata ttatttttgt cgtctttatc atctttgggt cattcttcac tttgaacttg 4320
ttcattgggtg tcatcataga taatttcaac caacagaaaa agaagcttgg aggtcaagac 4380
atctttatga cagaagaaca gaagaaatc tataatgcaa tgaaaaagct ggggtccaag 4440
aagccacaaa agccaattcc tcgaccaggg aacaaaatcc aaggatgtat atttgaccta 4500
gtgacaaatc aagcctttga tattagtatc atggttctta tctgtctcaa catggttaacc 4560
atgatggtag aaaaggaggg tcaaagtcaa catatgactg aagttttata ttggataaat 4620
gtggttttta taactctttt cactggagaa tgtgtgctaa aactgatctc cctcagacac 4680
tactacttca ctgtaggatg gaatattttt gattttgtgg ttgtgattat ctccattgta 4740
ggtatgtttc tagctgattt gattgaaacg tattttgtgt cccctaccct gttccgagtg 4800
atccgtcttg ccaggatttg ccgaatccta cgtctagtca aaggagcaaa ggggatccgc 4860
acgtctctct ttgctttgat gatgtccctt cctgcggtgt ttaacatcgg cctcctgctc 4920
ttcctggtca tgttcatcta cgccatctt ggaaatgtca actttgccta tgttaaaaaa 4980
gaagatggaa ttaatgacat gttcaatttt gagacctttg gcaacagtat gatttgcttg 5040
ttccaaatta caacctctgc tggctgggat ggattgctag cacctattct taacagtaag 5100
ccaccgact gtgacccaaa aaaagttcat cctggaagt cagttagaag agactgtggt 5160
aaccatctg ttggaatatt ctactttgtt agttatatca tcatatcctt cctggttggt 5220
gtgaacatgt acattgcagt catactggag aattttagtg ttgccactga agaaagtact 5280
gaacctctga gtgaggatga ctttgagatg ttctatgagg tttgggagaa gtttgatccc 5340
gatgcgaccc agtttataga gttctctaaa ctctctgatt ttgcagctgc cctggatcct 5400
cctcttctca tagcaaaacc caacaaagtc cagctcattg ccatggatct gcccatggtt 5460
agtgtgacc ggatccattg tcttgacatc ttatttgctt ttacaaagcg tgttttgggt 5520
gagagtgggg agatggattc tcttcgttca cagatggaag aaaggttcat gtctgcaaat 5580
ccttccaaag tgtctatga acccatcaca accacactaa aacggaaaca agaggatgtg 5640
tctgtactg tcatcagcg tgcttataga cgttaccgct taaggcaaaa tgtcaaaaat 5700
atatcaagta tatacataaa agatggagac agagatgatg atttactcaa taaaaaagat 5760
atggcttttg ataattgtta tgagaactca agtcagaaa aaacagatgc cacttcattc 5820
accacctctc caccttcata tgatagtgtg acaaagccag acaaagagaa atatgaacaa 5880
gacagaacag aaaaggaaga caaagggaaa gacagcaagg aaagcaaaaa atag 5934

```

<210> 13

<211> 5934

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =

synthetic construct

```

<400> 13
atggcaatgt tgcctccccc aggacctcag agctttgtcc atttcacaaa acagtctctt 60
gccctcattg aacaacgcat tgctgaaaga aaatcaaagg aacccaaaga agaaaagaaa 120
gatgatgatg aagaagcccc aaagccaagc agtgacttgg aagctggcaa acaactgccc 180
ttcatctatg gggacattcc tccggcatg gtgtcagagc ccctggagga cttggacccc 240
tactatgcag acaaaaagac ttctatagta ttgaacaaag ggaaaacaat cttccgtttc 300
aatgccacac ctgctttata tatgctttct cttttcagtc ctctaagaag aatatctatt 360
aagattttag tacactcctt attcagcatg ctcacatcatg gcactattct gacaaactgc 420
atattttatga ccatgaataa cccgccggac tggacaaaaa atgtcgagta cacttttact 480
ggaaatatata cttttgaaac acttgtaaaa atccttgcaa gaggtctctg tgtaggagaa 540
ttcacttttc ttcgtgaccc gtggaactgg ctggattttg tcttcattgt ttttgcgat 600
ttaacagaat ttgtaaacct aggcaatgtt tcagctcttc gaactttcag agtattgaga 660
gctttgaaaa ctattttctgt aatcccaggc ctgaagacaa ttgtaggggc tttgatccag 720
tcagtgaaga agctttctga tgtcatgatc ctgactgtgt tctgtctgag tgtgtttgca 780
ctaattggag ctagctgttt catgggaaac ctgaagcata aatgttttcg aaattcactt 840
gaaaataatg aaacattaga aagcataatg aataccctag agagtgaaga agactttaga 900
aaatattttt attacttgga aggatccaaa gatgctctcc tttgtggttt cagcacagat 960
tcaggtcagt gtccagaggg gtacacctgt gtgaaaattg gcagaaaccc tgattatggc 1020
tacacgagct ttgacacttt cagctgggcc ttcttagcct tgtttaggct aatgacccaa 1080
gattactggg aaaaacttta ccaacagacg ctgctgtctg ctggcaaaac ctacatgatc 1140
ttctttgtcg tagtgatttt cctgggctcc ttttatctaa taaacttgat cctggctgtg 1200
gttgccatgg catatgaaga acagaaccag gcaaacattg aagaagctaa acagaaagaa 1260
ttagaatttc aacagatgtt agaccgtctt aaaaaagagc aagaagaagc tgaggcaatt 1320
gcagcggcag cggctgaata tacaagtatt aggagaagca gaattatggg cctctcagag 1380
agttcttctg aaacatccaa actgagctct aaaaagtcta aagaaagaag aaacagaaga 1440
aagaaaaaga atcaaaagaa gctctccagt ggagaggaaa agggagatgc tgagaaattg 1500
tcgaaatcag aatcagagga cagcatcaga agaaaaagtt tccaccttgg tgtcgaaggg 1560
cataggcgag cacatgaaaa gaggttgtct accccaatc agtcaccact cagcattcgt 1620
ggctccttgt tttctgcaag gcgaagcagc agaacaagtc tttttagttt caaaggcaga 1680
ggaagagata taggatctga gactgaattt gccgatgatg agcacagcat ttttgagac 1740
aatgagagca gaaggggctc actgtttgtg cccacagac ccaggagcg acgcagcagt 1800
aacatcagcc aaagccagtag gtccccacca atgctgccgg tgaacgggaa aatgcacagt 1860
gtgtgggact gcaacgggtgt ggtctccctg gttgatggag gctcagccct catgctcccc 1920
aatggcagc ttctgccaag gggcacgacc aatcaaatat acaagaaaag gcgttgtagt 1980
tcctatctcc ttccagagga tatgctgaat gatecccaac tcagacagag agcaatgagt 2040
agagcaagca tattaacaaa cactgtggaa gaacttgaag agtccagaca aaaatgtcca 2100
ccttggttgt acagatttgc acacaaatc ttgatctgga attgctctcc atattggata 2160
aaattcaaaa agtgtactta ttttattgta attgatacct ttgtagatct tgcaattacc 2220
atttgcatag ttttaaacac attatttatg gctatggaa accaccaat gactgaggaa 2280
ttcaaaaatg tacttgctat aggaaatttg gtctttactg gaatctttgc agctgaaatg 2340
gtattaaaac tgattgccat ggatccatat gagtatttcc aagtaggctg gaatttttt 2400
gacagcctta ttgtgacttt aagtttagtg gagctcttcc tagcagatgt ggaaggattg 2460
tcagttctgc gatcattcag actgctccga gtcttcaagt tggcaaaatc ctggccaaca 2520
ttgaacatgc tgattaagat cattggtaac tcagtagggg ctctaggtaa cctcacctta 2580
gtgttgggcca tcacgtctct catttttgcg gtggtcggca tgcagctctt tggtaaagagc 2640
tacaaagaat gtgtctgcaa gatcaatgat gactgtacgc tcccacggtg gcacatgaac 2700
gacttcttcc actcttccct gattgtgttc cgctgtgtgt gtggagagtg gatagagacc 2760
atgtgggact gtatggaggt cgctgtgcaa gctatgtgcc ttattgttta catgatggtc 2820
atggtcattg gaaacctggt ggtcctaacc ctatttctgg ccttattatt gagctcattt 2880
agttcagaca atcttacagc aattgaagaa gacctgatg caaacaacct ccagattgca 2940
gtgactagaa ttaaaaaggg aataaattat gtgaaacaaa ccttacgtga atttattcta 3000
aaagcatttt ccaaaaagcc aaagatttcc agggagataa gacaagcaga agatctgaat 3060
actaagaagg aaaactatat ttctaaccat acacttgctg aatatgagca aggtcacaat 3120
ttcctcaagg aaaaagataa aatcagtggg ttggaagca gcgtggacaa acacttgatg 3180
gaagacagtg atggccaatc atttatccac aatcccagcc tcacagtgc agtgccaatt 3240
gcacctgggg aatccgattt ggaaaaatg aatgctgagg aacttagcag tgattcggat 3300
agtgaataca gcaaaagtga attaaaccgg tcaagctcct cagagtgcag cacagttgat 3360
aacccttttc ctggagaagg agaagaagca gaggtgaac ctatgaattc cgatgagcca 3420
gaggcctgtt tcacagatgg ttgtgtacgg aggttctcat gctgccaagt taacatagag 3480

```

ATTORNEY DOCKET NO. 21101.0048U1

```

tcagggaaag gaaaaatctg gtggaacatc agggaaacct gctacaagat tgttgaacac 3540
agttgggtttg aaagcttcat tgcctcatg atcctgctca gcagtgggtgc cctggctttt 3600
gaagatatttt atattgaaag gaaaaagacc attaagatta tcctggagta tgcagacaag 3660
atcttcactt acatcttcat tctggaaatg cttctaaaat ggatagcata tgggtataaa 3720
acatatttca ccaatgcctg gtgttggtg gatttcctaa ttgttgatgt ttctttgggt 3780
acttttagtg caaacactct tggctactca gatcttggcc ccattaaatc ccttcggaca 3840
ctgagagctt taagacctct aagagcctta tctagatttg aaggaatgag ggtcgttgtg 3900
aatgcactca taggagcaat tcttccatc atgaatgtgc tacttgtgtg tcttatattc 3960
tggctgatat tcagcatcat gggagtaaat ttgtttgtg gcaagtctta tgagtgtatt 4020
aacaccacag atgggtcacg gtctcctgca agtcaagttc caaatcggtc cgaatgtttt 4080
gcccttatga atgttagtca aaatgtgcga tggaaaaacc tgaaagtga ctttgataat 4140
gtcggacttg gttacctatc tctgcttcaa gttgcaactt ttaagggatg gacgattatt 4200
atgtatgcag cagtggatct tgtaaatgta gacaagcagc ccaaatatga atatagcttc 4260
tacatgtata tttattttgt cgtctttatc atctttgggt cattcttcac tttgaacttg 4320
ttcattggtg tcatcataga taatttcaac caacagaaaa agaagcttgg aggtcaagac 4380
atctttatga cagaagaaca gaagaaatac tataatgcaa tgaaaaagct ggggtccaag 4440
aagccacaaa agccaattcc tcgaccaggg aacaaaaatc aaggatgtat atttgacctc 4500
gtgacaaatc aagcctttga tattagtatc atgggtctta tctgtctcaa catggtaacc 4560
atgatggtag aaaaggaggg tcaaagtcac catatgactg aagttttata ttggataaat 4620
gtgggtttta taatcctttt cactggagaa tgtgtgctaa aactgatctc cctcagacac 4680
tactacttca ctgtaggatg gaatatcttt gattttgtgg ttgtgattat ctccattgta 4740
ggtagtcttc ttgctgattt gattgaaacg tattttgtgt cccctaccct gtcccgatg 4800
atccgtcttg ccaggattgg ccgaatccta cgtctagtca aaggagcaaa ggggatccgc 4860
acgtgtctct ttgctttgat gatgtccctt cctgcgttgt ttaacatcgg cctcctgctc 4920
ttcctggtca tgttcactca cgccatcttt ggaatgtcca actttgccta tgttaaaaag 4980
gaagatggaa ttaatgacat gttcaatttt gagaccttg gcaacagtat gatttgcctg 5040
ttccaaatta caacctctgc tggctgggat ggattgctag cacctattct taacagtaag 5100
ccaccgact gtgacccaaa aaaagtctat cctggaagtt cagtgaagg agactgtggt 5160
aaccatctg ttggaatatt ctactttgtt agttatatca tcatatcctt cctggttgtg 5220
gtgaacatgt acattgcagt catactggag aatttttagt ttgccactga agaaagtact 5280
gaacctctga gtgaggatga ctttgagatg ttctatgagg ttgggagaa gtttgatccc 5340
gatgcgaccc agtttataga gttctctaaa ctctctgatt ttgcagctgc cctggatcct 5400
cctcttctca tagcaaaacc caacaaagtc cagctcattg ccatggatct gcccatgggt 5460
agtgtgaccc ggatccattg tcttgacatc ttatttgcct ttacaaagcg tgttttgggt 5520
gagatggggg agatggattc tcttcgttca cagatggaag aaaggttcat gtctgcaaat 5580
ccttccaaag tgtcctatga acccatcaca accacactaa aacggaaaaca agaggatgtg 5640
tctgctactg tcattcagcg tgcttataga cgttaccgct taaggcaaaa tgtcaaaaat 5700
atatcaagta tatacataaa agatggagac agagatgatg atttactcaa taaaaaagat 5760
atggcttttg ataagttaa tgagaactca agtccagaaa aaacagatgc cacttcatcc 5820
accacctctc caccttcata tgatagtga acaaagccag acaaagagaa atatgaacaa 5880
gacagaacag aaaaggaaga caaagggaag gacagcaagg aaagcaaaaa atag 5934

```

<210> 14

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 14

gcccttcac tatgg

15

<210> 15

<211> 15

<212> DNA

<213> Artificial Sequence

ATTORNEY DOCKET NO. 21101.0048U1

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 15
aaccgcgcgg actgg 15

<210> 16
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 16
gctccccaat ggaca 15

<210> 17
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 17
atacacaaga aaagg 15

<210> 18
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 18
tcttgcaatt accat 15

<210> 19
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 19
accctttgcc tggag 15

<210> 20
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 20
gtcccgccca ttgcctgaca c 21

<210> 21
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 21
ttctggtcat gatatggta ttcac 25

<210> 22
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 22
tgatagatgc gttgatgaca ttgg 24

<210> 23
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 23
ttcataaatg cagtaacttc ctgg 24

<210> 24
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 24
tgtttctttt aagtcagtac agag 24

<210> 25
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =

synthetic construct

<400> 25
agagccattc acaagaccag ag 22

<210> 26
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 26
actcagaaag gcagagaggt g 21

<210> 27
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 27
ttgccatggt atcaatgtct gtg 23

<210> 28
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 28
gactgatttg tatctggtta ggag 24

<210> 29
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 29
gcaatgtaat taggaagggtg tgag 24

<210> 30
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 30
tttgaatgaa ctctaaatga actacc

26

<210> 31
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 31
taagtattag gcgttaagac aaacc

25

<210> 32
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 32
Pro Phe Val Tyr Gly
1 5

<210> 33
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 33
Asn Pro Gln Asp Trp
1 5

<210> 34
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 34
Leu Pro Tyr Gly Gln
1 5

<210> 35
<211> 5
<212> PRT

ATTORNEY DOCKET NO. 21101.0048U1

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 35

Ile His Arg Lys Arg
1 5

<210> 36

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 36

Leu Ala Val Thr Ile
1 5

<210> 37

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 37

Asn Pro Phe Pro Gly
1 5

<210> 38

<211> 1977

<212> PRT

<213> Homo Sapien

<400> 38

Met	Ala	Met	Leu	Pro	Pro	Gly	Pro	Gln	Ser	Phe	Val	His	Phe	Thr
1			5				10					15		
Lys	Gln	Ser	Leu	Ala	Leu	Ile	Glu	Gln	Arg	Ile	Ala	Glu	Arg	Lys
			20				25					30		
Lys	Glu	Pro	Lys	Glu	Glu	Lys	Lys	Asp	Asp	Asp	Glu	Glu	Ala	Pro
			35				40				45			
Pro	Ser	Ser	Asp	Leu	Glu	Ala	Gly	Lys	Gln	Leu	Pro	Phe	Ile	Tyr
			50			55				60				
Asp	Ile	Pro	Pro	Gly	Met	Val	Ser	Glu	Pro	Leu	Glu	Asp	Leu	Asp
65				70				75					80	
Tyr	Tyr	Ala	Asp	Lys	Lys	Thr	Phe	Ile	Val	Leu	Asn	Lys	Gly	Lys
				85				90					95	
Ile	Phe	Arg	Phe	Asn	Ala	Thr	Pro	Ala	Leu	Tyr	Met	Leu	Ser	Pro
			100				105						110	

ATTORNEY DOCKET NO. 21101.0048U1

Ser	Pro	Leu	Arg	Arg	Ile	Ser	Ile	Lys	Ile	Leu	Val	His	Ser	Leu	Phe
		115					120					125			
Ser	Met	Leu	Ile	Met	Cys	Thr	Ile	Leu	Thr	Asn	Cys	Ile	Phe	Met	Thr
		130					135				140				
Met	Asn	Asn	Pro	Pro	Asp	Trp	Thr	Lys	Asn	Val	Glu	Tyr	Thr	Phe	Thr
					150					155					160
Gly	Ile	Tyr	Thr	Phe	Glu	Ser	Leu	Val	Lys	Ile	Leu	Ala	Arg	Gly	Phe
				165					170						175
Cys	Val	Gly	Glu	Phe	Thr	Phe	Leu	Arg	Asp	Pro	Trp	Asn	Trp	Leu	Asp
			180					185					190		
Phe	Val	Val	Ile	Val	Phe	Ala	Tyr	Leu	Thr	Glu	Phe	Val	Asn	Leu	Gly
		195					200					205			
Asn	Val	Ser	Ala	Leu	Arg	Thr	Phe	Arg	Val	Leu	Arg	Ala	Leu	Lys	Thr
		210					215				220				
Ile	Ser	Val	Ile	Pro	Gly	Leu	Lys	Thr	Ile	Val	Gly	Ala	Leu	Ile	Gln
					230					235					240
Ser	Val	Lys	Lys	Leu	Ser	Asp	Val	Met	Ile	Leu	Thr	Val	Phe	Cys	Leu
				245				250						255	
Ser	Val	Phe	Ala	Leu	Ile	Gly	Leu	Gln	Leu	Phe	Met	Gly	Asn	Leu	Lys
		260					265						270		
His	Lys	Cys	Phe	Arg	Asn	Ser	Leu	Glu	Asn	Asn	Glu	Thr	Leu	Glu	Ser
		275					280					285			
Ile	Met	Asn	Thr	Leu	Glu	Ser	Glu	Glu	Asp	Phe	Arg	Lys	Tyr	Phe	Tyr
		290					295				300				
Tyr	Leu	Glu	Gly	Ser	Lys	Asp	Ala	Leu	Leu	Cys	Gly	Phe	Ser	Thr	Asp
		305			310					315					320
Ser	Gly	Gln	Cys	Pro	Glu	Gly	Tyr	Thr	Cys	Val	Lys	Ile	Gly	Arg	Asn
				325					330					335	
Pro	Asp	Tyr	Gly	Tyr	Thr	Ser	Phe	Asp	Thr	Phe	Ser	Trp	Ala	Phe	Leu
			340					345					350		
Ala	Leu	Phe	Arg	Leu	Met	Thr	Gln	Asp	Tyr	Trp	Glu	Asn	Leu	Tyr	Gln
		355					360					365			
Gln	Thr	Leu	Arg	Ala	Ala	Gly	Lys	Thr	Tyr	Met	Ile	Phe	Phe	Val	Val
		370					375				380				
Val	Ile	Phe	Leu	Gly	Ser	Phe	Tyr	Leu	Ile	Asn	Leu	Ile	Leu	Ala	Val
		385			390					395					400
Val	Ala	Met	Ala	Tyr	Glu	Glu	Gln	Asn	Gln	Ala	Asn	Ile	Glu	Glu	Ala
				405					410					415	
Lys	Gln	Lys	Glu	Leu	Glu	Phe	Gln	Gln	Met	Leu	Asp	Arg	Leu	Lys	Lys
			420					425					430		
Glu	Gln	Glu	Glu	Ala	Glu	Ala	Ile	Ala	Ala	Ala	Ala	Ala	Glu	Tyr	Thr
		435					440					445			
Ser	Ile	Arg	Arg	Ser	Arg	Ile	Met	Gly	Leu	Ser	Glu	Ser	Ser	Ser	Glu
		450				455					460				
Thr	Ser	Lys	Leu	Ser	Ser	Lys	Ser	Ala	Lys	Glu	Arg	Arg	Asn	Arg	Arg
		465			470					475					480
Lys	Lys	Lys	Asn	Gln	Lys	Lys	Leu	Ser	Ser	Gly	Glu	Glu	Lys	Gly	Asp
				485					490					495	
Ala	Glu	Lys	Leu	Ser	Lys	Ser	Glu	Ser	Glu	Asp	Ser	Ile	Arg	Arg	Lys
			500					505					510		
Ser	Phe	His	Leu	Gly	Val	Glu	Gly	His	Arg	Arg	Ala	His	Glu	Lys	Arg
		515					520					525			
Leu	Ser	Thr	Pro	Asn	Gln	Ser	Pro	Leu	Ser	Ile	Arg	Gly	Ser	Leu	Phe
		530				535						540			
Ser	Ala	Arg	Arg	Ser	Ser	Arg	Thr	Ser	Leu	Phe	Ser	Phe	Lys	Gly	Arg
		545			550					555					560
Gly	Arg	Asp	Ile	Gly	Ser	Glu	Thr	Glu	Phe	Ala	Asp	Asp	Glu	His	Ser
				565					570					575	
Ile	Phe	Gly	Asp	Asn	Glu	Ser	Arg	Arg	Gly	Ser	Leu	Phe	Val	Pro	His
			580					585					590		

ATTORNEY DOCKET NO. 21101.0048U1

Arg	Pro	Gln	Glu	Arg	Arg	Ser	Ser	Asn	Ile	Ser	Gln	Ala	Ser	Arg	Ser	595	600	605
Pro	Pro	Met	Leu	Pro	Val	Asn	Gly	Lys	Met	His	Ser	Ala	Val	Asp	Cys	610	615	620
Asn	Gly	Val	Val	Ser	Leu	Val	Asp	Gly	Arg	Ser	Ala	Leu	Met	Leu	Pro	625	630	635
Asn	Gly	Gln	Leu	Leu	Pro	Glu	Gly	Thr	Thr	Asn	Gln	Ile	His	Lys	Lys	645	650	655
Arg	Arg	Cys	Ser	Ser	Tyr	Leu	Leu	Ser	Glu	Asp	Met	Leu	Asn	Asp	Pro	660	665	670
Asn	Leu	Arg	Gln	Arg	Ala	Met	Ser	Arg	Ala	Ser	Ile	Leu	Thr	Asn	Thr	675	680	685
Val	Glu	Glu	Leu	Glu	Glu	Ser	Arg	Gln	Lys	Cys	Pro	Pro	Trp	Trp	Tyr	690	695	700
Arg	Phe	Ala	His	Lys	Phe	Leu	Ile	Trp	Asn	Cys	Ser	Pro	Tyr	Trp	Ile	705	710	715
Lys	Phe	Lys	Lys	Cys	Ile	Tyr	Phe	Ile	Val	Met	Asp	Pro	Phe	Val	Asp	725	730	735
Leu	Ala	Ile	Thr	Ile	Cys	Ile	Val	Leu	Asn	Thr	Leu	Phe	Met	Ala	Met	740	745	750
Glu	His	His	Pro	Met	Thr	Glu	Glu	Phe	Lys	Asn	Val	Leu	Ala	Ile	Gly	755	760	765
Asn	Leu	Val	Phe	Thr	Gly	Ile	Phe	Ala	Ala	Glu	Met	Val	Leu	Lys	Leu	770	775	780
Ile	Ala	Met	Asp	Pro	Tyr	Glu	Tyr	Phe	Gln	Val	Gly	Trp	Asn	Ile	Phe	785	790	795
Asp	Ser	Leu	Ile	Val	Thr	Leu	Ser	Leu	Val	Glu	Leu	Phe	Leu	Ala	Asp	805	810	815
Val	Glu	Gly	Leu	Ser	Val	Leu	Arg	Ser	Phe	Arg	Leu	Leu	Arg	Val	Phe	820	825	830
Lys	Leu	Ala	Lys	Ser	Trp	Pro	Thr	Leu	Asn	Met	Leu	Ile	Lys	Ile	Ile	835	840	845
Gly	Asn	Ser	Val	Gly	Ala	Leu	Gly	Asn	Leu	Thr	Leu	Val	Leu	Ala	Ile	850	855	860
Ile	Val	Phe	Ile	Phe	Ala	Val	Val	Gly	Met	Gln	Leu	Phe	Gly	Lys	Ser	865	870	875
Tyr	Lys	Glu	Cys	Val	Cys	Lys	Ile	Asn	Asp	Asp	Cys	Thr	Leu	Pro	Arg	885	890	895
Trp	His	Met	Asn	Asp	Phe	Phe	His	Ser	Phe	Leu	Ile	Val	Phe	Arg	Val	900	905	910
Leu	Cys	Gly	Glu	Trp	Ile	Glu	Thr	Met	Trp	Asp	Cys	Met	Glu	Val	Ala	915	920	925
Gly	Gln	Ala	Met	Cys	Leu	Ile	Val	Tyr	Met	Met	Val	Met	Val	Ile	Gly	930	935	940
Asn	Leu	Val	Val	Leu	Asn	Leu	Phe	Leu	Ala	Leu	Leu	Leu	Ser	Ser	Phe	945	950	955
Ser	Ser	Asp	Asn	Leu	Thr	Ala	Ile	Glu	Glu	Asp	Pro	Asp	Ala	Asn	Asn	965	970	975
Leu	Gln	Ile	Ala	Val	Thr	Arg	Ile	Lys	Lys	Gly	Ile	Asn	Tyr	Val	Lys	980	985	990
Gln	Thr	Leu	Arg	Glu	Phe	Ile	Leu	Lys	Ala	Phe	Ser	Lys	Lys	Pro	Lys	995	1000	1005
Ile	Ser	Arg	Glu	Ile	Arg	Gln	Ala	Glu	Asp	Leu	Asn	Thr	Lys	Lys	Glu	1010	1015	1020
Asn	Tyr	Ile	Ser	Asn	His	Thr	Leu	Ala	Glu	Met	Ser	Lys	Gly	His	Asn	1025	1030	1035
Phe	Leu	Lys	Glu	Lys	Asp	Lys	Ile	Ser	Gly	Phe	Gly	Ser	Ser	Val	Asp	1045	1050	1055
Lys	His	Leu	Met	Glu	Asp	Ser	Asp	Gly	Gln	Ser	Phe	Ile	His	Asn	Pro	1060	1065	1070

ATTORNEY DOCKET NO. 21101.0048U1

Ser Leu Thr Val Thr Val Pro Ile Ala Pro Gly Glu Ser Asp Leu Glu
1075 1080 1085
Asn Met Asn Ala Glu Glu Leu Ser Ser Asp Ser Asp Ser Glu Tyr Ser
1090 1095 1100
Lys Val Arg Leu Asn Arg Ser Ser Ser Ser Glu Cys Ser Thr Val Asp
1105 1110 1115 1120
Asn Pro Leu Pro Gly Glu Gly Glu Glu Ala Glu Ala Glu Pro Met Asn
1125 1130 1135
Ser Asp Glu Pro Glu Ala Cys Phe Thr Asp Gly Cys Val Arg Arg Phe
1140 1145 1150
Ser Cys Cys Gln Val Asn Ile Glu Ser Gly Lys Gly Lys Ile Trp Trp
1155 1160 1165
Asn Ile Arg Lys Thr Cys Tyr Lys Ile Val Glu His Ser Trp Phe Glu
1170 1175 1180
Ser Phe Ile Val Leu Met Ile Leu Leu Ser Ser Gly Ala Leu Ala Phe
1185 1190 1195 1200
Glu Asp Ile Tyr Ile Glu Arg Lys Lys Thr Ile Lys Ile Ile Leu Glu
1205 1210 1215
Tyr Ala Asp Lys Ile Phe Thr Tyr Ile Phe Ile Leu Glu Met Leu Leu
1220 1225 1230
Lys Trp Ile Ala Tyr Gly Tyr Lys Thr Tyr Phe Thr Asn Ala Trp Cys
1235 1240 1245
Trp Leu Asp Phe Leu Ile Val Asp Val Ser Leu Val Thr Leu Val Ala
1250 1255 1260
Asn Thr Leu Gly Tyr Ser Asp Leu Gly Pro Ile Lys Ser Leu Arg Thr
1265 1270 1275 1280
Leu Arg Ala Leu Arg Pro Leu Arg Ala Leu Ser Arg Phe Glu Gly Met
1285 1290 1295
Arg Val Val Val Asn Ala Leu Ile Gly Ala Ile Pro Ser Ile Met Asn
1300 1305 1310
Val Leu Leu Val Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile Met Gly
1315 1320 1325
Val Asn Leu Phe Ala Gly Lys Phe Tyr Glu Cys Ile Asn Thr Thr Asp
1330 1335 1340
Gly Ser Arg Phe Pro Ala Ser Gln Val Pro Asn Arg Ser Glu Cys Phe
1345 1350 1355 1360
Ala Leu Met Asn Val Ser Gln Asn Val Arg Trp Lys Asn Leu Lys Val
1365 1370 1375
Asn Phe Asp Asn Val Gly Leu Gly Tyr Leu Ser Leu Leu Gln Val Ala
1380 1385 1390
Thr Phe Lys Gly Trp Thr Ile Ile Met Tyr Ala Ala Val Asp Ser Val
1395 1400 1405
Asn Val Asp Lys Gln Pro Lys Tyr Glu Tyr Ser Leu Tyr Met Tyr Ile
1410 1415 1420
Tyr Phe Val Val Phe Ile Ile Phe Gly Ser Phe Phe Thr Leu Asn Leu
1425 1430 1435 1440
Phe Ile Gly Val Ile Ile Asp Asn Phe Asn Gln Gln Lys Lys Lys Leu
1445 1450 1455
Gly Gly Gln Asp Ile Phe Met Thr Glu Glu Gln Lys Lys Tyr Tyr Asn
1460 1465 1470
Ala Met Lys Lys Leu Gly Ser Lys Lys Pro Gln Lys Pro Ile Pro Arg
1475 1480 1485
Pro Gly Asn Lys Ile Gln Gly Cys Ile Phe Asp Leu Val Thr Asn Gln
1490 1495 1500
Ala Phe Asp Ile Ser Ile Met Val Leu Ile Cys Leu Asn Met Val Thr
1505 1510 1515 1520
Met Met Val Glu Lys Glu Gly Gln Ser Gln His Met Thr Glu Val Leu
1525 1530 1535
Tyr Trp Ile Asn Val Val Phe Ile Ile Leu Phe Thr Gly Glu Cys Val
1540 1545 1550

ATTORNEY DOCKET NO. 21101.0048U1

Leu Lys Leu Ile Ser Leu Arg His Tyr Tyr Phe Thr Val Gly Trp Asn
 1555 1560 1565
 Ile Phe Asp Phe Val Val Val Ile Ile Ser Ile Val Gly Met Phe Leu
 1570 1575 1580
 Ala Asp Leu Ile Glu Thr Tyr Phe Val Ser Pro Thr Leu Phe Arg Val
 1585 1590 1595 1600
 Ile Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg Leu Val Lys Gly Ala
 1605 1610 1615
 Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu Met Met Ser Leu Pro Ala
 1620 1625 1630
 Leu Phe Asn Ile Gly Leu Leu Leu Phe Leu Val Met Phe Ile Tyr Ala
 1635 1640 1645
 Ile Phe Gly Met Ser Asn Phe Ala Tyr Val Lys Lys Glu Asp Gly Ile
 1650 1655 1660
 Asn Asp Met Phe Asn Phe Glu Thr Phe Gly Asn Ser Met Ile Cys Leu
 1665 1670 1675 1680
 Phe Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly Leu Leu Ala Pro Ile
 1685 1690 1695
 Leu Asn Ser Lys Pro Pro Asp Cys Asp Pro Lys Lys Val His Pro Gly
 1700 1705 1710
 Ser Ser Val Glu Gly Asp Cys Gly Asn Pro Ser Val Gly Ile Phe Tyr
 1715 1720 1725
 Phe Val Ser Tyr Ile Ile Ile Ser Phe Leu Val Val Val Asn Met Tyr
 1730 1735 1740
 Ile Ala Val Ile Leu Glu Asn Phe Ser Val Ala Thr Glu Glu Ser Thr
 1745 1750 1755 1760
 Glu Pro Leu Ser Glu Asp Asp Phe Glu Met Phe Tyr Glu Val Trp Glu
 1765 1770 1775
 Lys Phe Asp Pro Asp Ala Thr Gln Phe Ile Glu Phe Ser Lys Leu Ser
 1780 1785 1790
 Asp Phe Ala Ala Ala Leu Asp Pro Pro Leu Leu Ile Ala Lys Pro Asn
 1795 1800 1805
 Lys Val Gln Leu Ile Ala Met Asp Leu Pro Met Val Ser Gly Asp Arg
 1810 1815 1820
 Ile His Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly
 1825 1830 1835 1840
 Glu Ser Gly Glu Met Asp Ser Leu Arg Ser Gln Met Glu Glu Arg Phe
 1845 1850 1855
 Met Ser Ala Asn Pro Ser Lys Val Ser Tyr Glu Pro Ile Thr Thr Thr
 1860 1865 1870
 Leu Lys Arg Lys Gln Glu Asp Val Ser Ala Thr Val Ile Gln Arg Ala
 1875 1880 1885
 Tyr Arg Arg Tyr Arg Leu Arg Gln Asn Val Lys Asn Ile Ser Ser Ile
 1890 1895 1900
 Tyr Ile Lys Asp Gly Asp Arg Asp Asp Asp Leu Leu Asn Lys Lys Asp
 1905 1910 1915 1920
 Met Ala Phe Asp Asn Val Asn Glu Asn Ser Ser Pro Glu Lys Thr Asp
 1925 1930 1935
 Ala Thr Ser Ser Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys
 1940 1945 1950
 Pro Asp Lys Glu Lys Tyr Glu Gln Asp Arg Thr Glu Lys Glu Asp Lys
 1955 1960 1965
 Gly Lys Asp Ser Lys Glu Ser Lys Lys
 1970 1975

Title: "MUTANT SODIUM CHANNEL Na_v1.7 AND METHODS ..."
Inventor: LEPPERT *ET AL.*
Application No.: UNASSIGNED
Docket No.: 21101.0048U1

EXPRESS MAIL LABEL NO. EL 997679835 US

Sheet 1 of 2

Sodium Channel




FIG. 1

Title: "MUTANT SODIUM CHANNEL α_1 1.7 AND METHODS ..."
 Inventor: LEPPERT *ET AL.*
 Application No.: UNASSIGNED
 Docket No.: 11101.0048U1

EXPRESS MAIL LABEL NO. EL 997679835 US

Sheet 2 of 2




FIG. 2





FIG. 3

012104
14230 U.S. PTO

ATTORNEY DOCKET NO.: 21101.0048U1
Pag 1 of 2

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a **PROVISIONAL APPLICATION FOR PATENT** under 37 C.F.R. § 1.53(c).

Docket Number		21101.0048U1		Type a Plus Sign (+) inside this box	+																												
INVENTOR(s)																																	
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (City and Either State or Foreign Country)																														
LEPPERT	MARK	F.	1466 WESTMINSTER AVENUE, SALT LAKE CITY, UTAH 84105																														
SINGH	NANDA	A.	101 TIMBERLAKES, HEBER CITY, UTAH 84032																														
TITLE OF INVENTION (500 characters max)																																	
MUTANT SODIUM CHANNEL NA _v 1.7 AND METHODS RELATED THERETO																																	
CORRESPONDENCE ADDRESS																																	
NEEDLE & ROSENBERG, P.C. Customer No. 23859																																	
 23859 <small>PATENT TRADEMARK OFFICE</small>																																	
ENCLOSED APPLICATION PARTS (Check All That Apply)																																	
<table style="width: 100%; border: none;"> <tr> <td style="width: 15%;"><input checked="" type="checkbox"/></td> <td style="width: 45%;">Provisional Application Title Page</td> <td style="width: 20%;">Number of Pages</td> <td style="width: 20%;">[1]</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>Specification</td> <td>Number of Pages</td> <td>[66]</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>Claims</td> <td>Number of Pages</td> <td>[8]</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>Abstract</td> <td>Number of Pages</td> <td>[1]</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>Drawing(s)</td> <td>Number of Sheets</td> <td>[2]</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>Sequence Listing</td> <td>Number of Sheets</td> <td>[48]</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>Diskette Containing Sequence Listing</td> <td></td> <td>[1]</td> </tr> </table>						<input checked="" type="checkbox"/>	Provisional Application Title Page	Number of Pages	[1]	<input checked="" type="checkbox"/>	Specification	Number of Pages	[66]	<input checked="" type="checkbox"/>	Claims	Number of Pages	[8]	<input checked="" type="checkbox"/>	Abstract	Number of Pages	[1]	<input checked="" type="checkbox"/>	Drawing(s)	Number of Sheets	[2]	<input checked="" type="checkbox"/>	Sequence Listing	Number of Sheets	[48]	<input checked="" type="checkbox"/>	Diskette Containing Sequence Listing		[1]
<input checked="" type="checkbox"/>	Provisional Application Title Page	Number of Pages	[1]																														
<input checked="" type="checkbox"/>	Specification	Number of Pages	[66]																														
<input checked="" type="checkbox"/>	Claims	Number of Pages	[8]																														
<input checked="" type="checkbox"/>	Abstract	Number of Pages	[1]																														
<input checked="" type="checkbox"/>	Drawing(s)	Number of Sheets	[2]																														
<input checked="" type="checkbox"/>	Sequence Listing	Number of Sheets	[48]																														
<input checked="" type="checkbox"/>	Diskette Containing Sequence Listing		[1]																														

22387 U.S. PTO
60/538149
012104

METHOD PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (Check One)	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR § 1.27.	FILING FEE AMOUNT \$80.00
<input checked="" type="checkbox"/> A Credit Card Payment Form PTO-2038 is enclosed to cover the filing fees.	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.	
<input type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number _____.	
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 14-0629.	

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☐ No.

☒ Yes. The name of the U.S. Government agency and the Government contract number are:
National Institutes of Health federal grant R01-NS-32666

Respectfully submitted,

Signature



Date 1/21/09

Typed or Printed Name:

Christopher L. Curfman, Ph.D.

Registration No.

52,787

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence and any items indicated as attached or included are being deposited with the United States Postal Service as Express Mail, Label No. EL 997679835 US, in an envelope addressed to: MAIL STOP PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.


Michael Laird

1/21/09
Date

ATTORNEY DOCKET NO.: 21101.0048U1
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
LEPPERT ET AL.)	
)	
Application No.: UNASSIGNED)	Examiner: UNASSIGNED
)	
Filing Date: JANUARY 21, 2004)	Group Art Unit: UNASSIGNED
)	
Confirmation No. UNASSIGNED)	
)	
Title: MUTANT SODIUM CHANNEL $Na_v1.7$)	
AND METHODS RELATED THERETO)	

AUTHORIZATION TO TREAT REPLY REQUIRING EXTENSION OF TIME
AS INCORPORATING PETITION FOR EXTENSION OF TIME

MAIL STOP PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer No. 23859

January 21, 2004


Sir:

Pursuant to 37 C.F.R. § 1.136(a)(3), the Commissioner is hereby requested and authorized to treat any concurrent or future reply in the above-identified application, requiring a petition for an extension of time for its timely submission, as incorporating a petition for extension of time for the appropriate length of time.

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,


NEEDLE & ROSENBERG, P.C.


Christopher L. Curfman, Ph.D.
Registration No. 52,787

ATTORNEY DOCKET NO.: 21101.0048U1
PATENT

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence and any items indicated as attached or included are being deposited with the United States Postal Service as Express Mail, Label No. EL 997679835 US, in an envelope addressed to: MAIL STOP PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date shown below.



Michael Laird

1/21/04

Date